var title_f23_44_24256="Wall climb exercises";
var content_f23_44_24256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wall climb exercises",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 406px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wall climbs should be performed in shoulder flexion (right) and abduction (left).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24256=[""].join("\n");
var outline_f23_44_24256=null;
var title_f23_44_24257="Endoscopic view of the papilla of Vater";
var content_f23_44_24257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic view of the papilla of Vater",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAVsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKkhieZ9sa5Pf2oAailmCqMk1bWJ4drxn94DnINRwgxy7SOR14rTiXK5bbj8Kd0O19ytd3t1e7Rctu2+tN2O+ASMDtUzhGkydu3vinReUFcOcEfd5ouCilsIuEUg8YqBi+/gY9KaHLyHOSPWrdtGpdSwBHrmoZcY3HQROw+bGK04PLijz0PaqLTbSRCCR7c0QW9zduAA209qzk0dUIdi2b0gnDZx6UxZppz8obPvWjZaKoO6RSce9bUNjGNuyLvzxXNOrFHRGn3Oet7GSQZkzWzpmlpKCpiyw44Fblhp8jyZSI7B6ituxtWWTKqgPQ1zyqtmqVtjKg0qOKNcIAT+daVvp6mLIUhh2rZitXkkVY0Bk681deEiYB0AKjHFZthcyLS0G5A65z7Ven01N/wApwmOAK2ILaLCnZ9anBihX96E2E8ZqHMls5wafcqylQSv1q1aaciLJJMpDHvW2JLeFTvYDd05qe0hjkVym0qPWsnMXMc7DpBnjEkKfMhqOSzj811IbewrpLK3YQymCUKSTwTUHkr5q7wN/cjvUNoaZyktlKIxGg+Yds1S1vQbS4tFJiHm9+Oc13UdtCLpgFy5GRVC5tEAcSgbieuazcraplp3PIb7RLi0I+z7gPTNVLQCF2N4cEHIB716tJpocMQqnHU1q/Cf4d6f4o1zU312LzbOBNiRrIVOT349K1pV3UfIyKkoQ1bPLTdLcwr5eNiHnHFXbac3MiRRACrPxR+H174G8TeRauW0yceZCTLvYDPQ8D+Vc9b74irxyEv7GqqUUiadVT+E6G8ciVIBzgZNPsA0kpC4UZ5JNZqmQoTkmQ+9TRzpHYBCD55bk5rm5bG1+5qX7LbptLhmPoapJc+VHvycnpzWfqchZFeNS20cnrXq3hvwNomveBbDxBHIVnicrMPtHytjqCNnB/OqUHIl1YRfvM4CO6835QRvxzWlodurzmORgSexNdtqMfgPSJftKJHJO6AhVZmGf5fpXI3upQ3erw3VrbrDDGcgBev6CpnTaHzp/CQX9s1rfMo5x2pWuI5I3gu4kkgkXa0bLlWHoaLu+kvtRkkSM5JwAFp7Wkoh82VMH3qIzcHdCcVJWkjyLxt4Mn0p5b7Tomk0onOc7jFnsfb3rjK+lrZg0DLKF2OCpVhkEehryjx34IewEmpaSm6yJy8Q5aL3x/dr38Hj41vcnozz8Rh+T3o7Hn9FL1or0rHIJRS0lIAooq9pmnTX8pEYIjX7z9h7fWk3bVgRWVpLdy7IxwPvMei101rZJbW+yPH+0e5NW7GySCMRqu1R696llwW2gcAdayc77G8IJbnK6lGI7vd0DV2nwd8I2XjbxVLpWo6ilgogMiPIQNxHYZrm9ZhBjyByvSsAO6uHjYow7g4q4MmbtsdD4u0keHfFOp6Sk4uY7aUosi9GrFf5gKam4hmYlmbkmkRS7HapIFVa2pEVJvUsWcLTOY0IGOasQWs904WLoDjirWj6fMXExG0Ht6119hphjjDsoUHmsKlVRO6nS7mPpuiSRgFmU+1dDBYpA6Fdpf2FX7S33HaPw4q/Hp/JP8Y7YrjlNyOhKxTitMvtK479K0rCw8yfBUD2JrS0+3ZyEnG044JrYgtQWDIMlOprCSHexji18puGI9u1XrdYA6q5O71zxWjcrlAvy/N3xUkEMcFuTMM7uhArJsd7kTo0NxC9s4I71MxRN80wP4VatYIl2hSDn2qxd2iTR+XFxgcnHek2zOUnbQl0vRNTubdbp7V7ewlHyTv09q7HwtofhNZYFvblJNSIKtHI4wT9K5678TXt34Xi0R7cKIsKZg3LAdOKyI1SQB2Hzr371MXGEuaTujlcakn72h6/e+BvDn2e5ae2CRsCzHdjYPb/69Zdt4L8L3Wmztp1zlNuDKHB2H1NefLczXMgYTuy42lS1QTiVEkWB2j3f3D1redfDP7JnOnVWzOy1b4Z3Frpry6PfedOi7hGyY3/Q5rLHhG8tNHiv7h0csPmjGdwPpXTaN4wW38HLHdLI1/HEYwM/eOMA5rgI7q9eL9/I2ck4zTqLDuKtoOnKstLFj7JNbzB5YXRT3YVU1GyXeW25DVsNeveWQWY/dGM5qpcvutowASqjk15c0uh3Rb6mSlsqwMEUEkYPNTfDrVP+EV8TTzXyy/Y502kpztPrj/69XFija0Lg/NVNEIcFfmqYVPZvmRM6Sqblf4o6hZ+LtaiuIg6wwRlAG9T3ryfV9DdRvsjznpXql9YCTfKrD3GKoTWkf2YssfI9qipj5817GlKhGC0PKZBdWUgW6Uq5HAJq3GrJbxTT9JDW94n0pr6FXA2so6kVyN3JcQ26QyxsY4z17V10qka0brcuScTZYoEYKvJGcGrGn3Woadpk1rYXkkVpO294kPGa522vdwKgfMeBmtqBnRUQYLdTjtRKMoE+7Lc1LTT5b21VkXcyDnINLHIkalXJVl4xUuk6osDOsh4b3qtcRRSSM6sOTWDbe5cVbY0bKcrOkmwYJ7Vpz3CXV2sR4TvzWFDGzwERnJXvVaC6kjm3BTnpWbVyzop4jNdFYyBHH1qtf3A8raBx0NV7aRDA7lyHbtTIQWBGwsB1qItxd0Fr6M8+8beCcJJqWiqGTG+W2Ucr6svqO+O1eddK+nUvYRbKsULBwPQV5l428HHUGkvtIhC3Qy0tuox5nqV9/avosFj1P3Km55uJwyiuaB5dRSsCrFWBBBwQe1JXrHCaejaTLqD7jlLdT8z+vsPeu1tbJIYAkChAo4ANJFAEgWNAETpgGp0DxxFV5Y+9YSndG0Y2KxVVOG3FgelJCmWY9OOnepihjQHB3+lXtIFrCJJL1WLMPlA4FZsu5zt2iyHBz+Nc9fafJFKXQHYea7GQJdXDMq7FVjgE9qyNZlaPcAAR0GKcZNDspHNCOSR9q5LdMV0mjaOybXl43Y4qfw1ojTKZpeDnOK6RIVjwp/ClUq9Eb0qaWrJIYgIlj2gAdwKvQxMxQDnHqarQxkHO3OfcVqW0BcbvmyK5XqdNi1p1stzMsbOsZ6itkwTQEOdrJ0yKradapvVt3zZ7muhitopHZY84A5DGobJbsLFbTJbLcIySKBnaQKWHex3R7V3dQeKieF48iKT5T/Camj+zrbN5pZX7GsZIW5OImYrvwdvYU+6jDKgY4NQWcjIpw4P1FOkleV/mA46EVD0KRbgRjOq7lCYx1qUOkMsilwQaoyyrGUIY7icU6ZwVJTDMBWcpWDlbZZ3jaVGTmqaXKWjuGBYt+lTx3CrGnmYj469qyru9gaZ42cHnrXPPU0UCx9sQ58pQCTzVqCRtoJI55rmxqdlFI8TMOO4q3/bumfZAvnr5g7A1g7lOCOnF2WTBAIHGRVczebncQuO1czZa/bbgiy5B7EVNb6xDNO0e4A560pSaQvZnS2sypG6swFX4L6FoRDjGeCa5wTq8mFA+tT2k0JIXOGFc7rpCdM15TEMQwyDk9Sau2WnFYHumwVX0Nc6pDSNyMryK07bU5hZTQKyBW6561Krp7kOLRWmeISsVVghPTFVr65ATEabh9KthUAXdhj3FWWgV4fMSL5Dx96sqslJaFxOdaBr+NVYLt74rn9a0oT74LdNwXlq6uNXikdVAx1PFFn5P2mZm6MNufesIVpU3dGujVjzC/wBEVrNTanZcIcGs4Q6hpcTPMN3mdDivTr/T4wXMZyXOcZrNudMaS3RZCp5/KvTpY+6tIzdNbo4ezWRwGbII5NXEmxKPkPHXFdRbaXDGCpB444py6QYIHlIDMeQM1q8RCROxgxXrxlwoChqasoKsME96fdRASF5FYZrNtbtBK6jGT61SXMropSLyRrOwCyFaljaS0JCyryccmqgcPJmFQcdR1pBOs8g3Y3elHKyr3OuhurZLUZdPM284rIiMl5cnyXUD1zWXI0OxgdyuOpzxT7Dc4Y2xxjqTUKFtUPyZi+O/Bs2oObu1WMXoHzKuMS//AGX868qlt5oZGjlidJFOGVlIINfQGm3UETSNeF5HxwFNQXN7aTTtJJZo7Hu3U16+FzJxjy1NTirYSLd46HCoTuw3SrcalOVbn3FZCTPvVm6jtir6XBddwIGO2K9Q5bFx3kKAOo+tK2doLMpHpVd5SQu45+lCyB02bfxJpPQViG6YE/uxg1ltam4veclQOlbCRuC/CkDoaZpyl5nkVgGU9PWoky4LU0bNZoI40UYz2qy0DIctnP0q4zNcQRSeUFIHYCpEiM6hlOD0xiudtnZEda2DuqPyAK1YoTsUYORUFq0yKY9wCj2FWorht4RSPY4pXNLlyICJ43RsOCOCK2ZUlVkkDIu84JArBRMMZHf5h2q7JqMMkaK0jBc/dI6fjWciGrmzcQib927hWUZDDvUMFvOybW2tET97uKzocSvued9mOuTVSfXJLCNobaTzAf73Nc86iWg402bytEplZiNqjriq8l1FHAJ0cFR1Fcs2oXU25dxUP1PrToYGC7ZHdkJ9TXPKr2N40jeOs2m/PlFwOcA1Q1DVLmd8WqCND0yc0yKxjMmUXCY7mplsow21iB/KuWdVmqppEbpeywossi+xFS6To2nvOx1a+MKnuFJq/BFHHbku2/HQCqFxGswIKc/WsfaNjcHb3TrdN+HnhfVWVbfxOgLkZQrgn26130fwP8GLAFFpOZMY8zzjkn1rxB9JjKBkmmjccq0chUg/hXU6T478Y6VYRWdveQzxxDajXChmI9yRk16GFr4eOlVHmVqWJT0dybxH8ENR06RptJ1GOa1JO1XjIZfY881wWoeG9Q027aGZlE6HnFd3/wAJ54xuJzJdagiIeBHFGAKoXb3V9debdyCSaTktxU4rEYVfw2b4aNdfxDmIdQeGMLLy44OK2tI1WGU+WgHPUt2pj6UjzOF2Hj061jT2M1mztCdr+xry/wB3V06na4nZI8KFmZhn271PGsUpQIduTya42xv1Zgk+44PPzV0LSxkKLXcF71yVKLg9SHE2wix7lYbgw4NSQKYZI9048s9RisyMySRZLcL70+ALIpDknHSsedpGbgXifMmlMeApGKq/ZhExJIGDmon3q6rFIVbPer0+P7NLyENOTj8Kz1+8EVtkLyCRmxx2FVjEJHZQvHYmnqp2gGrMeN+XO1cccVpCLE2UPsbNKixAZB5xTdYhDARjjjmtiyCrM7Y47VT1GHzJ854NdUZWI3OSvNPkMPylSMdO9czLo29pBH/rTyMV6K1tgMBjA7VkDTHWR5kwRnp6V1U8RybFclzgLe5nsHMUkWT0PvT7V1E5dvkbrjFdHqVnHcTBtoVgeTisy70l0ud7AFPbiu6NaMt9CbNDJOhZ8bevTrRDJy207Bjoe9MfKSFVLY9DUEkbpliPrinZMfMTqjbCS4xntTDJg4yait7ld2yVWANDGPccHj/dquXuF7nHo7GPnpVyFUCAn7x96xo2Aww6fWrlvOylVBr6JnmmwiBkLKCT6Vo6XpK3MMs8ku0IPu1jwSM+VLYq1FO0Ssu35WGODSTIdyyJhBEwQ7jnFVbI/vzuB2k/SmI+5SjDaOtT6SUYyCXJXPHtUVLWNqSN6JlMkcR6Z7VuvAqqqxKUOOtc1CoVyYT8w6V1cEEwhiFxIF8zuK5WzqM19yDB+ZqkQvHIGUDI5q7dwiCZVjfzQvJqK8eCWPdEuD354qHI0iM+1s3zTrgNxxxUUmMOQqlcVDNIjJjALDvWcm+SRhyFzXLUmzVRRZiluJWaJXYZ6cVat7Eqw83JJ65qa2jjSEFT8+PvVPabjI25y341g9TRWJkWJEMflc9jmrEVu1tG5Cjaw6dagWIOSXJAHpSqWLFbZmI7kispaFIsNavFbpLkgMeKtwKAo84bhjrUaWUjwIZEYqp55rahtLVooQIyqdG5rNxuDdjO8hQwMK/K3qac8UYXlSJPSulj0yCTCKdqYyvFRxW9urMjMC6H0rCVNk89jmgTC20jbnpnmr1rpc80P2g3ChOuNtdNPaQ7A4Ck46VmPape7kMW0DuDWUoSK50zEEUUgYvIQQcAYpDDIoDxdPXNXrqS4jjECRq6rxnFVooXbDyxfL3ANc0m1uaLUgljmjQvn5T6CqTzfLkpk9zzV+cvGzKI/wB0egzSSW0iRhhFvTqR7URkluVY5y7t0kDPF8rdc5o07WJrGIpcAYPAbbWz5SPK2yLy1PbrVLVbNZLdo3XjHBFdUakZe5NaESj1LP8Aau+MPEwPqKmh19IAWli+lefy28tncfJKyoe1IbuUIVdi3OOa2eBhLbVHPzWZ6KPENk7JLtJkB6Zp76j/AGpKxQGMJ2HevOjOAF5ArofCts9/FcyITuUYXFZzwUYLmQXR16hgkfzEA9ferF7+9hj2Mfl7CsSwmFvL9nn5lX1rZgAVg+QA3UYrlUHF2IkzbtSpsEI5YCqsUYmZyx6cVVivHtXZowHjbsavXJWWNJFwpP8ACO9EkZlWSL5toXHrVSW3CglQSp5NT3MbhwS3Wm27BVYN8wrFysaRMC9iG4+XGAO+DWbcIfs5V9xUevWuofLKQMAGqM6nO0gGtadWxdrnLC3jeMnZlsdTWa6NESOoPYiukuYikmEzisK9STf8w4r0aU7kyjYySm8scYpvlqOOauSREd85qs1oSxO412xkjNxPO4yyEgNkY6ZqeLfIudwGD61VKAkkdR3zTrY5bGe9fRtHmJm3aebkbV/Cr6CUP8yYrLhZ0KsHO3vWxZyuOfM5I4zish2L0KqsOSq5I5p2jwQGOVi4DbjwamtLN2iWaZvlb3FQWCRw380bEY+8BmlNaGlN2ZrWtvamJzNMYnB4461sxWyXDQeTPvyMc1hiNpGKoA2fTFWvs00CIVZ1I5HNch1I03H9n3ckb9D1z3qpM86xNtjPlNyCRSXVxLMoedt7AYBpZNQlksEgbGAOOKyq36FxM3zWSMjYD71diKQwgcNuHNUI5EMm2RRn9KvoyR4Y4b0Brla7nREsrEmxdw47VdtbeJ3PljfjlsDpVS3gvLk5KhYhzngV0OjRfZ4SXiXDMAWpcrL2JbS0jKk2y5PetCB1WF47yJU7q2O9TyXENrdRoqFYGX5iq5qB7qLz1k2+barwxx0o5O5JYsbb7XteO83IvBjxUepGZJPJtW2RD7xA71JbeQryT6ZEGGOT6frRDcyOkiT7VkJ4FQ3YVpFjTD5SebcT+Zxj5hjFMhto5XunjZWDHI5rP1K5kRY4d3zt1AGavWVmtnBHPJnL9s1jN3Hy9yS1mjnVIXYrNGcdOop+qX4s3igtE3M33uD/AIVWnEkd20kCKFYdalF2HQfaNuR/HgcVg9A5exPFBPGgaROGPOcVPKscELFSC3XGKpy6iYTHGzCWM8g4p9pepexTF4hHtJAY8ZrGdpFRTRFAtlfRu5zvHUEY5p9vYZAK8LnpU9lA0lqZ/KRDk+2atQXsUiGNF2zDrxUqlEbqOJhX+ls142xcqozgd6oxxq4MUkZUHoSK7TUIXWGO5VQWH3hnPFc9dTCaULbgZ6nA6VhVg47FQnzHH+KfDe2289Zs+1cWLUlWIYkivStehmEBRiWBrkRYi35cgsf4c124Su+S0mRUjqc3LbszRqByxwK9b8DaL9i0VZXDRP1LdzXARW+zUYJMYVXB9q9h065STToVLKdyjgV0VaraSOSTaZz76XH/AGnLcjLs3rVhwxHkYCg96W/Z0uWW3b5uwGKLeQwgvcgO+PutXG1fcSk3uP0+2syZBeXIxH0FTvKNreWVEfb6Vzs+z7W7OhVm5A54pzlmfHm7faplFJbmsYMuo7PMd0mQOlL9oj+4H284NVrYDO7eAo60bY3kZlxntmuSUU2aqJo3yRJEnlSqSazmO/P7zFV5BKkZJOSfaqss6xgGNjuH3lxmnCn2K5bD5QoDeWdxx3rOmjlKHIGKf58sqlwh8vucVBNdochycduK64RaBlB4tzcAcUhtx3Xn609ZYQGKt8x/WkFyDzhfyrqTZm0jxqQYG4A4NPt5FXcT1HeoxI4jwAcUMh7Dr1r65o8WzRs6UwnLqxwD0NbmnwTrgRRiVVP5VyVhcm2nCvnbXQWOpPBdpLDMY8ehxmpsDOlE84KARlfXNQaqqQ38UwzudcE44zVr/hIILjy1uCrHuTijWbm1ltQjSp6rjmhxughKzJbGQtIoZgDmtu7RECjcWyM5zXH6ZcRyDa7AFehNbNtbi5uVX7QIweAa45rlZ2xldEzAykoVzUVwqxxfKcjHOaW6SS0uijPnB4YdDVS4OTzyDWEjWMrEkGFQsV47VK2WkUxjOOcCqkcrF0iDZzxiuk0azlRjPHh8DpmsnY6ItGnp9vHJtlZyIwASDXSWd3byxtaC2G0j7+KwYMSxFxDtK85HerVjcSRGV5JWZSPl5qraD1exfil+zOCshaAcFSOlV7pp4G8xFV1c8IKpBzukYg4I5BqtZ3LeeVEp+meKxl7u5cYM055LmVv3MQiI5ZQetBhaWUSE7JVXFRFvmyHI98801bgl9plfaODXLUqmiiW4FkR9wUPIf4jUwluPMLTsPQDPSq0cIdgySBh3yelSC2XdlpA47qOa53UTK5RY4Ji4KPnJ5zTplhjkaJ5CN3oOKUMFbqcf3RT4yBCQUPJ6msZSuNKxFp0sEMzQrJ5jdgRVi4D3VrIijymHUZqnJbpbz+bEFLEdR606GWac7ZUA56setZWbegNGjbyXUmmpavjavUqeamtpF8tnim3beoIqoZDaXqGKBJGx1DDmtKY27WDO0Iikcf3eldMNNzJxRDbarNKXR1xCBw1NgtkMvnq2DWYUkVlVbhjH2Ga2LQpHCJJnHHGDSrLmRUYpFDWJIxC20ZJ9a8+uDulbOdw6V6Vf2omsriVXVWVSwFecWbtNI7SKd2cVhhlyJiqM19DtIJEZ5jmT+EGumilWHTGhVR5jH5Wz0rB0+C3t1NzcPtCjow5qaO8jmDOgYR54OK0ck9TlkrlxovIRJnIZ++TVc3Av5y7kps4HHFZ17fZkRRuMf0qe3nbYA0ZCnuR1qJXWo4wNy1jhRBJcuXY9MisC4gnmvZGTHlg/pWk94Htdinay1lW+ZWbdISfeso31Zookk3mptEcea0LfyzBunOHxwKS2n8sBV6DjiprGFLq9RZ8BByS1ZSl3LDCpENxbJ6UyeFZ0KRKN7DrV+4a3FyyYBjHA+Wo2RXU7AE9DjFZpvcTaKscMEVgIWf5jwcDpWBPBFHfKQnmRqemOtdXbW0NvIdwWRSOeO9FlHCbmfzY1CkccV0021qK5yE1rFd3ir5Hkq3Aqz/wiUB5N4AfpW5eyq0fCA7DxxWflZPmMYBPtWqqzWzJumfPQtXC/ICfamIroSW6+lbKlVIIJP4Us8McybkyG+nWvuEeU4ox51RwpVM0xYjjBJ2+lXPJEYOScelMwwI29PeqRk0L5KLZjEp3Z6Zp8YJQfOxx2zUZLCQZHHerKbVPy5wabFYsROybWBIPpmtnTdWRCBLwQetYpk2AHH1oU+fkrg496xlC5alY6ie5eY8SAr9abHNumUFy31rD3SKFZWCEDpmoXvJlcEYJrnlRNoVUdJprebrghQKSemT0r0vTNKZ4WQypHJjnkc15p8O8XWuC5lz8nYeteskxtNuQEFPvc9q53TaZ2xd0UzL9l/dPHhANuegP40+KID7pVhjIGc1aS1DylZZg8R5UZpjzKp2omwrwTntWckzWJj6vcOwMEX+sfjI7VFptr5EZjY+Y5PXHSlZ0kvWCHzJOmF7VsWcCW6EyFjIegHNcdVs6YuyM6aB1UM8nljsDxUcj5j/dyhz6Lgmr8w+0jdMhESnB7YqEWtoZA9oXZl6hea5XC5aZWiabyi4ZtueRWhYyMGByFz2NWItixkSW0oU9flNRTwwiDzELoy/3hUuhfYG0zSLKighUL0zziB++Rjn0XNM05vtNrtfG8d6cDMg2lVYCuacXHckZJEFZWDNg9BikEbMSc8e1SSmKWFG5WTpjHFNTEIw2OTRCQ00NbaXQIxVx3zV9ppblDCCpA/iLYzSR2yvC0rJ27VCGEa/6vcOgxmt1Imcox1ZXElurlSzJKvvx+dSwM1xP5e5Sh55bite5stOHhKa6uZWj1DPywhc9/rWTELSJEUlwzjrjpVSehhGvGbsiS8nihtZ/NJ4UiuVt7tFiBjtc4OckEV0uoQwyWE4Zl2AcE1zUdzttDboqs2etckUrstjhNPezqssQEftVm7URRLGPlTipdLTZGC4U7jj6VdVbKKY/amZgfuqvrUTnroQ0VUmjiiQtArRoOMjrTbm7hmiDttjY/dVe1TzuJmKqmyMfd+lUTGi3G0KXHfHapi77lKJJZRi8jlYHIX2otljjjKgcZ5OKml2W6AW7kK33sioEk+zwFd4ck9BTeuxSLEEKB8iZcdeSBRIss0+6PlB/dNLDHG6fMQD6Z5q3HdLZQNEI22nnJrJt303BkiQNNF8jKpHqcGniZWjVJEVXHBqrH5c4BjlbceSBViNoyRGSf941MdGQy6I0hALFGHXFNuMSy5iUKCMcVGoRSFZsj1FENwfM8sA7T/FW2hnYSGARxGOZQQT1Ipf7Pzyu0DsKttDM0WOCR0NRgSgYI5q4Eu58ziIr3BNSxhhExI/KnOih/k59RUhKRxMGxntX3dzzGzPlKmNm/iHY1WFwAQrDipLhwxO0gVVk6gcfWrRDLLKN4Kn5TSPhOpOPUUsBXyvnJz2pM7lxy31psRIpDrtQA8cZrtPDVn4RuPBNzJcX1zb+JI2Y+WUGxh2wc1xpmjITaBGyjDY71DM0JfKkjPXHespQUupjOnKT0lYvGSNm+ZuOxxSyPEV+U8gdhVASZOEDMvanIsrDAUj61DVlZG0Y2O4+Gq27STEcNg84Feh2roZg0sxU5wQe9eV/DaeWLVZYmyAVOR2r1qwitr2bY/wBnicc5DYY/rXLUi7no0tYmxFp0YmWUlfKHK8dao3u2WRlUDPqK04xcPaiF0AGdoYVnXdrDZsF83c3c1i1bc1i2Y9r5VhcEeV+9k4DYH86vJK7XkGRgE4JNJqEDTwpMqgPEc5UdRUstrI6wvbPh85wa5asUdcXcjuTLLdNajIU8/hVC+u59Gkiayt0YNwxPH9K0C00V+ZbmEYK7d4HSqurRvd26eQMsDkEVw1J8pb1Whr6EfE/iOVY9KsohGo+d5nIQfkDWjrOj61pCrHrWnxNHJ0lt23rn3yBWL4Q8ZeIfCDzxx2yXtq/PkyfLg+oIrV1H4k6j4sQW0unrYRxtkj7xJ+taw9m4Xc9TgnLEqekdCC2hMBVRHiM9DjpUrpsuWDBgCOOKaI7g2+2KdXzzjjIqTUna1037S5BlVT1rmqRU/hdzrhdr3ivGIyjCToDmnWzwSRttVnI6ZWqemXMdxaLLOmH7pjrXUX+q6dfabCumWH2V4wAzsDye9ZQo+YnNp2SMSC5nVXjwyj05ptpcEKwlh+6cg45qwl7uYI1vE0h6EdaRfLW6G8lT6Y4rTlaKsmhJ7vzbSSScyDdxgj/69U4rdNoZ3LK3QN1H0q/IPtEjERs0Q/2eKrGaK4mUrhRH1ArVJpE35dkY/iHy4tOKAPlj6UminSh4fmVhjUy3yfL2+tR+KI5Lk24QOElkWMEjjk9a7PxzoujeGrHR7eziZtRf5nPX5cd/xrKVNzi7M5qlaPMotnIwRtHDvkACk80XAiZVkMZODxxT55nlhQSRYOcjApNsrwbyoYA4wBXC009TpgtBREzlWUAAjHSnjZbYeIbieG4pLeQRMxI6j7rVds7L7VatIzpGQ3Ct1qdW7FFO3eGQsZYyeeBiobmCHzdyKvJzjHSta6tGt40DRlWI4JHWkVYYolIhDu33siq1QrlCS3WSdHZAoI4IGalljHllZJskVatJbRLZ1nEhmBOBjgVVjiExcsTt5wtTuPcRoo1iWS1cLIOq+tTKfNUZzj6VVWF2j3RI+QecipoxJEw8zIU+1KUWFi5aFmDIiqcD1pxhmYbsqpHbNQQF/NIty3rwKsQsrSlLiRkY96SdiGi5YCYIWEgY9xmkd5d5zmqixmNmNvdE47ZFILpu+4n/AHa3jNIzcT54eVcgqB71BcPvO0nj2pkL7zk8g1I8TFMgYFffHjlCXABHb1psa7t278KnmQEcKQBUBbYecke1UiSRV45NKoAYZPB9KhRi7cA1dt7bzW2uvzHvSbGQEFZGUKGNWLfTTKdz/dq6liEdQRyO9aKBhGFDdO1Q2K6RWWwjCgItPNuqMF2Ct7TItOe1lTUHnS6xmMrjb+PNUZYsOP3h44z61F7iU7mfp07afrkLx4VWIDe4r1rRbuya6Ek0JDjo2a8pvoCE3LyRyDXU+DdQS+jEFyAJMc+9Y1Eztozuj1i1kMsjGKRCMEha595JrkyrdrjDcEU/R0sVuFKF4Z14z2NaV9F5xdVlLgc8VzSOmOhUtGDxvGT8uMc1mQwXdjqa7pt0B6Ka00sJ7fLoR5bDkZ5pdyTBoLh2J6q2elc80dMZC3t0RcRpcRqYCOSOtQ3VoCiSWL+/NQ3VlewkFGWeH86hFtcMB5cjQHuFOK8uvSl0NkyO/mmt7NpZAGk6DimaNCGs5Jm5kc5OKbPYXb/K8zOvuauWdlPFHiFsN9K5uWysW5Kxd0+4dVVVwZQefSneMJmWK3hGB5n3sVNaxJa4nuMB+4A61jajcnUL/wA+UEKOEFdUKa5TC5csvLi4cfIABxV2eYNGscWY4j1IFLp0KyWu/Cke4qxCx8opIseAegFR7HW4cwWUFsqM6NK8oH3mpocTElVG4HvTreZRdCMRuqngntT7toopQkUUgz/GK6IQS3FzIsq4iOFVRkVisyWsVy7ouSeCvar1yjeTgOrZ6+orD1XNvCiO2/zDg57CnLRC3KZ1H7ZFEGyoikDAe4rXu7yfXL+G7u52cxLsC57VDBZWcUDF3LEDIGKlghhWFpYcBj0XFeXVdnuR7GDd2hmpYkZRbhl2+tNWTy7YoVGX6tVu188qWwMd+KhCTsZFlbETHPHUVz3voXzKJG8CCBCwZ5DyCKst5M9qpzNBIvXHQ1oXNpb21hBcWs7s44Kk1n3NyZoV3uMZ6d61imtSVIvfavtKQ+dn92MA461ClxGl07OBtxwKjuLppLaCLycY4z3NF2iJED5bMMfjVSvIJSsQSxCOQucNvOcL2q9Clsw8uNJDKw71spaaJrFjF/YNrdjUI1+ccEZ9xn61kwCa2ufNnDxsh2spGKTpOJnCvGTsihB5ovfs6soycEt2qe9tp7WdBKFlTOQRV+CyE149zsDRt0NOhD/2iMsWjU4KmlZmrkUS8aOJIk2M3BFVHRnnLSZAHpXSarBA6hokUMOQcVRRfNt5ImAz13YpuIlIzPL2pvjY7h2oF1IBgxR5+laDQwmBdylSvoOtNVYcDDL+JqEUfNNjbmRGyyjbzyetTqFcAbiBnHBrNinVeADz6GrkTgr8nXrX3/MeE0XWtAkPLIyms1rQFiexNTy3IIC8/nQk5wB37Zq0xajY7ZArEIQRUoBGM8D2qa18t8i4JHcHOKYZER2wQR2pNiuWbZJZAzAO+Op5qZBlT+8QEe/SnW2oyw2hSJEVW6nFZk0pDHZ1PWpsBLPer0dtxHQk0p1M7Rghvas9kDEFuaR48nMa4pDsW21l+VMWfqKbaavLZ3cV1HHja3IxxUMSKZFAxnvWutpFLCVwF4/OkylLlZ6dp1wupQwXOCVcAkJ1rZiujZnCwSc8ZKmvKfD2sPpU628shFo525J+7Xq9t5eoQI0U52KOHDZzXNNWO6nNSRYtb4SMVufM8v8AhznGaryaa6zMyuSjDg5p6W09oNz5niJ4AHT8qs27jzmKOCwX7hNYNG8XYoJPPZ/6qZ2IPKk5FTHVWkJWeKJj6qvNXZLYPaCV1Cbmxjuaj/s8qvyQu+ec4rCcTRSRA+pomxViwT6r0pLvUbqMhIIM55yFNWGREUB7aTzfQ5/wqs7vE+ZIpFB6CuWUEO6KjNNO+64bJ/uk9PwpbTT7i7LuqP5Q4yBWvZ2DSXXmPG23GelVo727bUvssAC25bHyrzRGCBvsbXha3gjtZLe4nTcTxvYZqW90+ztJ95n3Fj0DcCsa7h+y3oMgIXPU1p39o5jhljQvG2M8ZrRQRF2Vm/dzuHkJhHIweTV9NTM1qUNuitj5FK1WR7S1usvIkjAcITVLWNWa5j8tYlRicAp1AqmkkON2ViF8qWV3KSjJIzgVV062e58y4nUug6bhUt0k04itkTKsRubHOKs3bs7RwWx2xoPmIry8TVa0RdrbEdtay3DMYoQNvYrxWmbYaYkDzRq4LZOFyKpRXtxbuoQDH86mW5kmnJAJUdVPSvO5m3qLXqWb2WOa5aazdFVlwUHSqEdyW3xTRd+Din3E0SlWEYDewpsLxygse3pWq1JC3xbOxZQ2f4WqtdWokldgvl91A4p0u2TcAxGO+aUFPs5GWeU8A5q+S5UWOFzO0cYljUKOCwHNSpI5k8uFlkjbjJ5xTRBJDDGN28OPmB7VEUkjfyrNCzHrgZxStylNX3Og8O6i2hwXy20sQmfksSMms8tJq0vnXhIjB+fYTyKghsyJlWZCXPUGrrubRWggVTn9Kp1TCVGO6Olv006bSI5fDjykxY3xcnjvxWPb7ZgZmwufbBo0yGSyTzhPsZx8y8AUTAEkwgjufQ1Lq8z2JhTlHd3I5yxJLcj0qKAB7hAkbDPXAqzDDJPMu9sKOatCSITCS2Cloxg4NF7mjdjOv2SKVY3jfafaoRbW7DOwDParrTG8kcuFwPaniBQMYp8o1Js+QRPGIsggt6ilW7diCOlIlvuH3fwqeK3ZSAAAK+7aPHsxvnueQuCPalZppWGVwfWrRtyCCKf5bY5ByKQyqFnAGWyPrUoaYDDIGHtVuO3wgcYIPanhCCflzTvcNDOM7ox6j2ppkYnJyB9avfZJZZMLDz7CqNwpSVlZSpHUGgWhJAC7YAyK0HsZV06S5CsFUHkVVsIxIUDMEBOMscYrotSZ9HiW1tbuK6hkUM207ufxFKzZEr20PRr34L6XcfCmDxV4d1eW5vBaLdSL1R+Muo9COR+FeYWjIwQBjtYc5HSrsd/qFnorw6TrNza2s2TLZRzsqHPX5BxWLBKYgDnI70SiZRcm9Td0WHSFvZhrQeS3CnaE45pfDOvf2NrZhldzpbkgAn7o7VktMJUbA/CqkhSRcMR9DWfImdEJcrPZU1uGFPO0+58zJ+6xzWzp13bXBE8gQTkfdA5rw7QNTGkXP74h7duoPOK9F028W4hEtiPNU9SvJWspQO+E1JaHXXOqlLtIWZApGRuFPnupZZV5eM4+XbwDXOLcBrcLcJko3VhzV+Cf95HPK5EKDGDXPOBqomrNPJFFG0zbpSeD1xUtkft77rlvmU4VemfesuWG3uz5sV6iqfVjxU9jFDFKXmnDRp0IY1g6KY7G3cf6McSzhA3G0cVSt0NtqQlijbyxg7m5FQ+bbaxN5ZBO37pbP86v2lj9l3mSO4dB0BYkfzrLksJDrmyXUJ2lup1RGPFReIftcMUFtpt2oTgZbkVnxSX0zTGaeH7MD8o4yB+VT6TojatqEENtOXkkPDBjtH9KpJDc1FXZOrT7VikjtfPxy22qbaeLeGW5mkV2PTB4zXS6J4Pnn8Q3Nnq19Ewg5AVuSMe2K5bxTOtrLc2sZCxxuVCk5PFYVpcqFHEQk7Ipy3xjg2CRfPY4AXsKj84x8BiSeSRVbSkT7atw6gnGSCM4q7fXI+0FsJsIxworyKvvM2JYTv8AnZvm7A09P3koCZDegNZ1u7iTdv4PStFSImLgjOP1rJQ1C4ySceeY5VAGO9Kg4xGwGfSpp5bd7LmMiVj95hVPd5W3Pyr/AHgK3UQbFIC7kk5Oe1XDaTpaKIhvVuQR2qpbPE13tlcbWHU1bhumtJJbeOXMZORg5qopDUifTLP7TDKHkKyJwQTVa2L2Mrsr4Oepp+5IbsSOzBGGTyeaka5t5ZCqoCjdyKUooRPbSTXrTSlwMcZxTZZAibVyW6FqHVo49pHlIR24z+VMiZLeMqCJGbkZOa55PuUkXE3eQpkLcCrKTGWEiIFsVVTdOMFwW9KnthMhOF2oOuBWXN2BotWk5kMashGOtW32WspMSKA/3uOapNGoQvDMPM9jUkBn8tDdEYNbwl3MWrk0zwSIUQbQR8xHaswWKkZE7gf71XYVTMiqQQTUqpGoAwOK1VmLlZ8l2yYXsCfWrXlbWXeMg+lLCihcggmrQXcv8q+3PLbIRGrYO0rj170pUYJI49qnLoyjfwV71Wu7qIcAdutBNx8KINzdPTmlkuNhAYD8qoi7UMCW4Apkl+sjAbT9fWnZCL0krDEgZh9KzrhjJIWK59zVjzMJuIOOwqrK25xjv1p6ATl1KJ5a845rtdE07RYdBN3fXEVxMwz5Kvh1rgY2wxDHipCwXBVsClqtg1TudpejwXd6dG1pc3FrfAfOrvxn8q5Q3QiyiYkHYiqjyoUyACRSSTqqb1HP1od2XKV+hfN3EVHlqwcdeaiWUYYsDzVFpQwJ3gE9QKhE7KMKc/jSsRY1CUlHQ5FLoviC88L6ol1asXt8/vIjyCKyzcngMSKguJDjpkUcqe5UW47Hu3h/xLp/imB5bLYl0nLRNjI98VsMz3sJguQiqo7ACvAvAKzr4hWe3JQKDnsD7V7da/6dbKjttmrmqqMHY76VRtalqBbiIC3KpJAOdqqA350+3SNmcxK5GcMmTwaZIb3ToVbI8rpuJqz9pzYxyefHEjn58g5rGTvsbNt7HU6Rp8UVqrw7RMRwOpFUZRqaTuNTu18o52hRjArKt7iLePs6SsV435ABqy6vM+5nB7YNZtLqTfuWEuLWFFicozt7dRWpbRQWarPFOIWXkBDtar3hG1lgWe+tbq0DxLkxz5549qzQ93qF002yLeWLEqTiuWpOOxldN2ItdjWWSO5L3G8kE7XKsR35FVfFVh4b1KGGHw/p99cX6sGmkDMcDvn1q3fWxu3LSyhZF6gDimC5ksbOV1TCFcFhxmvPq1nHRIUoK90c2jmJfLT5VXggjmomdLidQ5AQdfSp9L0ua9+0XltIPKUFtrHmqkcnmGQqCwXhiO1cktdTaEiFyRdFYWyvr1q4okDKoYvnrVSaKOSBnU7CD6daiiaaNgI+VY45pWutDa7OgkPmWWGkRCD0Iqr5pdRCSGGO1PlKRwxidxuPpVfdB50fznn0qU31EP8AsybUBfLg8rnmpXdJrpY4kI2rg4qC4McdwGiJwRg1EGENxvDE7h2rW6KaN+5ktoLRBFEzMRhixzg1XCbERokJA6jFS2unwT2HnS3SxyZyFNLFqZdDAIWZV4Lr0qZNPqIsafI88nnXTAwxnBQjtSMbU3vm2y7kY9ual0yGyvNPu5Xm2OucKRzVCzhZ4FdXA2njispWQ09dC5eCJbvJyh68cVZXfJCRCxGfWoUuXjDLcQ5Y9GHNKl2qxEopV+hU1i0i2ieODcAZAQB1I4pWntpHWMzZx0G6kKSySoTwjVeS1gQgZXefYZpxjchu25FApCuqnr0NSoFCgE5P1qCRGjcbzhKtLd24AG6uqCtuQ9T5XjnVH2hePpS3V0kak7weOgrNlujlhFjJqptkmzuPSvurHjlqa93fLGrHPeoUieQ5c4HbJp1tEASu3n1qyEIPzcrSuO5WMQVcZyc9KkRCQN3BHSnuUXqOe1NVGlY7Scii4XELBXYHk/WoCwDHALfSraWYLZYnNXIrFAoO4DJ6GlcZlJLPuASIke9O8m4llOFAP1rda3WJl28n1xT0iXeAcZ744pcwrpGBHpNxICWlC+2ealXQImHEx3/U113hzw5eeJtXWw0jyVmILZmkVRgfU1W1nSbzRtVuLHUIlS4gbaxRgw/AjrUupYnmRzMmiQxnh2Zqf/ZiRoCOa2Qu4Yxk05oc4GPyqHNsdzn3tkCHcOarTqUh68ngCuhubcSEKFI9azdStWDQoO7D3q031KTOm8D6QIrSO4kJDlskZ7V6GxR1j8klSF4xxzWN4Ujh+xRRtIm8DHpW2bcwuY7g4iblWWsJ2b1Z1xskbVpO02mrHeHBzwp5qvLpz3n7uFeB69Kk061MypGtwCi9Nw5rbt7OZMpje45yvFRy2KUrGTbaVGkoE0nlSKAAc8fpWxBZwRqBuOOrOASKrtBulDXQKrnABPWtuF2WxmSJUEQHBPWuechSnfcrXFlBMgFpG7AjBcdKs2+mQwW7lbnyHUcBs81RN3PDEohZc4yQBU+iWPiLxWpxBFbWeSq3Dd8ewrkdpOxi5pEUk18c29iEnmkO1VGMkn61sJ8NNSu7RXvNT8ncu5oewPoTiqF7Bo3w5Qahr+oPf6wp3QW0IxuPauE1r4v+MdXSeOCK1srKQ/cCZkC+m7NOGHp6uqmYudWT9wqXCXukXt3GI2WHJUOHBH5ZplvdSG2ZRjYT8zCuevtYvJ+bg4Dc896u2LzXWnzfY4dypgyPvxgfSsa1Knb3Ttoppe/ubJkV5FUSLHHj7xB61A5eSYGR12Keo6GsaXWIfKjSR1UKeTVq2vVv3MUJWQAZwlcjpNLY6Y6mxZqbjUIYokaVz05q5fx+TOyTIYXXseaxrC4uLO7Lwryo4J7VJd3s15MXuGyTxnFZ8tizVtonkXcg3r1ppaSe4K+XtK8cmqVvdy2sJVWUg9AO1aejW0t6klwki71+8pxUySsUkOuYJTMkMmQSOK0dO1H+zYXtvK37uhxVJbmQXBLENjjp0pqQzTZlT+FskVyzDluaF3anIlQbQ45AOKrLZXSsU+6pGRzU0iPLa+aswUL2ot7S9dUuJH+Q/dyazctC1ZCJIflQtulXtVyFkMu64+XI6YpbG0iGpAzuAzDGKfd4S6+RMhaSelwvfQs29yi9DuC9K3IrJDZreM6jGDjNczFG8iM64UH2q15s7W3kRyZj6Hmrp1EtznqU29maGoot7Mq2zKygZbFQDTgBgkg1HEn2WPzIGOehz3qFruXcetdKmmTFSirHyZAMn5RyfWrEMZ5bII7io4G2HqCD7U+NSrfLnaea+8bPJJC258jjH60hbzHAGfrTQC5KAbc1dtbZBHhuSKgCAwI8i7eTirUdsgPJINT+SYnVgABjg8U9EkJJIBGehoC44QoU2rnI75qRFXb7jioTI5U4OSKqzXSg8ucnrikIvl1fsc1EzY+Y/e9azDqZQERnH1GartfuzErnNDiVymuZlWQeVK8cg/jQ4NKJIjIS8rOepY96xnnnkzxgmmMk4wck/jUuNyeWKN6C7iWU7Gzj2pY7xHdgzYHsKxFsb2O1+2eWPs543eYM/lnNMfdGAd2SaOQV10N93KruJBXNQSzI80LY4DDisr7Xchc7QR9ahWeVrqEyL8pYZwabjoOO56/4aNrjbKCAV4IrsbSG2exZgjZX7pJ61wdgVt4ILm1bIHVSK7zRrptSgDsUVkH+rCgZrlndbHTfQs6Y/wBtUxRMIpo/UZzWjfvLpSxuSCzjDY7U23+z/Ikfyux+bC/1qjrnnRS+UpzH6sc1hOdhRdxJrvz5Vi3ghuS2OlQXsq2swghnMjN6is/m3idnJ2jkMOahQI9uZd5YnncRyK4qtU6YxTJLm5v4SUBUsRzx0qfRfG/inRYDaaRNZ+VnlZoi2CfoRU1taeRaLdE/fHAbk00WkhcOV2o3J+XGa5FUkndClSpy+JHPamb3U9ck1HXplubh+uxdoFJ9njEbNbKQMfMCa6K60+SZ90ZHldwQM0qaShRkXOSO3Na80nuzSEKcNIo4eXT2nYl/lTOetQy6eIo3WF2+frz1rt00pipWRiR0HFV5dEWKVdhZwTyuMUuaxfLF7nKaHPp+n6jBLr+jPqWmRg74kk2nPr05+nFO1rUNHfXRdeEdJm0y2aPa8cj7gW9uOOPc119zoMZjIOI0PJXrms+7sIZFVIIguzvjGaftrKzQvYxvdNnPWN8ZJHifcs3XjpV6C8stjxSpIZV5yDWnBoazXcTQfu2PylqmuNGj0q+5H2guOcisJOL1SN0rIyNPniuZGjQEEn+KtG3ZraaTbLgjg8dauLotvqMO21jNtMpyzjiqA0G4juWxO0oHBJrGXK/IaZfsb1Ldi6p5jHtmrKahNJK52gBuwqkLG+srQywIHAPKnFOsLtXBkulaKT0xXPKKaujRJF5XJjKj7p6itSW9Aso0B+6BxXOxXPmyOI23c8dqnDl5FWRGUHrzWEqfcLG1bwTXJWbZsxznNPkuME49ear2uq+WBb4OwcZxUE1xGJWVEbbnrWLi72GbIbMKvEpEfQ1p22nHyzJGxKEZIrmrTUGQGPP7vvxXR22o7hFFBnH8VOKs7Mwqc32RnnDzfJCkge9PYISSOn1qtqV/FZ3cThMk8N8tIdatSeY/0rdNIzdz5R2oc8gAdaI5Sx2H8KjPzfKOPpVu1iGfm5NfoTPIQ+GLPUc1cQBeike9NXYpHBB60/cC+5ycdhUgTtIwQFz8vYEVXmujEM9qp32oMDsjwV6D2rPYvK+WPHaqSETTXskrN5Z2/jUISSQks5OKmjjVE+YZNOReT6dqdkNMbHajG5s4+tSBEAwq8mnuxCEdfpVcSSYI/pSsIsqMAcCmSdd24/TNQyMwUGRuPQVFLcRqBtUk/WjlJZPLHO6bI7lxCTnZnio5HSMBW6jvmqFzcu5+XpVZnJ681SiTZI0JbouCFP61Xe4dTGx52MDVfO0ZJxTSfMGFzk9KbiUm7nr3hCWG8sw8k7KuOFJ4zXW6JvSZ3gcv2IB7V5V4A1OWx320ig7uRmvStH1M2rNI8Y/ee+MVxVVY6Vex1VhN8zBlIZDnJPWoL+6mv7rCHJX+GmtqJliYW4GXXrWNa3v2W6KKmJj95uua4pK5cYmq1w8Fq0d5ajcSec1bt9IuJ4IGOIo37AdqSG0uLsCZ3VtvYg1pW107IUbPmLxn0rknFX2NFKw5bBbWbyw73EceCFzwKuXE/wBo2FYsR9CAvSpbLfDCShCs3PTOaux3flRbZIAHPUio5F0Ic7mOyxljHaA4IxVi20/aPlbEvcGtOyihkuCYxtk/SnXcTi4wSM+tJ0mhqpYzTFtBSVAXB4OMU6S2ktXWVog49xVq6BSNcDJznNW5Lqaa1C5DKMEjFZSXcr2jOa1C28x0mkDYz90cCtAaTp8duszRN7nJrT1W8tp9NSOCJRICM80sdv5unss5+b+EVHL5lKozno7W3uZLhbUbNgBBU806W3hlSKILmbu7da1bbTYrMsVLecwqK1Cy3w8+PcE6GjkubKd0RLaxWEBdeZGGCMdajcQpaHMIMh5Jq/d5S4JCgAdKsWMTGIswDFz1rOULApmJbRC4tmZMD1WqL+GpNSs3lC7CMj5RXRWFqrT3YXKhDyKfY3e61Ii4yxFY8iexXtnayOf0/wAB21pYR3n9oTvcEZaMjgfpWBIl3NcygJ8iHAOOuK7CS2MMExJYSEkinQRBLVFwBkZJNYzUnK71KpSe0mcF5zwuWZcAVdttThlAV9ob1xWjf2cl2j7EACHJIHWsO50yVmJVchuhweKm0ZaS0Oi/Y1opY1jfKZB71a0+6e0JZR9M1zcxvLRQNpx05zU0WoebDtlG0p71m6LauhWudJ5/2+X9/jaO+MVC8VtvPzfrWfZuHwEcgHsKnbSiWJDnFYuKi9XYW3Q+c7ZAuMDJNXlKJnkkn2qqrFcHIzSxvlm3tz2r9MseCWyyiMHcRz3FZ17eEs0cRznvTL65KqI42BqtCueWOSeTQoksfFGeS7HrnipCT/C2KavzNhTtA605wM8HIqrCAknqf605iSOpPvUaLnJQYpwyTg9aLBckTaBhqgaSNScZzTLyYRL8xGewqtFbXNywkfcsZ7DijYWpFPdq7sgQtUaRTyY2xnH1rXitIolLBRv9SaniiDKTuouNR7mKLKc9QoH1qVNOmZwGO0HuBWukBkztOVHU1fjT5AB0IqXJ9ClBGLBpFuCPMcufStOG2tokwigN24qaOJVJwm7NadlassTO8GTnj1FQ5Nj0RU/s9hAsy8SqflrovDN3DcK9vqBKyr90Y60ksUjGD91tdu2KTUtN2TxtBuFzgcCspxuOMzorOQWzkNCD/dYnqKuRQkuJnICE898Vy8WpGBhb6qsiMOhKmtOC4hkfclwvlgdN2K46kLm8WmdnaRBHQwNujbk84rZjuFBlwwVhwPeuG03VEglMcmxlPQjn+Vb8F7DJCVypY8jHWuSdOwNG/lC0b72Zj1x2rQju4rVim7cpH8QrmrCeVF2g5x1BqT7TG4bdisuUnlZ0ss8HkhrcbZD1NJaXMkqskjfKOjZ5rn7e6JZYuDxwavWz/ZZMsVII5Gc4obuPl7mtt/foZJBt703VJYLdw1oCQ3B9Kybi4FzBmOQbweBmmyvM1puBztPTNYza6FKNi/d3cMSRybFz3FSS3wvI1MTFAnpXOf2ipkEUyAux9K17gPb2qPAiFGOCBisNUbJdy8CjBXaQ7+mTVuzmMLuqfxc5rBsyRepHcDAPYmtK/SKCUPFL8mOVDU02FtDXtof7SlkQsSwFCE2S7HUkIcZ61Dpt8luytHj5hzTfMllvZUZ8rJ8y5qnJMyfMaCLHaQmSUZ+0cniqtvZpHFL5HQncM1ZtFnmjSOSPfs4zWhtCQlFQDHB9qap31FzNGXeymeyXK5lUdqzEiub5QsitGg4yO1bzNFGFtlGXYdhTxF9lJVl5YdxiocbuwKdtjMk02C008CFw8h4Pvmsy00CS4umyzbV5AArXvrcm0+QYIOak0+e4ihJYHp6daJUYPdGkak0tGYd5pyS+ZAeGWsq2sbWeKX7REMrwfet6JGu712csoJ/Ota00m3hgn3KvPPNcs8Kn8Jr9ZcdzzabTY9OJltwQhPeo/t0x+63Fd7q2l2k0IGAFx0z1rmjoNiD9/Htmud0Jfb1N41oyR8yEqMbScn1qtdzhRtH3jWjdyBbAMMDHeucZzIS7nPpX6IjxJSJVB3ZYAsak3sGxjGO1Rqc4NObecjOPemTclLsoyQB9KZv3E84FRk8jJNI2XJA5oC5IJmYEIjsF6lRwKeZAYBJu2/Wut8FfEK58JaDf6Xb6VDP9rzunYgMMjGORXEOH1C44XYm7JHalqTdktpB9pnV35jBrYPXapIA6VCkQgjCrkADoKtW8p8vcRmpZaK+Ruyyg+9S/KgztBBqPaGJJAIJ6050CjoD9KRRZtyscTFlHPpUwQGMyREhe9UreRFUjGGHY1ft3Mse0gIvfPek0JtkscWyEOzZNXNOSW5Zljcoe3uaziBIWGcqvpU9pfrCwQgn0PpSC5uWzT25xM7+ep+Xit/SpGlhklkh3ODgsc1g6WZjLJJIxyw4J5OK6HTLktZSxv1L454zSaTJshbuSJpGE8AckAKCOBVK48PRLGskhUCQ5wG4FdE9zaFfJuISQqcYGRmsHUWg2gQltoPPy4xXPKNy4y7EE2jpa3CKkmGIHOafb2csbO6TsrA+tSz3aTqispVlGMgVHBNhyjliB3Nc1SnodCuWY7u7XKpI2/wDvGrlrd3S5IbcxHORWVGwEzfNxmrztHbsgZiWYdhXFNWKVybz7lnz5jKx9BULtqEbllndge1WI5A3zDNTJOp4fJ5rnk2NMpwzXg+aOVgRVpbm9GWkZ2z6VJKkLqGUFT64qSN32gqScdc8Vi7lpksF20eJJE+Xoc9at2ty8zBRNjJ4BqnjKksN2exqC4gfKupEe30rJtlqRvCWS3c+c+W7YOatxNDJbbpGbf1rmrG6hjt5ftOWfPDEVr2tzBd2a/Z8hhwy4xU3fUuxt6I9u12Y7iTYhHymrV7ui1eMQPujxwaxXSJ4R8nzL+lX9BjW4u41eXaMY5pcyIlY6a1vJY1fYPmNS21wbqcbvlbPOO9U7pJLO/wDKSX5cZznrS2gK3cj5BHrXTCbsZOKeqNC9t1h1COaJskYJAqzc3Hm3CZGQRk54rCN4y3MjKW2n3q/aut6yLGduB19aSkrmbg1uXVjmmL5j2xEcUsTBh5W0lgMdKdaXr29wbWTPse1LIZIm38Z7V1RSsZ3ZRazMu4RgiROelSWMVxeFhISCDgiptPuwZ5NzMJQOlR6XcTDWggZihJJBNQ4pMblKw+60pbuBl/ij7A1ykumyrIyhWIBrtNU3R3olRtqMcNSGCNjuJXn2p+xUtRwqNI+DNQuGEYj5IPaq8Y4GAAKS4O6bgE46VKg45FfV2OZk0cRGCcE+1EuSMAU4Zx8mPzpjOQcH8aYgER25bKj1pI8RYKSFifapHk3IEU5Hc1WmkSMYXOfakJiTyM52Ac9zWhaII40VuD61UtIGIDHvV7EgZTtyBSZSViw4wcD5gfSh2ZGwvGB0FO89McjBFZd7qSiTbHyTwTUpA2XZLlVHJHPvUP2vLAr90VSxu+Y5Ip8Q9QAT0q0hcxd+0Bz8yAe4FWzOzW4CYKj8Kzkx3JyKFPGFJpWHzF+G5WJs8jPBBFLLdQGTKAj61QYlFPmMOahEwwcrmpcLhodVpGrSmZFBXCep611NteBl86Qx7SRkBua8sR2J3RkqRWrpuqPZrtmG8HvUuFhqzPWxcwGWNIXDwsmXycYqtexpGoWJxIpbOAcmuWsdWhubbEbhJMdM1b0W6+zTyNOTv/hzWMrIpWRrmYzSS7IVGBg5GMVAkarH0ySecUbpLjzGDBFJ5xU6D5IoEiZmB5Yd6zkro3jJWJHSCGBDg+YR71JMizSQqExxyTU8VsJZP3mQF6g0k0BlBMTkleneuWcC00QXvl2Mu2B2kHcCnwXcUiKQW3emKktY4hLm6wFI6mqGwrduIVyvOM8GuOpSa1LSRqBXLHacKe2akDshCs3B981liScD95Gwx9anW4w4Cxs3c1zNdyuQ01yCCSQKmR0Knc4yOxNU3d0aJcAeYcCrFzp6xRu0swWUjIANYT0APJSbCqv6Vcs2Wxk3LH1GD71Qska2Od7SBumK07VH8wPIC6noGrKUl1K5rFiK7KsHReWboavX1yLaeFlAVyM8Vn3EPQglATkClmQ3DoC3Ke9ck73ugVmdNC5ubdZrl9hxxk9ak04PsldZA654GeawhdO0QjboDitC3kktLhMKSrjtRGs1oy0rD0aRrhoypDE9DW1CVs4Ad/zD0PSskTpPeNIqkMnbNWTPHNEwOAx7VtTqJhJXNyxnWRTJKd7Y4NWWuZJpY8qQnvWDZzrDEYzjd6E81qaddB54lbIXOcGu+nUOScbFq5uoLe4U+WcnjgZNR6W7/wBqeY6lQQduat6tc2xn3Rxjcvei4kDT2s0cY2DqK35b9TFvTYs3FmbmKQ5yeuKW3NqIUDNGCBzmrVvfWyzhHOAw+lV5rGBpWMcqhSeBmuiCXUycmfnuqMGyMZzVpFLA9Peoox8mHyKkU4QnOB7mvoiLgzHGBwBxUMm/gKPmNM8wtnsD6VNb8ks2eBwaLdwGlSFAfHuKjVN8vygFamuGyRwDT7KL96O2e2aTCJdibYoBUAjpUhkYL6n3p17AsLqok3cdqp3EqxAjJ4FBTZDdXWW2ryaqLGDycE0BV3b26E56dafLHLGymW2mijflWZCAapKxmTK2Ux/OpVjz2GajAVdqqpqyowd3PSlcpDVXbxjJ+lOZ/LQtwvsaepyCWFUbt/NbYM4HXNIbGli5y5GKkTA45A9aYMAfKBgetOWQHI4FMkmhQAE5H1qTqhDHp0ptuisyLjIPXFWb9oIsJbhtwHzFvWkPQz/OkhfMXXPfiug0/wARDdGJ4vmRcZrm2bexz1pwUMACcH16VMoJgpHottqaywExsCzc8Vr6JqLwg5Ql88V5XaajLZOFHzL+ddlomvRkhWVRI3Fc04tG8ZI7Dz2YFix3Mcn0q0uSoC8E1nhRH5YkYMW5xWiCzWuYkGR2rmkmaJk0tvGm1pCCAOlRQKgkL4yT0p1uvnwF58hqsNbRuIRDLhj156Vk13NkyrNKBK4UHJ7Gq6eaX2ogAI61oyW28uUAJXqxNTRNEYjtQ+ZjBrmnBFqRFDaM+1pVI2HjirU1oZ5lLKWHenRtLsTc45PGa3LeAQxF5GDe9clSmS5GdDYoWUEYWtdbdIkC5zjuKbGI2AZDmpAjbu3PauOdNszux1zBE9uCOuKox2+EBP51spF5ihMAYFNS2GcE55xg1zuFioyMpDH8ysGJB6gVdbURujyp+Xirb2EbEngGoL3TAIw8eCR6GspQubKZUgaRLmWYD5GOTWvayWkkayknjqCKzI1+UqwPI6YqJIHBwoIHvSUbFrU37d7T7fG+Tt7girdzOou0+zLlAefauWR9k+7AIBweK0Fv3s5kk8sMhxmt4VmtCZQ6nUzRoLYkj539arW00jRlXB2ofXrWmL6wubBH2lXxn8ay7J/OeVMYI9a9CnUTRz6vobkNmLyHcnYZzVY22DhmXNVdP1Ge1mKR5KE4KitN0DuWKsCa66euxzyi76n59Wt0QBHJgg9GParVw+IwAOayKnhlwQHJK+vpX05yJloAADOKsxtsj2gDnnNRJtIJ5JPrTmYKn3c/SgoIx5khYgn0Aq9CmPm/iHaqsZKKMHjrV1NjIG5zUlrQVjuBZiOO1ZlwfPlwpIA71buXCRnbkH61WRAYdxyKaQnYvjRJn0iK+iu4HcsQsAPzcV0HiK/0nUPCln9r1OU6/EPLe1SELGgB45x1xXHeY9tteIlWzwc9K1tY0J9PtbW5uLuKea5XzCFJJAPrUyv3Ia7FCAE4JJ46GrUbBsgtUUChU+9ggda0VEsGnBmgjxLwH5zTRaKMx8tSSTz3qsqBjuJPNF3I28I3QH1oWQpjABqhNiNGwzjBFXrGGwbRZ5LmbF3uxGijk1UlyVJxioo5NpUooypyeKTEi7YhzKqxjnHeor1mWZtx+Yda0NH1A28s8z2yT/IRhhnHvWPdymWR32hdxJ24oLaGRncctkD2qU4UZ2kgdzTIsbeDj1p+cA5yaRIxzu5xj6UI8sbBoZCGHPNKQD2xSZwcY4otcFodv4b8Vi8eO21AfvgQqsK9BsnBLhmwoGRXgkilcSx8ODkYrtvCHippZY7a/wA7z8obiuWrTtqjaE7npEcxWLYV696vXKxQxReQcynnrWOJF2kFTjHFXZZFaOF9u0cDiuSSOhMmiuXwVZQF7mnW2171dq4THzYpYYlEMrNnIHpVSCbYp4YE9655RLRsEI3BGApq7cvviVd+EPXFZEMgXYSGwT3rTS6WQhNuVPFYuCCxo2NsqD/WEpjIqad/K2SBgy9xWfOPs8QKO2D2PamM7yBUBODzWLp3E4mzbXAJLlcLjrUluTN9zru6mqWmhlgljcZHUGpbOTyM7gSCfWsalFE2sb7wgoAc5xmoPLEfU7wfU9KY12qsisGAI9aq3kxD4QEfU1zeySGrkjRxmUhQBmo3ReQcnFIs+11DLy3vV23jUg7gTn2pOkaptGeYEMZyD9cVLHGk0O1scevWrn2HLcGkFo0ZJBBxWcqLLUyKErCirubArQsA4u/MKHy8c1nsnncEKD7Vg/EHx1b+AdEWSZRc6ncAi1ti3B/237hR+vT3rXD4epUlywV2Kckldmv448daP4F0dr++hae7kJFraA4MrepPZR3P5V84aj8bfH15ezXEeuy2iSNlYLdFWNB6KMVxXiPX9S8R6k99rF09xcNwN3RBnOFHQD2rLr7DBYX6vC0tzyalVzemwlFFFdRkTQTeW3Iyv8qvZU7SDuDdhWXU1vOYW9VPUUxp2NNmRVBYgL0q/fo1tDasbS5hjlXcryoVD+4J61RsZYhdwSzRiS3Vssp6H2rr/iZ44l8Z3mnxQ2NvaWNhCIokhj29upqHe+wOc07JHGX+C6gZx3pzjbAoBPTtVcuWlY46cUsrOE4xVlX7j2kQjy+CT61LjDKWkLHGOTnFaerXGjrodha2UA+27SZpdxJJzWUcfKpIH40FFqIGQomQodguT2zW54l0ubSJ4bWXUUuVChhsk3AcZ6Vk6ULeTV7Rbx9loJAXIPIFXPG15aXXiG6l005tRwh3k8AUkkxtKxz5cNOx+Y84qQuc8ioFPXjn2p+fQ07EXJw5Kk7iPQVbXUdumNZiyXzGbd5uBuxVfRLX+0datLMsVEzhc+lX/E+lNofiGSzMwfaoOQc1LRLtcXT5Hh065xKqBhjBHNZE2cjDAse9aEOn3M1lLdKp8iM4NZtzhSOMZpJWGh6ErgMAT609yPx9qij6D+tSNtBBP86sYMpIGOM+9RMQh5PApWY7u5HtUc3KZ7Z5FIbY5ZF3Dg89DT3UqyyKcOORjrW34iubC70zTDptqlu8Me2XGcu3rWGG6buaV7ijN9jt/Cni53kS01ABQBgOa72FkeAOH3d1yeK8QwsiZHDetdH4a8TS2rR219IDD0BbtXJVo9UdEJnqxkkltWkJHyjBANSwohsvND4cds1g6dexXCbYJVdTzgMDV2GR3LIRyOeK5JROiMjRhYTwuzcMvT3rX0xFaIOWTP8AOucdyAAvBPWr+irKZ9pPydTxWMoGl7m87ATqsmHT3p1qw+3jywChHIHOKqzAi4QFTtPHStzSbKOCXzD0YcZxWLjYTkMnWWRkWEH3xVa4Lo2xgQwqw9zJZ6jIpJ8t+RntVm5KXMSvwGFZtAhIyJYopGHTg80l+R5gZGJ47HNQTJImwRElW61JbRl2KsePpUciZResbZJtryAHHcitaQCCMhNpH0rG89oYSiEYq1FcNNbKGFDikLcsJdFhjODn6VbvI5I4ElQ5B6rWKVImUJn864n4rfFSPwxp0mlaNNDPrp+Rv4haDHU9i/oO3f0p0sPOu+WCJk1BXZc+KXxCtfBeneTZ+Rca7MMJCSCIOM73H4jA718t6tqd7q9/Le6ncy3N1KSzySNkn/PpUF1cTXdzLcXUrzTysXeR2yzE9STUVfQ4TCxw0LLc8+pVdR67BRmjNFdVzISiiipAKKKKAJreZoXyOR3FaPnCRC6c/wBKKKY0yuCcZBHPUU7sOKKKChWKDHTd7UKfnH86KKBotREkfMKiu/ubRgZ9KKKLFNEScL15FIQeTmiimZk2ms41K3dGCbTndU2ozPNqUkjP5pP8VFFKSKshFlYIUDMFPYHrVadVJBNFFSiBq54wM1KvJJPWiiqGhrZLelMcnHI4oooGX30O5TRk1QlPIYkAZ5OPwqqhJA+Xg0UUiia2inupmitbaSdgCxCDOAO9VZyJRjbtx+YoorZUouNweiHWlzd2EyyW8rAKfWvRfDvjC3u18q7YJNjhs9aKK461NNXKhJnVQXMcyFQQS3Qg1paRK0BlyPujjNFFefI64yZpW9z5yBsjdngVqxSyvZ7iCu3ofWiiuaSuWPtJDOwMqkgDg9zV6Ab2bI+UcUUVnJA2TqD5gAztqW6/duCnVutFFZ2BMlks5Utg+Mg89KW3IMRUrz60UUS2KPJfir8UE0lJ9H8NTK2ofcmuk5EPqFP9737fWvn2R2kdnkYs7HJZjkk+tFFe/hKUadNcvU8yrNylqNNJRRXSZhRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The papilla of Vater, also known as the ampulla, is a small nipple-like structure located in the duodenum (first part of the intestine). Bile is coming out through the orifice.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Silvano Loperfido, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24257=[""].join("\n");
var outline_f23_44_24257=null;
var title_f23_44_24258="Treatment protocols for lymphoma";
var content_f23_44_24258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment protocols for lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24258/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24258/contributors\">",
"     Tim Brenner, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24258/contributors\">",
"     Shrina Duggal, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24258/contributors\">",
"     Jim Natale, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24258/contributors\">",
"     Scott M Wirth, PharmD, BCOP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24258/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24258/contributors\">",
"     John W Mucenski, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24258/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/44/24258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4993771\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with lymphoma.",
"    <strong>",
"     This is",
"    </strong>",
"    <strong>",
"     not an exhaustive list",
"    </strong>",
"    ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with lymphoma. Additional regimens may be added over time, particularly as treatment for lymphoma evolves.",
"   </p>",
"   <p>",
"    This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with lymphoma. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=see_link\">",
"       \"Initial treatment of limited stage diffuse large B cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"       \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=see_link\">",
"       \"Treatment of relapsed or refractory diffuse large B cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"       \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link\">",
"       \"Initial treatment of advanced stage (III/IV) follicular lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link\">",
"       \"Treatment of relapsed or refractory follicular lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=see_link\">",
"       \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link\">",
"       \"Initial treatment of peripheral T cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4993783\">",
"    <span class=\"h1\">",
"     REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4994024\">",
"    <span class=\"h2\">",
"     Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone with 21 days between cycles (R-CHOP-21)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4994079\">",
"    <span class=\"h2\">",
"     Rituximab plus ifosfamide, carboplatin, and etoposide (R-ICE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef76030 \" href=\"UTD.htm?17/18/17710\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935886705\">",
"    <span class=\"h2\">",
"     Cyclophosphamide plus doxorubicin, vincristine, and prednisone with 21 days between cycles (CHOP-21)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef81762 \" href=\"UTD.htm?8/46/8942\">",
"     table 3",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H935886730\">",
"    <span class=\"h2\">",
"     Doxorubicin plus bleomycin, vinblastine, and dacarbazine (ABVD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef68131 \" href=\"UTD.htm?0/59/958\">",
"     table 4",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H546943109\">",
"    <span class=\"h2\">",
"     Fludarabine plus rituximab (FR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef86798 \" href=\"UTD.htm?1/32/1550\">",
"     table 5",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H546943159\">",
"    <span class=\"h2\">",
"     Fludarabine, cyclophosphamide, and rituximab (FCR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef86797 \" href=\"UTD.htm?22/3/22590\">",
"     table 6",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21931978\">",
"    <span class=\"h2\">",
"     Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (daEPOCH-R)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef88411 \" href=\"UTD.htm?30/9/30878\">",
"     table 7",
"    </a>",
"    )",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85686 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-3918385851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24258=[""].join("\n");
var outline_f23_44_24258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4993771\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4993783\">",
"      REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4994024\">",
"      Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone with 21 days between cycles (R-CHOP-21)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4994079\">",
"      Rituximab plus ifosfamide, carboplatin, and etoposide (R-ICE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H935886705\">",
"      Cyclophosphamide plus doxorubicin, vincristine, and prednisone with 21 days between cycles (CHOP-21)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H935886730\">",
"      Doxorubicin plus bleomycin, vinblastine, and dacarbazine (ABVD)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H546943109\">",
"      Fludarabine plus rituximab (FR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H546943159\">",
"      Fludarabine, cyclophosphamide, and rituximab (FCR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21931978\">",
"      Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (daEPOCH-R)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85686\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85686|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/2/22574\" title=\"table 1\">",
"      R-CHOP21 regimen for non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/18/17710\" title=\"table 2\">",
"      R-ICE recipe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/46/8942\" title=\"table 3\">",
"      CHOP-21",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/59/958\" title=\"table 4\">",
"      ABVD chemotherapy for Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/32/1550\" title=\"table 5\">",
"      FR for CLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/3/22590\" title=\"table 6\">",
"      FCR for CLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/9/30878\" title=\"table 7\">",
"      daEPOCH-R for non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=related_link\">",
"      Initial treatment of advanced stage (III/IV) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=related_link\">",
"      Initial treatment of limited stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=related_link\">",
"      Initial treatment of peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=related_link\">",
"      Overview of the treatment of classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=related_link\">",
"      Treatment of relapsed or refractory diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=related_link\">",
"      Treatment of relapsed or refractory follicular lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_44_24259="CT reconstruction of trachea";
var content_f23_44_24259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Focal tracheal stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shaded surface display reconstruction of a high resolution chest computed tomographic data set reveals a focal area of tracheal stenosis (red arrows) just above the thoracic inlet.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24259=[""].join("\n");
var outline_f23_44_24259=null;
var title_f23_44_24260="Ceftibuten: Pediatric drug information";
var content_f23_44_24260=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ceftibuten: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/58/8101?source=see_link\">",
"    see \"Ceftibuten: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/56/17284?source=see_link\">",
"    see \"Ceftibuten: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cedax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1004206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Cephalosporin (Third Generation)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1004235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/58/8101?source=see_link\">",
"      see \"Ceftibuten: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &lt;12 years: 9 mg/kg/day once daily for 10 days (maximum dose: 400 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;12 years, Adolescents, and Adults: 400 mg once daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: 4.5 mg/kg or 200 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5-29 mL/minute: 2.25 mg/kg or 100 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hemodialysis: Administer 9 mg/kg (maximum dose: 400 mg) after hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F148008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cedax&reg;: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cedax&reg;: 90 mg/5 mL (60 mL, 90 mL, 120 mL); 180 mg/5 mL (60 mL) [contains sodium benzoate, sucrose ~1 g/5 mL; cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F147992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1004241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: Administer without regard to food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension: Shake suspension well before use. Administer 2 hours before or 1 hour after meals.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1004226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store capsules and powder for oral suspension at room temperature; reconstituted suspension is stable for 14 days if refrigerated",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1004207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute exacerbations of  chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis due to",
"     <i>",
"      H. influenzae",
"     </i>",
"     and",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     (both beta-lactamase-producing and nonproducing strains),",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (penicillin-susceptible strains only), and",
"     <i>",
"      S. pyogenes",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3195416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cedax&reg; may be confused with Cidex&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cedax [U.S. and multiple international markets] may be confused with Codex brand name for acetaminophen/codeine [Brazil] and",
"       <i>",
"        Saccharomyces boulardii",
"       </i>",
"       [Italy]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F148066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, loose stools, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophils increased, hemoglobin decreased, platelets increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agitation, alkaline phosphatase increased, anorexia, aphasia, AST increased, constipation, creatinine increased, dehydration, diaper rash, dyspnea, dysuria, eructation, fatigue, fever, flatulence, hematuria, hyperkinesia, insomnia, irritability, jaundice, leukopenia, melena, moniliasis, nasal congestion, paresthesia, platelets increased, pruritus, pseudomembranous colitis, psychosis, rash, rigors, serum-sickness reactions, somnolence, Stevens-Johnson syndrome, stridor, taste perversion, thrombocytopenia, toxic epidermal necrolysis, urticaria, vaginitis, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional reactions reported with other cephalosporins: Allergic reaction, agranulocytosis, angioedema, aplastic anemia, anaphylaxis, asterixis, cholestasis, drug fever, encephalopathy, erythema multiforme, hemolytic anemia, hemorrhage, interstitial nephritis,  neuromuscular excitability, neutropenia, pancytopenia, prolonged PT, renal dysfunction, seizure, superinfection, toxic nephropathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1004211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ceftibuten, any component, or cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5720765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment, history of colitis, or in penicillin-sensitive patients; modify dosage in patients with moderate-to-severe renal impairment. May cause diarrhea, incidence is higher in younger patients (8% in patients &le;2 years; 2% in patients &gt;2 years).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1004212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in superinfection. Pseudomembranous colitis has been reported with ceftibuten. Do not use in patients with immediate-type hypersensitivity reactions to penicillin. Cross hypersensitivity among beta-lactam antibiotics may occur in up to 10% of patients with penicillin allergy history.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Suspension contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use suspension containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F148001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Ceftibuten. Specifically, the zinc contained in many multivitamins may decrease ceftibuten absorption. Management: Consider administering oral zinc-containing multivitamins at least 3 hours after ceftibuten.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the serum concentration of Ceftibuten. Management: Consider administering oral zinc salts at least 3 hours after ceftibuten.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5720803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases rate and extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F148004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5952486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1004243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for signs and symptoms of anaphylaxis during first dose; with prolonged therapy, monitor renal, hepatic, and hematologic function periodically; number and type of stools/day for diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1004228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins resulting in disruption of cell wall synthesis and cell lysis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1004230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid; food decreases peak concentration and lowers AUC",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into middle ear fluid, bronchial secretions, sputum, tonsillar tissue, and blister fluid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 0.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 0.21 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 75% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1.9-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2-3 hours; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: 7 hours; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5-29 mL/minute: 13 hours; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;5 mL/minute: 22 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 60% to 70% excreted unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: 39% to 65% removed by a 2-4 hour hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1004247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/56/17284?source=see_link\">",
"      see \"Ceftibuten: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report persistent diarrhea to physician",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barr WH, Affrime M, Lin CC, et al, \"Pharmacokinetics of Ceftibuten in Children,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(7 Suppl):S93-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/44/24260/abstract-text/7567317/pubmed\" id=\"7567317\" target=\"_blank\">",
"        7567317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/44/24260/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guay DR, &ldquo;Ceftibuten: A New Expanded-Spectrum Oral Cephalosporin,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1997, 31(9):1022-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/44/24260/abstract-text/9296244/pubmed\" id=\"9296244\" target=\"_blank\">",
"        9296244",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13059 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24260=[""].join("\n");
var outline_f23_44_24260=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148028\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004206\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004235\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148008\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147992\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004241\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004226\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004207\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3195416\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148066\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004211\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720765\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004212\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298997\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148001\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720803\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148004\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5952486\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004243\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004228\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004230\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1004247\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13059\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13059|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/58/8101?source=related_link\">",
"      Ceftibuten: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/56/17284?source=related_link\">",
"      Ceftibuten: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_44_24261="Pseudoxanthoma elasticum neck 1";
var content_f23_44_24261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudoxanthoma elasticum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This woman with pseudoxanthoma elasticum has numerous yellow asymptomatic papules on her neck and upper chest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Yahia Albaili, DO, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24261=[""].join("\n");
var outline_f23_44_24261=null;
var title_f23_44_24262="Recurrent cellulitis after saphenous venectomy for coronary artery bypass graft surgery";
var content_f23_44_24262=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Recurrent cellulitis after saphenous venectomy for coronary artery bypass graft surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24262/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24262/contributors\">",
"     Larry M Baddour, MD, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24262/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24262/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24262/contributors\">",
"     Edward Verrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24262/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24262/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24262/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/44/24262/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower extremity cellulitis following saphenous venectomy for coronary artery bypass graft (CABG) surgery was initially described as a novel syndrome in 1982 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Since that time, many patients manifesting this complication, often on a recurrent basis, have been recognized. Preventing recurrent episodes of cellulitis is important, since many of the patients are older and have had prior myocardial injury. The extreme systemic toxicity associated with acute cellulitis, which can include high fever, prolonged rigors, and hypotension, can pose a significant stress for these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellulitis is an infrequent complication of coronary artery bypass grafting but is a significant cause of morbidity.",
"   </p>",
"   <p>",
"    In a 1987 report, cellulitis (erysipelas) developed in 21 of 302 (7 percent) of patients following venectomy for CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, the incidence of cellulitis has declined since use of internal mammary artery grafts and percutaneous coronary stenting have increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors that predispose to postvenectomy cellulitis have not been well defined. A case control study of a heterogeneous population of 461 patients with lower extremity cellulitis found the following risk factors on multivariate analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disruption of the cutaneous barrier, including the presence of a leg ulcer, wound, fissurated toe-web intertrigo, pressure ulcer, or leg dermatosis (odds ratio 23.8)",
"     </li>",
"     <li>",
"      Lymphedema (odds ratio 71.2)",
"     </li>",
"     <li>",
"      Venous insufficiency (odds ratio 2.9)",
"     </li>",
"     <li>",
"      Leg edema (odds ratio 2.5)",
"     </li>",
"     <li>",
"      Being overweight (odds ratio 2.0)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This report and another study did not distinguish saphenous venectomy from other types of leg surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This issue was addressed in a large, prospective case control study in which prior saphenous venectomy was a risk factor for the subsequent development of lower extremity cellulitis (odds ratio 8.5).",
"   </p>",
"   <p>",
"    A series in which skin biopsies were obtained from five patients with previous bouts of lower extremity cellulitis after saphenous venectomy attempted to address the predisposing mechanisms that might be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/7\">",
"     7",
"    </a>",
"    ]. The findings were compared to control biopsies from the contralateral nonvenectomy lower extremity. There were no histologic, immunologic, or inflammatory findings that could be linked to pathogenetic mechanisms of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with acute cellulitis present with the acute onset of high fever, often greater than 40&ordm;C, systemic toxicity, and erythema and swelling of the lower extremity. Because of the sudden onset this syndrome, patients may be misdiagnosed as having influenza or sepsis of undetermined origin if careful attention is not paid to physical examination of the lower extremities. This is particularly true if clinicians fail to remove the pants of patients to perform the physical examination.",
"   </p>",
"   <p>",
"    Clinical features of postvenectomy cellulitis include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prominent rigors that can last for minutes to over one hour.",
"     </li>",
"     <li>",
"      Extreme fatigue and myalgias.",
"     </li>",
"     <li>",
"      Lower extremity pain.",
"     </li>",
"     <li>",
"      Hypotension has also been observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical examination usually establishes the diagnosis. There are two important features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythema of the lower extremity usually begins along the medial aspect of the mid-tibial region at the saphenous venectomy site (",
"      <a class=\"graphic graphic_picture graphicRef62183 \" href=\"UTD.htm?29/13/29904\">",
"       picture 1",
"      </a>",
"      ). It then spreads posteriorly and anteriorly and can involve the dorsal aspect of the ankle and foot, and can extend proximally to involve the medial thigh.",
"     </li>",
"     <li>",
"      Many patients have maceration and erythema of interdigital spaces indicative of tinea pedis infection (athlete's foot), which may represent the source of the infection. In one small study, for example, tinea pedis was present in seven of nine patients with recurrent cellulitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/8\">",
"       8",
"      </a>",
"      ]. There is a paucity of data examining the prevalence of tinea pedis in cellulitis and whether patients with tinea pedis are at increased risk for cellulitis. One report, which lacked statistical comparison, found a slight increase in tinea pedis in patients who developed cellulitis after CABG (52 versus 43 percent in those in whom cellulitis did not occur) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/4\">",
"       4",
"      </a>",
"      ]. Despite the lack of definitive information, it is our impression that tinea pedis plays a critical role in the pathogenesis of postvenectomy cellulitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to postoperative wound infection, which may occur acutely after the procedure, cellulitis tends to occur months to years after saphenous venectomy. In one series, for example, the mean interval between surgery and the initial bout of cellulitis was 15 months, with a range of 2 to 46 months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Recurrent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent episodes will occur in most if not all patients who develop an initial episode of postvenectomy cellulitis. In our initial report of this syndrome, for example, five patients had 20 episodes of cellulitis. Other estimates of recurrence rates may be lower but they are usually based upon a limited duration of follow-up. The timing of recurrence appears to be random and extremely variable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;No pathogen is identified in most cases of postvenectomy cellulitis. As in many cellulitis syndromes, blood cultures are usually not helpful. The utility of skin lesion aspirate cultures and cultures of skin biopsies of involved areas have been evaluated in a variety of cellulitis syndromes; a pathogen is found in only a minority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The limited yield of these tests can be explained in part by findings in previous studies that the concentration of bacteria in the skin was low [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/12\">",
"     12",
"    </a>",
"    ]. Other factors that might contribute to the local skin findings in patients with cellulitis are the extracellular release of bacterial exotoxins and the local release of cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When isolates have been recovered with these techniques, non-group A beta-hemolytic streptococci have been the most commonly isolated organisms. These organisms seem to have a proclivity to produce infection in the setting of venous and lymphatic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Concurrent athlete's foot",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultures taken from the involved interdigital interspaces of patients with associated athlete's foot and lower extremity cellulitis are extremely helpful in identifying potential pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/14\">",
"     14",
"    </a>",
"    ]. In this study, which included three patients who were postvenectomy for coronary artery bypass grafting, athlete's foot was found in 20 of 24 episodes of cellulitis. Beta-hemolytic streptococci were isolated in 17 (85 percent) and Staphylococcus aureus in eight (40 percent) of these 20 episodes. In contrast, streptococci were not recovered in a group of patients seen with athlete's foot and no cellulitis; 23 percent of patients in this latter group were colonized with S. aureus. Molecular typing of beta-hemolytic streptococci isolated a with lower extremity cellulitis following saphenous venectomy demonstrated clonality between blood culture and toe web culture isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our experience, toe web cultures have been useful in establishing a probable pathogen in patients with active cellulitis and tinea pedis. Less is known about the yield of potential pathogens in patients with cellulitis who do not have tinea pedis. As discussed above, the pathogenesis of recurrent cellulitis after saphenous venectomy is probably extremely complex; it may directly involve Trichophyton antigens and bacterial exotoxins in the appropriate host [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major disorders considered in the differential diagnosis of postvenectomy cellulitis: deep venous thrombosis (DVT) and complications of medical devices.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute DVT is the most commonly considered entity. Many patients undergo evaluation for DVT, including venography, and some are empirically begun on high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      until the correct diagnosis is established.",
"     </li>",
"     <li>",
"      Infections of underlying medical devices may also present similarly to postvenectomy cellulitis.&nbsp;These include infections of prosthetic vascular grafts and prosthetic joints.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recognition of the clinical syndrome of postvenectomy cellulitis hopefully will reduce the likelihood of administration of empiric anticoagulation for suspected deep venous thrombosis or the pursuit of diagnostic procedures to evaluate for medical device infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy should be divided into two phases: acute; and chronic suppressive. Multiple effective regimens are available for treatment of the acute cellulitis. The appropriate approach to chronic therapy is less clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is uncommon to identify an infecting pathogen, antimicrobial therapy directed against beta-hemolytic streptococci and S. aureus usually results in the prompt resolution of systemic complaints and slower resolution of the lower extremity changes. Whether treatment for methicillin-resistant S. aureus should be included must be determined by epidemiologic and clinical information in the individual patient. For most patients, however, methicillin-resistant S. aureus is not a likely cause of acute cellulitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple classes of antibiotics are available for use:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several types of beta-lactam antibiotics including the semi-synthetic penicillins and the early generation cephalosporins are effective. Whether parenteral or oral therapy is used is determined by the clinical picture. Most patients treated parenterally have a rapid response with resolution of fever and systemic complaints within two to three days; they can then be switched to oral agents. The usual duration of therapy is 12 to 14 days.",
"      <br/>",
"      <br/>",
"      One regimen that we use is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      , 2 g IV every eight hours, in patients who require hospitalization. The patient can be switched to oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      , 500 mg four times daily, once the patient has defervesced. Oral therapy can be used from the beginning if the patient does not require parenteral therapy.",
"     </li>",
"     <li>",
"      Other drugs which are usually effective in this setting are the macrolides, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      . Because of increasing macrolide and clindamycin resistance among group B streptococci isolated in the United States,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      may be required in patients who cannot take beta-lactam antibiotics and are treated with parenteral therapy due to more severe infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"       \"Cellulitis and erysipelas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fluoroquinolones are not appropriate treatment agents unless there is strong evidence of the presence of an aerobic gram-negative bacillus, either as the sole pathogen or as part of a mixed infection, or if beta-lactam intolerance or macrolide or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    resistance are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic suppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of chronic suppressive therapy is less well studied and more questions than answers exist with regard to its efficacy. The rationale for chronic suppressive therapy is that recurrent bouts of cellulitis can occur.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    was given in one study to evaluate the efficacy and safety of daily administration of this agent over 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/16\">",
"     16",
"    </a>",
"    ]. No patient treated with erythromycin (250 mg BID) developed cellulitis versus 8 of 16 who did not receive prophylactic therapy.",
"   </p>",
"   <p>",
"    There are no published clinical data to indicate which patients should receive chronic suppressive therapy, and if so, for how long. The empiric decision is based upon several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number and frequency of attacks. Chronic suppressive therapy should be considered if a patient has had more than two acute cellulitis episodes over the past six months. On the other hand, there is a lesser indication if a patient has had just one episode of cellulitis or if the episodes are spread over a longer duration.",
"     </li>",
"     <li>",
"      The severity of toxicity of the previous episodes of cellulitis.",
"     </li>",
"     <li>",
"      The medical condition of the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of chronic suppressive therapy should probably be a minimum of twelve months. Due to increasing macrolide resistance among beta-hemolytic streptococci, macrolides are no longer recommended. Penicillin VK (250 mg PO twice daily) can be used in patients with previous beta-hemolytic streptococcal cellulitis. However, this drug would not be active against the large majority of S. aureus strains. If no prior identification of a pathogen has been done, then",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"     dicloxacillin",
"    </a>",
"    (500 mg PO twice daily) can be used to cover both beta-hemolytic streptococci and S. aureus, provided methicillin-resistant S. aureus (MRSA) have not been previously recovered from the patient or is a frequent cause of cellulitis in the local community.",
"   </p>",
"   <p>",
"    If MRSA has been previously identified and is susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , then this agent can be administered as 150 mg PO once daily. Clindamycin can also be given in the penicillin-allergic patients who have had beta-hemolytic streptococcal cellulitis. Patients who are given clindamycin should be educated to seek medical attention should diarrhea develop so that evaluation for Clostridium difficile is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Preemptive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One alternative to long-term suppressive therapy taken on a daily basis is preemptive therapy. In this option, the patient has an oral antibiotic with activity against beta-hemolytic streptococci and S. aureus at home for immediate initiation of treatment at the first sign of cellulitis onset. The patient is advised to follow-up with his physician for further evaluation. It is hoped that with immediate antibiotic administration that the clinical severity of the bout of cellulitis will be significantly reduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment of tinea pedis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether or not chronic suppressive therapy is used, all patients should have a thorough examination of the feet to exclude predisposing conditions such as tinea pedis. If tinea pedis is present, then aggressive therapy against tinea pedis using one of multiple available forms of topical therapy should be instituted in an effort to diminish the number of recurrent episodes of acute cellulitis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/61/28627?source=see_link\">",
"     Tolnaftate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12146?source=see_link\">",
"     undecylenic acid",
"    </a>",
"    in spray power formulations can be used to treat uncomplicated tinea pedis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8643?source=see_link\">",
"     Naftifine",
"    </a>",
"    gel and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    cream are allylamine-class products that are appropriate treatment options for topical therapy. One trial found them to be more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7827?source=see_link\">",
"     oxiconazole",
"    </a>",
"    lotion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24262/abstract/17\">",
"     17",
"    </a>",
"    ]. Every effort should also be made to keep the feet (including the toe web spaces) as dry as possible.",
"   </p>",
"   <p>",
"    In the more severe cases of tinea pedis, which may include nail involvement (onychomycosis), consideration should be made for dermatologic consultation for possible oral antifungal therapy which may include several months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15117715\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower extremity cellulitis following saphenous venectomy is an infrequent complication of coronary artery bypass grafting and risk factors that predispose to its development have not been well defined. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with cellulitis following venectomy present months to years after the procedure with the acute onset of high fever, systemic toxicity, and lower extremity erythema and swelling. Erythema typically begins along the medial aspect of the mid-tibial region at the saphenous venectomy site and can spread from there. Recurrences are common. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cultures of blood, skin biopsies, and lesion aspirates usually do not identify a pathogen. Toe web cultures may be useful in establishing a probable pathogen in patients with active cellulitis and tinea pedis. When an isolate is identified, non-group A beta-hemolytic streptococci are the most common. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deep vein thrombosis and infections of underlying medical devices (eg, a prosthetic vascular graft) are the two major differential diagnoses of postvenectomy cellulitis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the acute setting, antimicrobial therapy against beta-hemolytic streptococci and methicillin-susceptible Staphylococcus aureus usually results in prompt resolution of systemic complaints and slower resolution of the lower extremity changes. The use of antibiotics with activity against methicillin-resistant S. aureus depends on the epidemiologic and clinical characteristics of the individual patient. The duration of therapy is typically 12 to 14 days. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Acute therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link&amp;anchor=H14500218#H14500218\">",
"       \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\", section on 'Methicillin-resistant Staphylococcus aureus infection'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link&amp;anchor=H9#H9\">",
"       \"Cellulitis and erysipelas\", section on 'Cellulitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have frequent recurrences of substantial severity and underlying comorbidities, chronic suppressive therapy may be a reasonable approach to prevent additional episodes of cellulitis. The duration of suppressive therapy is typically at least 12 months. Antimicrobial options for suppression include penicillin VK (250 mg orally twice daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"       dicloxacillin",
"      </a>",
"      (500 mg orally twice daily), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (150 orally once daily). Preemptive therapy, in which a patient-initiated antibiotic regimen is begun at the first sign of cellulitis with subsequent clinician follow-up, is an alternative to chronic suppressive therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Chronic suppressive therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Preemptive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of tinea pedis, if present, in an effort to decrease the risk of recurrent episodes, is thought to be an important element in the prevention of recurrent bouts of lower extremity cellulitis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment of tinea pedis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/1\">",
"      Baddour LM, Bisno AL. Recurrent cellulitis after saphenous venectomy for coronary bypass surgery. Ann Intern Med 1982; 97:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/2\">",
"      Greenberg J, DeSanctis RW, Mills RM Jr. Vein-donor-leg cellulitis after coronary artery bypass surgery. Ann Intern Med 1982; 97:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/3\">",
"      Mehra A, Faxon DP. Current status of percutaneous transluminal coronary angioplasty. Curr Probl Cardiol 1994; 19:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/4\">",
"      Dan M, Heller K, Shapira I, et al. Incidence of erysipelas following venectomy for coronary artery bypass surgery. Infection 1987; 15:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/5\">",
"      Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999; 318:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/6\">",
"      Roujeau JC, Sigurgeirsson B, Korting HC, et al. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology 2004; 209:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/7\">",
"      Baddour LM, Googe PB, Stevens SL. Biopsy specimen findings in patients with previous lower extremity cellulitis after saphenous venectomy for coronary artery bypass graft surgery. J Am Acad Dermatol 1997; 37:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/8\">",
"      Baddour LM, Bisno AL. Recurrent cellulitis after coronary bypass surgery. Association with superficial fungal infection in saphenous venectomy limbs. JAMA 1984; 251:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/9\">",
"      Hook EW 3rd, Hooton TM, Horton CA, et al. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986; 146:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/10\">",
"      Sachs MK. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med 1990; 150:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/11\">",
"      Duvanel T, Auckenthaler R, Rohner P, et al. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Arch Intern Med 1989; 149:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/12\">",
"      Baddour LM. Primary skin infections in primary care: An update. Infect Med 1993; 10:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/13\">",
"      Baddour LM, Bisno AL. Non-group A beta-hemolytic streptococcal cellulitis. Association with venous and lymphatic compromise. Am J Med 1985; 79:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/14\">",
"      Semel JD, Goldin H. Association of athlete's foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin Infect Dis 1996; 23:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/15\">",
"      Hilmarsd&oacute;ttir I, Valsd&oacute;ttir F. Molecular typing of Beta-hemolytic streptococci from two patients with lower-limb cellulitis: identical isolates from toe web and blood specimens. J Clin Microbiol 2007; 45:3131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/16\">",
"      Kremer M, Zuckerman R, Avraham Z, Raz R. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. J Infect 1991; 22:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24262/abstract/17\">",
"      Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Int J Dermatol 1996; 35:591.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7647 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24262=[""].join("\n");
var outline_f23_44_24262=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15117715\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Recurrent infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Concurrent athlete's foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Preemptive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment of tinea pedis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15117715\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7647\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7647|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/13/29904\" title=\"picture 1\">",
"      Postvenectomy cellulitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_44_24263="Acute lobular hepatitis high serum bilirubin - high power";
var content_f23_44_24263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute lobular hepatitis in a 62-year-old woman with an unusually high serum bilirubin level, 55 mg/dL (high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is central vein periphlebitis, an area of cholestasis (a dilated bile canaliculus with a bile droplet), lipofuscin-filled macrophages, and necrotic hepatocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mashall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24263=[""].join("\n");
var outline_f23_44_24263=null;
var title_f23_44_24264="Rheumatoid arthritis treatment";
var content_f23_44_24264=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24264/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24264/contributors\">",
"     PJW Venables, MA, MB BChir, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24264/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24264/contributors\">",
"     James R O'Dell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24264/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24264/contributors\">",
"     Jerry M Greene, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/44/24264/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     RHEUMATOID ARTHRITIS OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis (RA) is a chronic inflammatory condition affecting the joints. The condition can also affect other tissues throughout the body. The specific causes of rheumatoid arthritis are unknown.",
"   </p>",
"   <p>",
"    Rheumatoid arthritis symptoms develop gradually, and it is not always possible to know when the disease first developed. Many people have symptoms that are present continuously, some have symptoms that completely resolve, and others have alternating periods of bothersome symptoms and complete resolution. The onset, severity, and specific symptoms of this condition can vary greatly from person to person.",
"   </p>",
"   <p>",
"    Treatment plays a key role in controlling the inflammation of rheumatoid arthritis and in minimizing joint damage. Treatment usually entails a combination of drug therapy and other non-drug therapies. In some cases, treatment may also involve surgery.",
"   </p>",
"   <p>",
"    The treatment of rheumatoid arthritis must be tailored to each patient's individual case, including the severity of the condition, the effectiveness of specific therapies, and the occurrence of any side effects. Treatment choices may be different for a person with rheumatoid arthritis who has other illnesses, especially those of the liver or kidneys. It is important to work with a healthcare provider to create an effective and acceptable plan for treating rheumatoid arthritis.",
"   </p>",
"   <p>",
"    This topic review discusses the medical treatments that are used for patients with rheumatoid arthritis. A number of other topics about rheumatoid arthritis are available separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"     \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"     \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12098?source=see_link\">",
"     \"Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"     \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF RHEUMATOID ARTHRITIS TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aim of rheumatoid arthritis treatment is to control a patient's signs and symptoms, to prevent joint damage, and to maintain the patient&rsquo;s quality of life and ability to function [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24264/abstract/1\">",
"     1",
"    </a>",
"    ]. Joint damage caused by rheumatoid arthritis generally occurs within the first two years of diagnosis, and it is difficult to predict which individuals will develop long-term complications. Therefore, the initial treatment of RA aims to eliminate or minimize inflammation. However, the risk of side effects from treatment must be weighed against the benefits. Treatments that can potentially stop joint damage are generally recommended for all patients with rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term medical care with regularly scheduled visits is essential for the successful treatment of rheumatoid arthritis. This care often entails medical visits and tests to assess the effectiveness of treatment and to monitor for side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic therapies include treatments other than medications and are the foundation of treatment for all people with rheumatoid arthritis. There are a wide variety of nonpharmacologic therapies available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Education and counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Education and counseling can help you to better understand the nature of rheumatoid arthritis and cope with the challenges of this condition. You and your healthcare providers can work together to formulate a long-term treatment plan, define reasonable expectations, and evaluate both standard and alternative treatment options.",
"   </p>",
"   <p>",
"    Nonpharmacologic measures such as biofeedback and cognitive behavioral therapy may help in controlling rheumatoid arthritis symptoms. These measures can reduce pain and disability and improve self-esteem. Programs on topics such as self-management skills, social support, biofeedback, and psychotherapy are offered by the Arthritis Foundation in the US (",
"    <a class=\"external\" href=\"file://www.arthritis.org/local-offices/\">",
"     file://www.arthritis.org/local-offices/",
"    </a>",
"    ) and by similar organizations worldwide. These services are also offered by many hospitals and clinics. These programs have been shown to reduce pain, depression, and disability in people with arthritis and to allow them to gain some control over their illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is a common symptom of rheumatoid arthritis. Inflamed joints should be rested, but physical fitness should be maintained as much as possible. Several studies have shown that physical fitness improved the quality of sleep, which in turn helped with fatigue. The advice of physical and occupational therapists should be sought for help with fitness programs, if joint pain or limited joint motion interferes with exercise activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain and stiffness often prompt people with rheumatoid arthritis to become inactive. Unfortunately, inactivity can lead to a loss of joint motion, contractions, and a loss of muscle strength. Weakness, in turn, decreases joint stability and further increases fatigue.",
"   </p>",
"   <p>",
"    Regular exercise can help prevent and reverse these effects [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24264/abstract/2\">",
"     2",
"    </a>",
"    ]. Several different kinds of exercise can be beneficial, including range-of-motion exercises to preserve and restore joint motion, exercises to increase strength (isometric, isotonic, and isokinetic exercises), and exercises to increase endurance (walking, swimming, and cycling).",
"   </p>",
"   <p>",
"    Exercise programs for people with rheumatoid arthritis should be designed by a physical therapist and tailored to the severity of your condition, your build, and your former activity level. A separate article discusses exercise and arthritis. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=see_link\">",
"     \"Patient information: Arthritis and exercise (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical and occupational therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical and occupational therapy can relieve pain, reduce inflammation, and help preserve joint structure and function for patients with rheumatoid arthritis.",
"   </p>",
"   <p>",
"    Specific types of therapy are used to address specific effects of rheumatoid arthritis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The application of heat or cold can relieve pain or stiffness.",
"     </li>",
"     <li>",
"      Ultrasound may reduce inflammation of the sheaths surrounding tendons (tenosynovitis).",
"     </li>",
"     <li>",
"      Passive and active exercises can improve and maintain range of motion of the joints.",
"     </li>",
"     <li>",
"      Rest and rest splinting can reduce joint pain and improve joint function.",
"     </li>",
"     <li>",
"      Finger splinting and other assistive devices can prevent deformities and improve hand function.",
"     </li>",
"     <li>",
"      Relaxation techniques can relieve secondary muscle spasm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical therapy may also include a consultation with a podiatrist who can make foot orthotics (devices that ensure correct position of the foot) and supportive footwear. Occupational therapists also focus on helping people with rheumatoid arthritis to be able to continue to actively participate in work and recreational activity with special attention to maintaining good function of the hands and arms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nutrition and dietary therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;People with active rheumatoid arthritis sometimes lose their appetite or are unable to eat an adequate amount of food. Dietary therapy helps to ensure that you eat an adequate amount of calories and nutrients. However, weight loss may be recommended for overweight and obese people to reduce stress on inflamed joints. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"     \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    People with rheumatoid arthritis have a higher risk of developing coronary artery disease. High blood cholesterol is one risk factor for coronary disease that can respond to changes in diet. A nutritionist can recommend specific foods to eat or avoid to achieve a desirable cholesterol level. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"     \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Changes in diet have been investigated as treatments for rheumatoid arthritis. The addition of fish oils and some plant oils, such as borage seed oil, have modestly improved arthritis pain and joint swelling. However, there is no diet that can cure rheumatoid arthritis. No herbal or nutritional supplements, such as cartilage or collagen, can cure rheumatoid arthritis; these treatments can be dangerous and are not usually recommended. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"     \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1854462\">",
"    <span class=\"h2\">",
"     Smoking and alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different studies have shown that smoking is a risk factor for rheumatoid arthritis and that quitting smoking can improve disease. People who smoke need to quit completely. Assistance in quitting should be obtained, if needed. Moderate alcohol consumption is not harmful to rheumatoid arthritis, although it may increase the risk of liver damage from some drugs such as",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=see_link\">",
"     methotrexate",
"    </a>",
"    . People should discuss the safety of alcohol use with their doctor, because recommendations depend on the medications a person is taking and on their other medical conditions. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"     \"Patient information: Quitting smoking (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Measures to reduce bone loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis causes bone loss, which can lead to osteoporosis. Bone loss is more likely in people who are inactive. The use of glucocorticoids, such as",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=see_link\">",
"     prednisone",
"    </a>",
"    , further increases the risk of bone loss, especially in postmenopausal women. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"     \"Patient information: Bone density testing (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several measures can minimize the bone loss associated with steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24264/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use the lowest possible dose of glucocorticoids for the shortest possible time, when possible, to minimize bone loss.",
"     </li>",
"     <li>",
"      Consume an adequate amount of calcium and vitamin D, either in the diet or by taking supplements. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use medications that can reduce bone loss, including that which is caused by glucocorticoids. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"       \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RHEUMATOID ARTHRITIS MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications are the cornerstone of treatment for active rheumatoid arthritis. The goals of treatment with rheumatoid arthritis medications are to achieve remission and to prevent further damage of the joints and loss of function, without causing permanent or unacceptable side effects.",
"   </p>",
"   <p>",
"    The type and intensity of rheumatoid arthritis treatment with medication depends upon individual factors and potential drug side effects. In most cases, the dose of a medication is increased until inflammation is suppressed or until drug side effects become unacceptable.",
"   </p>",
"   <p>",
"    The challenge of using medications is to balance the side effects against the need to control inflammation. All patients with rheumatoid arthritis who use medications need regular medical care and blood tests to monitor for complications. If side effects occur, they can often be minimized or eliminated by reducing the dose or by switching to a different drug.",
"   </p>",
"   <p>",
"    Several classes of drugs are used to treat rheumatoid arthritis: nonsteroidal antiinflammatory drugs (NSAIDs), disease modifying antirheumatic drugs (DMARDs) (which include both traditional DMARDs and biologic agents), glucocorticoids, and, if needed, pain medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) may be recommended to relieve pain and reduce minor inflammation. However, NSAIDs do not reduce the long-term damaging effects of rheumatoid arthritis on the joints.",
"   </p>",
"   <p>",
"    NSAIDs must be taken continuously and at a specific dose to have an antiinflammatory effect. Even at the correct doses, NSAIDs must usually be taken for several weeks before their effectiveness is known. If the initial dose of NSAIDs does not improve symptoms, a clinician may recommend increasing the dose gradually or switching to another NSAID. You should not take two NSAIDs at the same time.",
"   </p>",
"   <p>",
"    Many NSAIDS have significant side effects, including gastrointestinal bleeding, fluid retention, and an increased risk of heart disease. The risks need to be weighed carefully against the benefit when taking these drugs.",
"   </p>",
"   <p>",
"    More detailed information about NSAIDs is available separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"     \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Disease-modifying antirheumatic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease-modifying antirheumatic drugs (DMARDs) can substantially reduce the inflammation of rheumatoid arthritis, reduce or prevent joint damage, preserve joint structure and function, and enable a person to continue his or her daily activities. Although some DMARDs act slowly, they may allow you to take a lower dose of glucocorticoids to control pain and inflammation.",
"   </p>",
"   <p>",
"    Drugs in this class include",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?17/39/18037?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?12/24/12677?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?23/42/24229?source=see_link\">",
"     leflunomide",
"    </a>",
"    . Detailed information about these medications is available in a separate topic review. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"     \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An improvement in symptoms may require four to six weeks of treatment with",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=see_link\">",
"     methotrexate",
"    </a>",
"    , one to two months of treatment with",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?12/24/12677?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , and two to three months of treatment with",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?17/39/18037?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    . Even longer durations of treatment may be needed to derive the full benefits of these drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Biologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologic agents, also known as biologics, are disease-modifying antirheumatic drugs (DMARDs) that were designed to prevent or reduce the inflammation that damages joints. Biologics target molecules on cells of the immune system, joints, and the products that are secreted in the joints, all of which can cause inflammation and joint destruction. There are several types of biologics, each of which targets a specific type of molecule involved in this process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biologics are often reserved for people who have not completely responded to DMARDs and for those who cannot tolerate DMARDs in doses large enough to control inflammation.",
"   </p>",
"   <p>",
"    Biologics that bind tumor necrosis factor (TNF) include",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?35/34/36389?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?2/61/3030?source=see_link\">",
"     adalimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?2/23/2422?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?4/54/4966?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    , and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?1/13/1238?source=see_link\">",
"     golimumab",
"    </a>",
"    . These are called anti-TNF agents or TNF inhibitors. There are additional biologics that target other molecules instead of TNF. These are usually used for people with arthritis that is not well-controlled with",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=see_link\">",
"     methotrexate",
"    </a>",
"    and one of the anti-TNF agents.",
"   </p>",
"   <p>",
"    Unlike DMARDs, which can take a month or more to begin working, biologics tend to work rapidly, within two weeks for some medications and within four to six weeks for others. Biologics may be used alone or in combination with other DMARDs (eg,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=see_link\">",
"     methotrexate",
"    </a>",
"    ), NSAIDs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glucocorticoids (steroids).",
"   </p>",
"   <p>",
"    All biologic agents must be injected. Some can be injected under the skin by the patient, a family member, or nurse. There are others that must be injected into a vein, which is typically done in a doctor's office or clinic; this takes between one and three hours to complete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologic agents interfere with the immune system's ability to fight infection and should not be used in people with serious infections.",
"   </p>",
"   <p>",
"    Testing for tuberculosis (TB) is necessary before starting anti-TNF therapy. People who have evidence of prior TB infection should be treated because there is an increased risk of developing active TB while receiving anti-TNF therapy. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=see_link\">",
"     \"Patient information: Tuberculosis (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-TNF agents are not recommended for people who have lymphoma or who have been treated for lymphoma in the past; people with rheumatoid arthritis, especially those with severe disease, have an increased risk of lymphoma regardless of what treatment is used. Anti-TNF agents have been associated with a further increase in the risk of lymphoma in some studies but not others; more research is needed to define this risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Steroids (glucocorticoids)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids, also called steroids, have strong antiinflammatory effects. Drugs in this class include",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?38/10/39072?source=see_link\">",
"     prednisolone",
"    </a>",
"    . Glucocorticoids may be taken by mouth, injected into a vein, or injected directly into a joint. Glucocorticoids quickly improve symptoms of rheumatoid arthritis such as pain and stiffness and also decrease joint swelling and tenderness.",
"   </p>",
"   <p>",
"    Glucocorticoids are generally used to treat rheumatoid arthritis that severely limits a person's ability to function normally. For such people, glucocorticoid treatment may help control symptoms and preserve function until other slower-acting drugs with greater ability to prevent joint damage begin to work. They may also be used to treat flares of disease, while a person is receiving other treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steroids have many possible side effects, including weight gain, worsening diabetes, promotion of cataracts in the eyes, thinning of bones (osteopenia and osteoporosis), and an increased risk of infection. Thus, when steroids are used, the goal is to use the lowest possible dose for the shortest period of time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pain relievers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain relievers relieve pain, but they have no effect on inflammation. Drugs in this class include",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?30/5/30805?source=see_link\">",
"     tramadol",
"    </a>",
"    , and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?35/41/36500?source=see_link\">",
"     capsaicin",
"    </a>",
"    cream or ointment. Use of narcotics like",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?13/44/14021?source=see_link\">",
"     codeine",
"    </a>",
"    ,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?6/3/6198?source=see_link\">",
"     oxycodone",
"    </a>",
"    , and hydrocodone is generally discouraged because they also have no effect on inflammation and because of the long-term nature of rheumatoid arthritis and the risk of dependence and addiction.",
"   </p>",
"   <p>",
"    However, people with a badly damaged joint who cannot undergo joint replacement surgery may benefit from use of a long-acting narcotic under the supervision of a rheumatologist or pain specialist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment of flares",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flares are temporary exacerbations of rheumatoid arthritis that can occur in addition to the ongoing inflammation. In people who are already taking",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=see_link\">",
"     methotrexate",
"    </a>",
"    or oral steroids, flares can often be controlled by increasing the doses of these drugs. Alternatively, flares can be controlled by steroids that are given by injection. Rest is often helpful during flares; hospitalization is rarely necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Which rheumatoid arthritis treatment will I get?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of drugs that your doctor recommends will depend on how severe your arthritis is and how well you respond to the medications. If you have early, mild arthritis, your treatment may be different from someone who has more severe arthritis or whose arthritis persists despite initial treatment efforts. In general, nearly all patients with rheumatoid arthritis will receive a disease modifying antirheumatic drug (DMARD) as part of their treatment program. A different DMARD, whether one of the traditional DMARDs or a biologic agent, will be used either instead of or in addition to the initial drug, if the treatment used is judged to be inadequate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15385?source=see_link\">",
"     \"Initial treatment of mildly active rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=see_link\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A person with end-stage rheumatoid arthritis has little or no evidence of ongoing inflammation but often has significant joint damage with deformity and loss of joint function. End-stage rheumatoid arthritis treatment includes therapies that reduce pain and slow or prevent additional changes in joint structure and function.",
"   </p>",
"   <p>",
"    Patients with end-stage rheumatoid arthritis may have pain due to joint damage rather than inflammation. In this case, surgery may be recommended to replace a damaged joint. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=see_link\">",
"     \"Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=see_link\">",
"     \"Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some joints cannot be successfully replaced. For such joints, a surgical fusion may be recommended to limit movements that cause pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of rheumatoid arthritis during pregnancy is discussed in detail in a separate topic review. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12098?source=see_link\">",
"     \"Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3498567743\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1945250\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"     Patient information: Rheumatoid arthritis (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?38/14/39138?source=see_link\">",
"     Patient information: Rheumatoid arthritis and pregnancy (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=see_link\">",
"     Patient information: Hip replacement (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?9/22/9571?source=see_link\">",
"     Patient information: Arthritis and exercise (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=see_link\">",
"     Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1945267\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"     Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"     Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12098?source=see_link\">",
"     Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"     Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=see_link\">",
"     Patient information: Arthritis and exercise (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"     Patient information: Weight loss treatments (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"     Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"     Patient information: Bone density testing (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"     Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"     Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"     Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=see_link\">",
"     Patient information: Tuberculosis (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=see_link\">",
"     Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=see_link\">",
"     Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"     Patient information: Quitting smoking (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=see_link\">",
"     Assessment of rheumatoid arthritis activity in clinical trials and clinical practice",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=see_link\">",
"     Cervical subluxation in rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     Clinical features of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=see_link\">",
"     Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link\">",
"     Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     Diagnosis and differential diagnosis of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=see_link\">",
"     Disease outcome and functional capacity in rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39593?source=see_link\">",
"     Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37861?source=see_link\">",
"     Evaluation and medical management of end-stage rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     General principles of management of rheumatoid arthritis in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link\">",
"     Interstitial lung disease in rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=see_link\">",
"     Leflunomide in the treatment of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17162?source=see_link\">",
"     Polyarticular onset juvenile idiopathic arthritis: Management",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/566?source=see_link\">",
"     Miscellaneous novel therapies in rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22903?source=see_link\">",
"     Ocular manifestations of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"     Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=see_link\">",
"     Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40791?source=see_link\">",
"     Rheumatoid arthritis and pregnancy",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link\">",
"     Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=see_link\">",
"     Sulfasalazine in the treatment of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=see_link\">",
"     T cell targeted therapies for rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32073?source=see_link\">",
"     Total joint replacement for severe rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15385?source=see_link\">",
"     Initial treatment of mildly active rheumatoid arthritis in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=see_link\">",
"     Initial treatment of moderately to severely active rheumatoid arthritis in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=see_link\">",
"     Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41065?source=see_link\">",
"     Use of glucocorticoids in the treatment of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"     Use of methotrexate in the treatment of rheumatoid arthritis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     Overview of biologic agents in the rheumatic diseases",
"    </a>",
"    <br/>",
"   </p>",
"   <p>",
"    The following organizations also provide reliable health information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/arthritis.html\">",
"       www.nlm.nih.gov/medlineplus/arthritis.html",
"      </a>",
"      , available in Spanish)",
"     </li>",
"     <li>",
"      American College of Rheumatology",
"      <br/>",
"      (404) 633-3777",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/patients/index.asp\">",
"       www.rheumatology.org/practice/clinical/patients/index.asp",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Arthritis Foundation",
"      <br/>",
"      (800) 283-7800",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://www.arthritis.org/\">",
"       www.arthritis.org",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Patient support",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://about.com/\">",
"       About.com",
"      </a>",
"      Arthritis Forum",
"      <br/>",
"      (",
"      <a class=\"external\" href=\"file://arthritis.about.com/forum\">",
"       file://arthritis.about.com/forum",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24264/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24264/abstract/1\">",
"      American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24264/abstract/2\">",
"      Van Den Ende CH, Vliet Vlieland TP, Munneke M, Hazes JM. Dynamic exercise therapy for rheumatoid arthritis. Cochrane Database Syst Rev 2000; :CD000322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24264/abstract/3\">",
"      Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001; 44:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24264/abstract/4\">",
"      Geusens P, Wouters C, Nijs J, et al. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study. Arthritis Rheum 1994; 37:824.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 513 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24264=[""].join("\n");
var outline_f23_44_24264=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      RHEUMATOID ARTHRITIS OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES OF RHEUMATOID ARTHRITIS TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Education and counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical and occupational therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nutrition and dietary therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1854462\">",
"      Smoking and alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Measures to reduce bone loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RHEUMATOID ARTHRITIS MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Disease-modifying antirheumatic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Biologic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Steroids (glucocorticoids)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pain relievers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment of flares",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Which rheumatoid arthritis treatment will I get?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3498567743\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1945250\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1945267\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Patient support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/33/7706?source=related_link\">",
"      Assessment of rheumatoid arthritis activity in clinical trials and clinical practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=related_link\">",
"      Cervical subluxation in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39593?source=related_link\">",
"      Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37861?source=related_link\">",
"      Evaluation and medical management of end-stage rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15385?source=related_link\">",
"      Initial treatment of mildly active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/3/31802?source=related_link\">",
"      Initial treatment of moderately to severely active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=related_link\">",
"      Interstitial lung disease in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/566?source=related_link\">",
"      Miscellaneous novel therapies in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22903?source=related_link\">",
"      Ocular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=related_link\">",
"      Patient information: Arthritis and exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/22/9571?source=related_link\">",
"      Patient information: Arthritis and exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=related_link\">",
"      Patient information: Bone density testing (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=related_link\">",
"      Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=related_link\">",
"      Patient information: Hip replacement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12098?source=related_link\">",
"      Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/14/39138?source=related_link\">",
"      Patient information: Rheumatoid arthritis and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=related_link\">",
"      Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=related_link\">",
"      Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=related_link\">",
"      Patient information: Tuberculosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/48/17162?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35016?source=related_link\">",
"      Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40791?source=related_link\">",
"      Rheumatoid arthritis and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=related_link\">",
"      Sulfasalazine in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=related_link\">",
"      T cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32073?source=related_link\">",
"      Total joint replacement for severe rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/6/42090?source=related_link\">",
"      Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41065?source=related_link\">",
"      Use of glucocorticoids in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_44_24265="Differential diagnosis of microbial foodborne disease";
var content_f23_44_24265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differential diagnosis of microbial foodborne disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24265/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24265/contributors\">",
"     David WK Acheson, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24265/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24265/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24265/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24265/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/44/24265/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinicians consider a foodborne illness when a patient presents with gastrointestinal symptoms including nausea, vomiting, abdominal pain, diarrhea and fever. However, patients with foodborne illness may present initially with other complaints such as neurologic symptoms (eg, headaches, paralysis or tingling), hepatitis, and renal failure.",
"   </p>",
"   <p>",
"    Since foodborne illness is common and the presenting symptoms may be protean, it is important to develop a consistent clinical diagnostic and treatment approach to these patients. The possible public health implications in cases of suspected foodborne illness must also be addressed.",
"   </p>",
"   <p>",
"    This topic focuses on foodborne illness attributable to microbial causes, although chemicals and other agents transmissible via food can also lead to clinical illness. With more than 200 known agents capable of transmission through food [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/1\">",
"     1",
"    </a>",
"    ], there are no simple algorithms to diagnose foodborne illness. However, there are some key factors that will point the physician in the right diagnostic direction. Three key questions will be reviewed here:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What are the probable microbial causes of foodborne disease?",
"     </li>",
"     <li>",
"      How do time course and types of symptoms serve as clues?",
"     </li>",
"     <li>",
"      How can a food history help to narrow the diagnosis?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 350 million episodes of diarrhea are estimated to occur annually in the United States, according to the Centers for Disease Control and Prevention (CDC). Approximately 48 million of these are thought to be due to foodborne disease, accounting for an estimated 125,000 hospitalizations and 3000 deaths at a total estimated cost of over $150 billion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A registry-based study from Denmark further emphasized the potential seriousness of foodborne illness. The study found that of 52,121 patients with foodborne bacterial gastroenteritis, 7524 (14.4 percent) were hospitalized within 90 days of a microbiologic diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/3\">",
"     3",
"    </a>",
"    ]. Some of the complications were serious with 647 (1.2 percent) having complications such as intestinal perforation or invasive illness. The risk of complications and sequelae depended greatly on the bacterial species; Listeriosis, Shiga toxin producing E. coli and nontyphoidal Salmonella are particularly associated with severe morbidity.",
"   </p>",
"   <p>",
"    The CDC began an active surveillance program called FoodNet in 1996 that is designed to determine the prevalence of specific enteric bacterial and protozoal pathogens in various parts of the United States (",
"    <a class=\"graphic graphic_table graphicRef66327 \" href=\"UTD.htm?5/47/5883\">",
"     table 1",
"    </a>",
"    ). Currently, FoodNet has sites in ten states and covers over 46 million Americans.",
"   </p>",
"   <p>",
"    The data from FoodNet have led to an appreciation that close to one in five episodes of diarrhea is likely to be due to a foodborne disease and that each person in the United States on average probably has diarrhea once or twice per year. Based upon these numbers, the average person in the United States will have a foodborne illness once every three to four years.",
"   </p>",
"   <p>",
"    The estimated frequency of foodborne diseases for a variety of microbes has been assembled, with the percentage of disease that is actually transmitted by food determined for each microbe [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/1\">",
"     1",
"    </a>",
"    ]. The more common of these pathogens are listed in the following table, ranked according to their frequency (",
"    <a class=\"graphic graphic_table graphicRef75429 \" href=\"UTD.htm?33/24/34190\">",
"     table 2",
"    </a>",
"    ). Five organisms account for 90 percent of the deaths, most notably Salmonella spp.",
"   </p>",
"   <p>",
"    The 2010 FoodNet data indicates little change overall in the incidence of many important foodborne infections from the previous four years with the exception of a decline in Shiga toxin producing E. coli O157:H7 infections and Shigella [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/4\">",
"     4",
"    </a>",
"    ]. The incidence of Vibrio infections continued to increase, a trend that has been manifest for several years although Vibrio still accounts for only a small proportion of foodborne infections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/4\">",
"     4",
"    </a>",
"    ]. Also of concern is that the levels of Salmonella have remained constant despite many efforts to reduce them.",
"   </p>",
"   <p>",
"    The incidence of laboratory-confirmed cases per 100,000 persons in 2010 was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Salmonella &ndash; 17.6",
"     </li>",
"     <li>",
"      Campylobacter &ndash; 13.6",
"     </li>",
"     <li>",
"      Shigella &ndash; 3.8",
"     </li>",
"     <li>",
"      Cryptosporidium &ndash; 2.8",
"     </li>",
"     <li>",
"      Shiga toxin producing E. coli O157 &ndash; 0.9",
"     </li>",
"     <li>",
"      Shiga toxin producing E. coli non-O157 &ndash; 1.0",
"     </li>",
"     <li>",
"      Yersinia &ndash; 0.3",
"     </li>",
"     <li>",
"      Vibrio &ndash; 0.4",
"     </li>",
"     <li>",
"      Listeria &ndash; 0.3",
"     </li>",
"     <li>",
"      Cyclospora &ndash; 0.1",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A probable diagnosis for the etiology of foodborne disease can be entertained based upon the combination of clinical manifestations exhibited, features of the food history, and which pathogenic mechanism appears relevant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to make a diagnosis of foodborne disease, one first has to consider the spectrum of clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/5\">",
"     5",
"    </a>",
"    ]. A foodborne disease will typically manifest as a mixture of nausea, vomiting, fever, abdominal pain and diarrhea. However, some foodborne diseases may not have gastrointestinal symptoms. As examples, botulism and some types of shellfish poisoning can present with paralysis, ciguatera fish poisoning or scombroid with headaches and tingling, amnesic shellfish poisoning with amnesia, hepatitis A or E with hepatitis and Listeria monocytogenes with meningitis or spontaneous abortion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Food history",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three important elements of the history that the physician should consider while trying to determine the differential diagnosis of foodborne diseases:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presenting symptoms",
"     </li>",
"     <li>",
"      Exposure to a particular type of food associated with foodborne disease",
"     </li>",
"     <li>",
"      The time interval between exposure to the suspect food and the onset of symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to determine what the person ate in the week before they became sick, though a longer window of exposure may require consideration for some infections (such as hepatitis A). Examples of the types of foods that may be linked to specific pathogens are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef58714 \" href=\"UTD.htm?21/32/22027\">",
"     table 3",
"    </a>",
"    ). The type of tests to order, if any, can then be determined based upon which diagnosis seems probable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pathogenic mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thinking about the basic pathogenic mechanisms can also assist in understanding the differential diagnosis of foodborne disease. Pathogenic mechanisms by which microbes cause foodborne disease can generally be categorized in three ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Organisms that make a toxin in the food before the food is consumed. Consumption of the toxin-contaminated food will usually lead to the rapid onset of symptoms (6 to 12 hours) that are predominantly upper intestinal. Examples of this are Staphylococcus aureus, Bacillus cereus emetic toxin and botulism.",
"     </li>",
"     <li>",
"      Pathogens that make toxin once they have been ingested. This usually takes longer (approximately 24 hours or longer), causes diarrhea that may be watery (eg, Vibrio cholerae or Enterotoxigenic Escherichia coli) or bloody (eg, Shiga toxin-producing E. coli).",
"     </li>",
"     <li>",
"      Microbes that cause pathology by either damaging the epithelial cell surface or by actually invading across the intestinal epithelial cell barrier. This group of pathogens can produce a wide spectrum of clinical presentations from watery diarrhea (eg, Cryptosporidium parvum, enteric viruses) to inflammatory diarrhea (eg, Salmonella, Campylobacter, Shigella) or systemic disease (eg, L. monocytogenes).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In order to simplify the diagnostic approach, various major presenting symptoms will be discussed below in the context of the most likely microbial causes (",
"    <a class=\"graphic graphic_table graphicRef56595 \" href=\"UTD.htm?31/24/32140\">",
"     table 4",
"    </a>",
"    ). It is beyond the scope of this review to discuss management of foodborne disease, but treatment of many types of foodborne diseases producing diarrhea have been reviewed by a panel of experts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/6\">",
"     6",
"    </a>",
"    ] and are also discussed separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VOMITING AS THE MAJOR PRESENTING SYMPTOM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sudden onset of nausea and vomiting is likely due to the ingestion of a preformed toxin, such as S. aureus enterotoxin or B. cereus emetic toxin, or a chemical irritant. Both microbial toxins will induce vomiting as the primary symptom. Because these are preformed toxins, there is no risk of person-to-person spread. However, identification of the contaminated food is important to prevent exposure of others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Staphylococcus aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the case of S. aureus enterotoxin, symptoms usually begin within one to six hours of ingestion with nausea, vomiting and abdominal cramps. Fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea may occur in a minority of patients. S. aureus toxin is heat-stable and is often associated with the consumption of foods prepared by a food handler such as dairy, produce, meats, eggs, and salads [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/7\">",
"     7",
"    </a>",
"    ]. The food handler usually contaminates the product; after the food is left at room temperature, the organisms multiply and can produce a substantial quantity of toxin. Vomitus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    food can be tested for the enterotoxin, but the diagnosis of food poisoning due to S. aureus is usually clinical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bacillus cereus",
"    </span>",
"    &nbsp;&mdash;&nbsp;B. cereus is also capable of producing a heat-stable emetic enterotoxin, typically in starchy foods such as rice [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/8\">",
"     8",
"    </a>",
"    ]. The preformed B. cereus emetic enterotoxin causes a rapid (within one to six hours) onset of nausea and profuse vomiting. The disease is usually self-limited, although very rarely associated with acute hepatic necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/9\">",
"     9",
"    </a>",
"    ]. The diagnosis is usually clinical; reference laboratories have the capability of testing food or vomitus for the toxin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6729?source=see_link\">",
"     \"Bacillus cereus and other non-anthracis Bacillus species\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Noroviruses (Norwalk-like viruses)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infections, due to agents such as noroviruses, are the other major foodborne diseases that typically cause vomiting as the predominant symptom. Noroviruses (also known as small round structured viruses) are now considered to be among the most common foodborne diseases and the most frequent cause of acute gastroenteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/1\">",
"     1",
"    </a>",
"    ]. These viruses usually produce nausea, vomiting and watery diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43241?source=see_link\">",
"     \"Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noroviruses appear to have a low infectious dose (around 10 particles) and have been associated with large outbreaks on cruise ships, are readily transmitted from the vomitus of an infected person, and may be transmitted in aerosol form or via person-to-person [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/10\">",
"     10",
"    </a>",
"    ]. With regard to transmission via food, shellfish are known to harbor noroviruses, but otherwise they are usually transmitted from a food handler via food. Thus, exposure to prepared food (eg, salads, sandwiches, fruit) is a risk factor.",
"   </p>",
"   <p>",
"    The illness usually lasts for 48 to 72 hours with a rapid and full recovery but without long-lasting immunity. Diagnosis of several viruses (rotavirus, enteric adenovirus) can be made by enzyme immunoassay [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/11\">",
"     11",
"    </a>",
"    ]. Reverse transcriptase polymerase chain reaction (RT-PCR)-based assays and electron microscopy can also be used [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anisakiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal symptoms can occur after ingestion of raw fish containing nematodes such as those from the anisakis or eustrongylides family. When acute, this can lead to nausea, vomiting, and epigastric pain 1 to 12 hours after ingestion of raw fish. The symptoms typically resolve after regurgitation of the worm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44168?source=see_link&amp;anchor=H8121222#H8121222\">",
"     \"Miscellaneous nematodes\", section on 'Anisakiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106092312\">",
"    <span class=\"h2\">",
"     Kudoa septempunctata",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2012, the parasite Kudoa septempunctata was identified as the probable etiologic agent for multiple outbreaks of food-borne illness of previously unknown etiology in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/13\">",
"     13",
"    </a>",
"    ]. Intense vomiting and diarrhea occurred 3 to 16 hours after ingestion of raw olive flounder. Symptoms generally resolved within 24 hours. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     WATERY DIARRHEA AS THE MAJOR PRESENTING SYMPTOM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since many foodborne microbes cause watery diarrhea, the presence of this symptom alone is of little help in the differential diagnosis. The finding of inflammatory cells in the stool may suggest a more limited group of pathogens. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Inflammatory diarrhea as the major presenting symptom'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some foodborne microbes such as V. cholerae may cause massive watery diarrhea, but this is unlikely to be seen in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link\">",
"     \"Overview of Vibrio cholerae infection\"",
"    </a>",
"    .) Other microbial causes of watery diarrhea include: Clostridium perfringens, enterotoxigenic E. coli (ETEC), B. cereus, many of the enteric viruses such as rotavirus, astroviruses, enteric adenoviruses, and Noroviruses, and the parasitic organisms, Cryptosporidium parvum and Cyclospora cayetanensis. Protozoal pathogens, such as C. parvum, generally produce enteric illness after an incubation period of approximately seven days, in contrast to the preformed toxin-mediated illnesses, which occur only hours after ingestion, and the organisms that produce toxins once ingested typically have an incubation period of 24 to 48 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clostridium perfringens",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. perfringens is an important cause of watery diarrhea in the United States. The spores of C. perfringens can germinate in foods such as meats, poultry or gravy. Following ingestion of a large quantity of organisms with the food; C. perfringens toxin is produced in the host GI tract. Outbreaks of C. perfringens foodborne illness in psychiatric inpatient facilities have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/14\">",
"     14",
"    </a>",
"    ]; impaired intestinal motility caused by antipsychotic medications may increase susceptibility to infection.",
"   </p>",
"   <p>",
"    Testing of stool or food for the toxin can be undertaken at reference laboratories. C. perfringens type C produces a beta toxin, which can cause enteritis necroticans (pigbel), a hemorrhagic necrosis of the jejunum. Pigbel occurs in developing countries but has also been described in the United States in association with consumption of pig intestines (chitterlings) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/15\">",
"     15",
"    </a>",
"    ]. The simultaneous ingestion of sweet potatoes, which contain trypsin inhibitors preventing the intestinal degradation of the toxin, may be a potentiating factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Enterotoxigenic Escherichia coli and enteric viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;ETEC is a common cause of traveler's diarrhea but has not been identified as frequently in cases in the United States. However, this pathogen has been linked to a number of outbreaks of diarrhea in the United States, including one associated with the consumption of potato salad in Wisconsin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/16\">",
"     16",
"    </a>",
"    ] and has also become a common pathogen in cruise ship diarrhea outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37960?source=see_link\">",
"     \"Pathogenic Escherichia coli\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=see_link\">",
"     \"Travelers' diarrhea\"",
"    </a>",
"    .) Both ETEC and enteric viruses are transmitted via fecal contamination of food or water from an infected person. Prepared food is therefore at the top of the list of likely sources for these pathogens.",
"   </p>",
"   <p>",
"    There are no specific tests for ETEC in routine use, which may be partially responsible for underdiagnosis as a cause of foodborne diarrhea. ETEC look like any other E. coli on standard laboratory media; if ETEC are suspected, a special request should be made to the testing laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cryptosporidium and Cyclospora",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two other foodborne pathogens that often induce predominantly watery diarrhea are C. parvum, and C. cayetanensis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/18\">",
"     18",
"    </a>",
"    ]. While C. parvum is estimated to be responsible for 300,000 cases annually, only 10 percent is considered to be foodborne (",
"    <a class=\"graphic graphic_table graphicRef75429 \" href=\"UTD.htm?33/24/34190\">",
"     table 2",
"    </a>",
"    ). By contrast, C. cayetanensis causes only approximately 16,000 cases, but 90 percent of these are believed to be foodborne, based upon outbreak data [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     C. parvum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptosporidium parvum has gained notoriety for causing persistent chronic diarrhea in immunocompromised patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/19\">",
"     19",
"    </a>",
"    ]. The organism is endemic in cattle and is usually acquired in humans from contaminated water, fresh produce, unpasteurized milk or person-to-person spread. The incubation period is typically approximately one week, but can be as long as 28 days. C. parvum is known to cause large outbreaks, the largest of which was waterborne in Milwaukee, affecting approximately 400,000 individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    C. parvum can be diagnosed by acid-fast staining of stools, immunofluorescence microscopy, or enzyme immunoassay. One test designed to screen stools simultaneously for Giardia lamblia, Entamoeba",
"    <span class=\"nowrap\">",
"     histolytica/Entamoeba",
"    </span>",
"    dispar, and C. parvum may be useful as a rapid screen for these pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link\">",
"     \"Intestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    .) There is no current reliable therapy for cryptosporidiosis, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    elixir has been approved for use in children aged one to 11 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     C. cayetanensis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclospora cayetanensis infection has been associated in the past with consumption of imported berries; the fruit was probably infected via fecally contaminated water. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31493?source=see_link\">",
"     \"Cyclospora infection\"",
"    </a>",
"    .) The parasite has also been linked to fresh basil [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/22\">",
"     22",
"    </a>",
"    ]. It can be diagnosed by direct acid-fast microscopy of stool [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/23\">",
"     23",
"    </a>",
"    ], but most microbiology laboratories will not routinely look for either C. parvum or C. cayetanensis unless specifically requested. The diagnosis of C. cayetanensis is important because it is readily treatable with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Intestinal tapeworms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal tapeworms can cause diarrhea in addition to a variety of other symptoms. Examples include the tapeworms Taenia saginata, Taenia solium and Diphyllobothrium latum. These are acquired by consumption of undercooked beef, pork and fish, respectively. These intestinal tapeworms are discussed in further detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4519?source=see_link\">",
"     \"Intestinal tapeworms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28232?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cysticercosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     INFLAMMATORY DIARRHEA AS THE MAJOR PRESENTING SYMPTOM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of inflammatory cells or a marker of inflammatory cells, such as fecal lactoferrin, defines an inflammatory diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/6\">",
"     6",
"    </a>",
"    ]. However, neither test is sufficiently sensitive or specific to exclude an invasive pathogen, if negative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=see_link\">",
"     \"Approach to the adult with acute diarrhea in developed countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are clinical clues that should increase suspicion that a foodborne microbe is causing inflammatory diarrhea. Such symptoms and signs include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Passage of diarrhea with blood or mucus",
"     </li>",
"     <li>",
"      Presence of severe abdominal pain",
"     </li>",
"     <li>",
"      Occurrence of fever",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These symptoms and signs do not distinguish among the microbial causes of inflammatory diarrhea. When considering foodborne diseases, statistically the most likely pathogens in patients with inflammatory diarrhea are Salmonella or Campylobacter, currently, the two most common bacterial pathogens isolated from diarrheal stools in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Salmonella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are many types of Salmonella, they can be divided into two broad categories: those that cause typhoid and enteric fever and those that primarily induce gastroenteritis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The typhoidal Salmonella, such as S. typhi or S. paratyphi primarily colonize humans, are transmitted via the consumption of fecally contaminated food or water, and cause a systemic illness usually with little or no diarrhea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=see_link\">",
"       \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The much broader group of nontyphoidal Salmonella are found in the intestines of other animals and are acquired from the consumption of products that have become contaminated with animal feces [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=see_link\">",
"       \"Microbiology and epidemiology of salmonellosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Traditionally salmonellosis has been associated with raw meat or poultry products. Salmonella has also been associated with foods such as fresh produce (sprouts, hot peppers, tomatoes, lettuce, melons) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/25\">",
"     25",
"    </a>",
"    ] and a variety of other foods including spices such as black and white pepper, peanut butter, chocolate and dried milk. Eggs are a common source of S. enteritidis, which may be present in chicken ovaries, resulting in transovarian contamination of eggs as they are being formed in the chicken. &nbsp;The incubation period for non-typhoidal Salmonella is usually one to three days, and the diagnosis is undertaken with routine stool cultures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Campylobacter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foodborne disease due to Campylobacter species was not recognized until the mid-1970s. C. jejuni accounts for the vast majority of foodborne campylobacteriosis, with C. coli responsible for most of the remainder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5065?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of Campylobacter infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incubation period usually ranges from two to five days, and poultry is a frequent source of the organism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of Campylobacter infection\"",
"    </a>",
"    .) Studies from various locations, including the United States, indicate that 70 to 80 percent of retail poultry is contaminated with Campylobacter [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/26\">",
"     26",
"    </a>",
"    ], thus making cross-contamination during food preparation an important hazard. Although Campylobacter are fastidious and slow-growing, they can be diagnosed using routine microbiologic techniques on selective plates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Shiga toxin producing E. coli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shiga toxin producing E. coli (STEC), also known as enterohemorrhagic E. coli (EHEC), are now the most frequent cause of acute renal failure in children in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. While E. coli O157:H7 is the serotype most frequently causing human disease in the US, it is now clear there are many other STEC serotypes, over 50 of which have been associated with diarrheal disease as well as the hemolytic uremic syndrome (HUS). STEC typically have been found in ground beef, unpasteurized juice, raw fruits and vegetables including alfalfa sprouts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18745?source=see_link\">",
"     \"Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incubation period ranges from approximately one day up to a week. The presentation usually begins with watery diarrhea that becomes bloody. Data from the United States indicate that up to 50 percent of STEC isolates are non-O157:H7 strains [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/1\">",
"     1",
"    </a>",
"    ]. Non-O157 strains cause severe illness comparable to the illness caused by O157, but the frequency of bloody diarrhea appears to be lower (eg, 42 versus 97 percent with O157 in a review of sporadic diarrhea from Canada) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=see_link\">",
"     \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    STEC can be diagnosed using Shiga toxin based assays, which have advantages over the more conventional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    MacConkey test. The majority of clinical microbiology laboratories will only test for O157:H7 STEC using sorbitol MacConkey plates (O157:H7 ferments sorbitol slowly compared with other E. coli). Use of sorbitol MacConkey plates will fail to detect non-O157:H7 strains and appears to have diminished sensitivity compared with Shiga toxin based tests [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/31\">",
"     31",
"    </a>",
"    ]. Determining whether a patient is positive for STEC has important therapeutic implications, since data indicate that antibiotic treatment of STEC-infected patients may increase the risk of developing HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=see_link\">",
"     \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Shigella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shigella will only colonize humans and some nonhuman primates; therefore, transmission of Shigella in food or water is most likely from either fecal contamination or direct contamination from a food handler. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42008?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of Shigella infection\"",
"    </a>",
"    .) S. sonnei or S. flexneri are the two species most likely to be isolated in the United States. A variety of foods have been implicated in the spread of Shigella, including salads (potato, tuna, shrimp, macaroni, and chicken), raw vegetables, milk and dairy products and poultry, as well as common-source water supplies. The organism is isolated routinely in clinical microbiology laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Enterobacter sakazakii",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterobacter sakazakii is a gram-negative rod that causes invasive disease among neonates and children aged three days to four years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/34\">",
"     34",
"    </a>",
"    ]. Infection with this pathogen has been associated with contamination of powdered formula. Manifestations may include necrotizing enterocolitis, bacteremia or meningitis; mortality ranges from 40 to 80 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Vibrio",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have consumed raw shellfish in the proceeding 48 hours and develop diarrhea should be cultured for Vibrio spp; the most likely organism is V. parahaemolyticus. Most laboratories do not routinely culture for any Vibrio spp; thus, a specific request should be made to the laboratory in suspected cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27878?source=see_link\">",
"     \"Vibrio parahaemolyticus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Yersinia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another unusual cause of foodborne disease that will cause an inflammatory diarrhea is Yersinia enterocolitica, which is typically associated with consumption of undercooked pork, unpasteurized milk or fecally contaminated water. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31062?source=see_link\">",
"     \"Epidemiology of yersiniosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Yersinia infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     NON-GASTROINTESTINAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some foodborne pathogens cause serious illness but are not necessarily associated with gastrointestinal disease. Neurologic symptoms are a common feature of many of these other foodborne agents. While a detailed discussion is beyond the scope of this topic review, the most clinically important will be discussed (",
"    <a class=\"graphic graphic_table graphicRef69368 \" href=\"UTD.htm?39/19/40251\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Botulism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulism (due to Clostridium botulinum toxin) is one of the most important of this group because of its life-threatening consequences. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link\">",
"     \"Botulism\"",
"    </a>",
"    .) A detailed food history should be obtained in any patient with visual disturbance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    descending paralysis. Botulism is associated with the consumption of foods in which C. botulinum spores have germinated and the resulting vegetative cells have produced toxin. Typical foods associated with botulism are those canned at home, fermented fish, herb-infused oils, and foods held warm for extended periods of time. Stool and serum can be tested for toxin by reference laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Ciguatera toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ciguatera toxin may cause nausea, vomiting, diarrhea and abdominal pain in the first two to six hours. The onsets of paresthesia, weakness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reversal of hot or cold are among the neurologic symptoms that follow; cardiovascular abnormalities can develop in two to five days. Ciguatera toxin disease is associated with consumption of large reef fish such as grouper, red snapper, amberjack and barracuda. These fish can become contaminated during consumption of algal blooms containing dinoflagellates, which produce the heat-stable ciguatoxin; the toxin becomes concentrated as it moves up the food chain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19096?source=see_link\">",
"     \"Marine toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Scombroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scombroid occurs within minutes to hours of consumption of certain fish, or occasionally cheese, in which there has been a build-up of biogenic amines, especially histamine. Patients complain of flushing, burning sensation, urticaria, dizziness, and paresthesia after consumption of certain types of fish, typically blue fish, tuna, mackerel, marlin, or mahi mahi. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19096?source=see_link\">",
"     \"Marine toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Other shellfish and mushroom toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shellfish may also contain toxins that fall into three groups (diarrheic, neurotoxic, and amnesic) causing the various symptoms that their names imply. Symptoms usually occur within 30 minutes to several hours following exposure. There are a variety of mushroom toxins that result in a mixture of gastrointestinal and neurologic disturbances, including hallucinations and confusion. Tetrodotoxin from puffer fish causes neurologic, respiratory and cardiac complications usually in less than 30 minutes; this condition is generally fatal. A careful food history is key if tetrodotoxin is in the differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Listeria monocytogenes",
"    </span>",
"    &nbsp;&mdash;&nbsp;L. monocytogenes is the cause of listeriosis, which is a rare but deadly foodborne disease with a mortality of approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/1\">",
"     1",
"    </a>",
"    ]. It is most likely to occur in the immunocompromised, elderly, or pregnant patient. Exposure to delicatessen meat, raw hot dogs and unpasteurized soft cheese are risk factors that need to be taken into consideration. The incubation period may be as long as six weeks in these populations at increased risk, but can be as short as 6 to 10 hours during outbreaks in normal adults [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9993?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and pathogenesis of Listeria monocytogenes infection\", section on 'Food epidemiology and outbreaks'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is usually made by culturing L. monocytogenes from the blood or cerebrospinal fluid (CSF). Stool cultures are unhelpful since 5 to 10 percent of the general population have L. monocytogenes in their stool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Vibrio vulnificus",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. vulnificus is another unusual but deadly microbe that affects the immunocompromised, especially those with chronic liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=see_link\">",
"     \"Vibrio vulnificus infections\"",
"    </a>",
"    .) It is associated with exposure to raw shellfish and has an incubation period of one to seven days. It may present with gastrointestinal symptoms or skin infections that rapidly develop into bacteremia and systemic disease. Culture for Vibrios requires special media and is not routinely performed. Thus, as noted above, a special request should be made to the laboratory if V. vulnificus is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Toxoplasma gondii",
"    </span>",
"    &nbsp;&mdash;&nbsp;T. gondii are usually ingested from the accidental contamination of food with the parasite oocysts from cat litter boxes or the garden, or from undercooked meats, such as lamb or hamburger (steak tartar). Infection is frequently asymptomatic in normal hosts but may produce fatal pneumonitis, myocarditis, and neurologic symptoms in the immunocompromised. Vertical transmission from mother-to-child can occur during pregnancy, leading to congenital toxoplasmosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link\">",
"     \"Toxoplasmosis in immunocompetent hosts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"     \"Toxoplasmosis and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Hepatitis A virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis A is transmitted from raw shellfish and other foods, such as fresh produce. However, transmission is more common via a variety of foods after contamination by an infected food handler. The incubation period varies from 15 to 50 days. This long incubation period often complicates the determination of a source of infection. The diagnosis is confirmed by serology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=see_link\">",
"     \"Overview of hepatitis A virus infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A large outbreak of hepatitis A linked to ingestion of green onions imported from Mexico occurred in four different states in the United States during the fall of 2003. The largest number of cases arose in Pennsylvania among 555 patrons and workers linked to a single restaurant; a case-control study implicated green onions, which were used in the mild but not hot salsa [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24265/abstract/37\">",
"     37",
"    </a>",
"    ]. Sequencing analysis of the virus in three restaurant patrons revealed the viruses to be identical and similar to sequences from patients in smaller hepatitis A outbreaks in three other states earlier in the fall. These other outbreaks were also linked epidemiologically to the consumption of green onions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Liver flukes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fascioliasis is biliary tract infection caused by liver flukes Fasciola hepatica or Fasciola gigantica. Humans are often infected by consuming watercress grown in infected areas (sheep and cattle are a common source). Infection is often mild but can cause fever, right upper quadrant pain, and hepatomegaly 6 to 12 weeks after ingestion, often accompanied by eosinophilia. Chronic infection can lead to biliary colic, cholangitis, cholelithiasis, and even obstructive jaundice. When infections are prolonged, sclerosing cholangitis and biliary cirrhosis can result. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31735?source=see_link\">",
"     \"Liver flukes: Fascioliasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Brucellosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brucellosis is acquired from consuming unpasteurized dairy products or from undercooked meat from animals that are infected with Brucella. Four species, Brucella melitensis, B. abortus, B. suis, and B. canis, are known to cause disease in humans and typically lead to fever and a variety of other symptoms such as weight loss, malaise, night sweats, and arthralgias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of brucellosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No discussion of foodborne disease is complete without considering the issue of prevention. Upon making the diagnosis of a foodborne disease, the clinician has responsibilities to both the patient and the general public.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The local health authorities must be notified in all cases of reportable diseases; these vary from state to state. Techniques, such as pulsed field gel electrophoresis (PFGE), allow public health departments to determine outbreaks much earlier than in the past permitting an earlier alert to the public about infected food sources.",
"     </li>",
"     <li>",
"      The infected patient must be instructed to avoid spreading the infection to others, either at home or at work. The most important preventive measure for patients is careful handwashing, particularly after using bathroom facilities.",
"     </li>",
"     <li>",
"      High-risk patients should be made aware of the dangers of certain foods, which carry a greater risk of contamination with foodborne microbes. These patients must also be careful about cross-contamination in the kitchen. This is important for both the elderly and immunocompromised in order to avoid exposure to many foodborne pathogens. Pregnant women need to be careful to avoid L. monocytogenes. Specific educational materials directed toward the populations at risk are available from federal agencies (eg, CDC, United States Department of Agriculture [USDA], and the Food and Drug Administration [FDA]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=see_link\">",
"       \"Patient information: Food poisoning (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"       \"Patient information: Food poisoning (food-borne illness) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of foodborne disease is transient and self-limited. Many of the diagnoses are clinical and do not require confirmatory laboratory tests. However, patients presenting with inflammatory and bloody diarrhea should have an etiologic diagnosis made since empiric antibiotic therapy may be dangerous in patients infected with STEC. While unusual, infection with some foodborne agents, such as C. botulinum, L. monocytogenes, or V. vulnificus, can be rapidly life-threatening and speedy therapy may be life saving. Maintaining an open mind in relation to the plethora of presentations of foodborne disease and remembering to ask about food exposures are both key elements in the diagnosis of foodborne diseases.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/1\">",
"      Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis 1999; 5:607.",
"     </a>",
"    </li>",
"    <li>",
"     Scharff RL. Health-related costs from foodborne illness in the United States. The Produce Safety Project at Georgetown University. www.producesafetyproject.org (Accessed on April 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/3\">",
"      Helms M, Simonsen J, M&oslash;lbak K. Foodborne bacterial infection and hospitalization: a registry-based study. Clin Infect Dis 2006; 42:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/4\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: incidence and trends of infection with pathogens transmitted commonly through food--foodborne diseases active surveillance network, 10 U.S. sites, 1996-2010. MMWR Morb Mortal Wkly Rep 2011; 60:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/5\">",
"      American Medical Association, Centers for Disease Control and Prevention, Center for Food Safety and Applied Nutrition, Food and Drug Administration, Food Safety and Inspection Service, US Department of Agriculture. Diagnosis and management of foodborne illnesses: a primer for physicians. MMWR Recomm Rep 2001; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/6\">",
"      Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/7\">",
"      Balaban N, Rasooly A. Staphylococcal enterotoxins. Int J Food Microbiol 2000; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/8\">",
"      Drobniewski FA. Bacillus cereus and related species. Clin Microbiol Rev 1993; 6:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/9\">",
"      Mahler H, Pasi A, Kramer JM, et al. Fulminant liver failure in association with the emetic toxin of Bacillus cereus. N Engl J Med 1997; 336:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/10\">",
"      Becker KM, Moe CL, Southwick KL, MacCormack JN. Transmission of Norwalk virus during football game. N Engl J Med 2000; 343:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/11\">",
"      Lipson SM, Svenssen L, Goodwin L, et al. Evaluation of two current generation enzyme immunoassays and an improved isolation-based assay for the rapid detection and isolation of rotavirus from stool. J Clin Virol 2001; 21:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/12\">",
"      Glass RI, Noel J, Ando T, et al. The epidemiology of enteric caliciviruses from humans: a reassessment using new diagnostics. J Infect Dis 2000; 181 Suppl 2:S254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/13\">",
"      Kawai T, Sekizuka T, Yahata Y, et al. Identification of Kudoa septempunctata as the causative agent of novel food poisoning outbreaks in Japan by consumption of Paralichthys olivaceus in raw fish. Clin Infect Dis 2012; 54:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Fatal foodborne Clostridium perfringens illness at a state psychiatric hospital--Louisiana, 2010. MMWR Morb Mortal Wkly Rep 2012; 61:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/15\">",
"      Petrillo TM, Beck-Sagu&eacute; CM, Songer JG, et al. Enteritis necroticans (pigbel) in a diabetic child. N Engl J Med 2000; 342:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/16\">",
"      Roels TH, Proctor ME, Robinson LC, et al. Clinical features of infections due to Escherichia coli producing heat-stable toxin during an outbreak in Wisconsin: a rarely suspected cause of diarrhea in the United States. Clin Infect Dis 1998; 26:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/17\">",
"      Daniels NA, Neimann J, Karpati A, et al. Traveler's diarrhea at sea: three outbreaks of waterborne enterotoxigenic Escherichia coli on cruise ships. J Infect Dis 2000; 181:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/18\">",
"      Slifko TR, Smith HV, Rose JB. Emerging parasite zoonoses associated with water and food. Int J Parasitol 2000; 30:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/19\">",
"      Mosier DA, Oberst RD. Cryptosporidiosis. A global challenge. Ann N Y Acad Sci 2000; 916:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/20\">",
"      Mac Kenzie WR, Hoxie NJ, Proctor ME, et al. A massive outbreak in Milwaukee of cryptosporidium infection transmitted through the public water supply. N Engl J Med 1994; 331:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/21\">",
"      Sharp SE, Suarez CA, Duran Y, Poppiti RJ. Evaluation of the Triage Micro Parasite Panel for detection of Giardia lamblia, Entamoeba histolytica/Entamoeba dispar, and Cryptosporidium parvum in patient stool specimens. J Clin Microbiol 2001; 39:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/22\">",
"      Lopez AS, Dodson DR, Arrowood MJ, et al. Outbreak of cyclosporiasis associated with basil in Missouri in 1999. Clin Infect Dis 2001; 32:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/23\">",
"      Ranjitham M, Madan M, Chandrasekharan S. Cyclospora cayetanensis--an emerging coccidian parasite. J Assoc Physicians India 1999; 47:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/24\">",
"      Hohmann EL. Nontyphoidal salmonellosis. Clin Infect Dis 2001; 32:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/25\">",
"      Backer HD, Mohle-Boetani JC, Werner SB, et al. High incidence of extra-intestinal infections in a Salmonella Havana outbreak associated with alfalfa sprouts. Public Health Rep 2000; 115:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/26\">",
"      Kramer JM, Frost JA, Bolton FJ, Wareing DR. Campylobacter contamination of raw meat and poultry at retail sale: identification of multiple types and comparison with isolates from human infection. J Food Prot 2000; 63:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/27\">",
"      Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998; 11:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/28\">",
"      Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998; 11:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/29\">",
"      Johnson KE, Thorpe CM, Sears CL. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Clin Infect Dis 2006; 43:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/30\">",
"      Pai CH, Ahmed N, Lior H, et al. Epidemiology of sporadic diarrhea due to verocytotoxin-producing Escherichia coli: a two-year prospective study. J Infect Dis 1988; 157:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/31\">",
"      Kehl KS, Havens P, Behnke CE, Acheson DW. Evaluation of the premier EHEC assay for detection of Shiga toxin-producing Escherichia coli. J Clin Microbiol 1997; 35:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/32\">",
"      Zhang X, McDaniel AD, Wolf LE, et al. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000; 181:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/33\">",
"      Tarr PI, Fouser LS, Stapleton AE, et al. Hemolytic-uremic syndrome in a six-year-old girl after a urinary tract infection with Shiga-toxin-producing Escherichia coli O103:H2. N Engl J Med 1996; 335:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/34\">",
"      Bowen AB, Braden CR. Invasive Enterobacter sakazakii disease in infants. Emerg Infect Dis 2006; 12:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/35\">",
"      Ooi ST, Lorber B. Gastroenteritis due to Listeria monocytogenes. Clin Infect Dis 2005; 40:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/36\">",
"      Aureli P, Fiorucci GC, Caroli D, et al. An outbreak of febrile gastroenteritis associated with corn contaminated by Listeria monocytogenes. N Engl J Med 2000; 342:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24265/abstract/37\">",
"      Centers for Disease Control and Prevention (CDC). Hepatitis A outbreak associated with green onions at a restaurant--Monaca, Pennsylvania, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:1155.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2685 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24265=[""].join("\n");
var outline_f23_44_24265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Food history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pathogenic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VOMITING AS THE MAJOR PRESENTING SYMPTOM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bacillus cereus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Noroviruses (Norwalk-like viruses)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anisakiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106092312\">",
"      Kudoa septempunctata",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      WATERY DIARRHEA AS THE MAJOR PRESENTING SYMPTOM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clostridium perfringens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Enterotoxigenic Escherichia coli and enteric viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cryptosporidium and Cyclospora",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - C. parvum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - C. cayetanensis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Intestinal tapeworms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      INFLAMMATORY DIARRHEA AS THE MAJOR PRESENTING SYMPTOM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Salmonella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Campylobacter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Shiga toxin producing E. coli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Shigella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Enterobacter sakazakii",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Vibrio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Yersinia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      NON-GASTROINTESTINAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Ciguatera toxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Scombroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Other shellfish and mushroom toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Listeria monocytogenes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Vibrio vulnificus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Toxoplasma gondii",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Hepatitis A virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Liver flukes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Brucellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2685\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2685|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/47/5883\" title=\"table 1\">",
"      Foodnet surveillance pathogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/24/34190\" title=\"table 2\">",
"      Foodborne illnesses in the United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/32/22027\" title=\"table 3\">",
"      Ddx foodborne disease by food",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/24/32140\" title=\"table 4\">",
"      Food poisoning GI sxs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/19/40251\" title=\"table 5\">",
"      Food poisoning non-GI sxs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=related_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6729?source=related_link\">",
"      Bacillus cereus and other non-anthracis Bacillus species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=related_link\">",
"      Clinical manifestations and diagnosis of Yersinia infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28232?source=related_link\">",
"      Clinical manifestations and diagnosis of cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of Campylobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of brucellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31493?source=related_link\">",
"      Cyclospora infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9993?source=related_link\">",
"      Epidemiology and pathogenesis of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31062?source=related_link\">",
"      Epidemiology of yersiniosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43241?source=related_link\">",
"      Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42008?source=related_link\">",
"      Epidemiology, microbiology, and pathogenesis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=related_link\">",
"      Intestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4519?source=related_link\">",
"      Intestinal tapeworms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31735?source=related_link\">",
"      Liver flukes: Fascioliasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19096?source=related_link\">",
"      Marine toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=related_link\">",
"      Microbiology and epidemiology of salmonellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5065?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of Campylobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18745?source=related_link\">",
"      Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44168?source=related_link\">",
"      Miscellaneous nematodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=related_link\">",
"      Overview of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=related_link\">",
"      Overview of hepatitis A virus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37960?source=related_link\">",
"      Pathogenic Escherichia coli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=related_link\">",
"      Patient information: Food poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=related_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=related_link\">",
"      Toxoplasmosis and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=related_link\">",
"      Toxoplasmosis in immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=related_link\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27878?source=related_link\">",
"      Vibrio parahaemolyticus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=related_link\">",
"      Vibrio vulnificus infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_44_24266="Treatment of hidradenitis suppurativa";
var content_f23_44_24266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hidradenitis suppurativa",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24266/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24266/contributors\">",
"     Lynne J Margesson, MD, FRCPC, FAAD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24266/contributors\">",
"     F William Danby, MD, FRCPC, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24266/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24266/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24266/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24266/contributors\">",
"     Mark V Dahl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/44/24266/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24266/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/44/24266/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/44/24266/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hidradenitis suppurativa (HS) is a chronic follicular occlusive disease that affects the intertriginous axillary, groin, perianal, perineal, and inframammary skin. The clinical course is highly variable, ranging from relatively mild cases characterized by the recurrent appearance of papules, pustules, and a few inflammatory nodules to severe cases demonstrating deep fluctuant abscesses, draining sinuses, and severe band-like scars.",
"   </p>",
"   <p>",
"    The management and prognosis of HS will be reviewed here. The pathogenesis, clinical features, and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6265?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H856174\">",
"    <span class=\"h1\">",
"     PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HS is not life-threatening, the pain, odor, drainage, and disfigurement associated with this disorder regularly have deleterious effects on patient quality of life. Patients often experience feelings of sadness or depression related to the disease, and feelings of shame may contribute to self-imposed social isolation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Because of the significant physical and emotional toll of HS, treatment is often aggressively sought by patients, sometimes despite past therapeutic disappointments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H856823\">",
"    <span class=\"h2\">",
"     Treatment goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of successful treatment, HS can remain active for many years. The treatments for HS target one or more of three major goals:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      To reduce the extent and progression of disease by healing existing inflammatory lesions and preventing the formation of new lesions",
"     </li>",
"     <li>",
"      To remove chronic sinuses",
"     </li>",
"     <li>",
"      To limit scar formation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interventions utilized to achieve these goals include nonpharmacologic measures, topical and systemic medications, and surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/5\">",
"     5",
"    </a>",
"    ]. The level of disease severity strongly influences the selection of the treatment regimen. Factors such as patient tolerance of specific agents, patient comorbidities, treatment cost, and treatment availability also determine treatment selection. (See",
"    <a class=\"local\" href=\"#H3023157\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16990907\">",
"    <span class=\"h2\">",
"     Staging and scoring systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Hurley clinical staging system is frequently utilized to describe the severity of HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/6\">",
"     6",
"    </a>",
"    ]. In accordance with this system, HS is divided into three stages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stage I",
"      </strong>",
"      &minus; Abscess formation, single or multiple, without sinus tracts or cicatrization (scarring)",
"     </li>",
"     <li>",
"      <strong>",
"       Stage II",
"      </strong>",
"      &minus; Recurrent abscesses with tract formation and cicatrization; single or multiple widely separated lesions",
"     </li>",
"     <li>",
"      <strong>",
"       Stage III",
"      </strong>",
"      &minus; Diffuse or near diffuse involvement, or multiple interconnected sinus tracts and abscesses across the entire area (",
"      <a class=\"graphic graphic_picture graphicRef65188 \" href=\"UTD.htm?41/14/42212\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Methods of assessing the response to treatment vary widely across studies. The Hidradenitis Suppurativa Score (also known as the Sartorius score) and a subsequent revised version, the modified Hidradenitis Suppurativa Score, are measurements of disease severity that have been utilized in a number of studies (",
"    <a class=\"graphic graphic_table graphicRef67798 \" href=\"UTD.htm?25/60/26572\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. These score systems are not typically utilized in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3023157\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive guidelines for the management of HS are lacking due to a paucity of high quality data and the often unpredictable nature of the response to treatment. Thus, there are multiple therapeutic approaches to this disorder.",
"   </p>",
"   <p>",
"    Our approach to the management of patients with HS typically includes a discussion of nonpharmacologic measures that may be beneficial for reducing disease morbidity. Then, based upon the clinical severity of disease, as well as an assessment of the patient&rsquo;s treatment history, we proceed with the institution of disease-directed medical or surgical therapy. In general, medical therapy is most beneficial for reducing the inflammatory component of disease. Surgical intervention may improve nodules and sinus tracts in moderate HS and is the only effective treatment for the interconnected sinus tracts and extensive scarring seen in severe disease.",
"   </p>",
"   <p>",
"    Although the text below divides the approach to treatment according to the stage of disease, overall assessment of an individual patient is necessary to formulate the appropriate treatment plan. As an example, a patient with severe stage III disease in the groin that requires surgical intervention may also have clinical findings of earlier stage disease in the axilla that may respond to less aggressive therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;We utilize multiple nonpharmacologic and nonsurgical measures in the management of patients with HS in an attempt to reduce the severity and emotional impact of the disease. Although formal studies evaluating the efficacy of such measures have not been performed, our clinical experiences and the experiences of others suggest that patients benefit from these interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/5,10\">",
"     5,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Education and support",
"      </strong>",
"      &minus; Because HS is a psychologically distressing disorder, patient education and support are important components of management. Patients should be informed that the disease is neither contagious nor due to poor hygiene and they should be offered resources for psychological support [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Avoidance of skin trauma",
"      </strong>",
"      &minus; Factors that promote follicular maceration and follicular trauma may contribute to worsening of HS due to the promotion of inflammation, follicular occlusion, and follicular rupture. We advise patients to wear loose, light clothing to aid in the avoidance of excessive heat, friction, and shearing trauma. In addition, patients should not squeeze or otherwise manipulate the lesions. Daily use of antiperspirants may minimize maceration; however, products that induce irritation should be discontinued.",
"     </li>",
"     <li>",
"      <strong>",
"       Hygiene",
"      </strong>",
"      &minus; Daily, gentle cleansing of affected areas may help to reduce odor and the occurrence of secondary infection. We typically instruct patients to use a gentle, non-soap cleanser and to wash gently with only their fingers. Scrubbing with washcloths, loofahs, or brushes causes unnecessary trauma and irritation. If malodor is a problem, daily use of an antibacterial cleanser, (eg, a soap or body wash containing triclosan) to reduce bacterial colonization on the skin may be of benefit.",
"     </li>",
"     <li>",
"      <strong>",
"       Smoking cessation",
"      </strong>",
"      &minus; Although smoking is commonly associated with HS, it has not been definitively identified as a causative factor [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/8,10-13\">",
"       8,10-13",
"      </a>",
"      ], and documentation of improvement in HS after smoking cessation is limited to a few case reports [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/14\">",
"       14",
"      </a>",
"      ]. Despite the fact that the impact of smoking cessation on HS is unclear, this observed association and the overall negative impact on smoking on health lead us to routinely encourage smoking cessation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"       \"Smoking cessation counseling strategies in primary care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Weight management",
"      </strong>",
"      &minus; As with smoking, excess weight has been linked to HS, but a causative association between weight and HS has not been definitively established [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/8,10,11\">",
"       8,10,11",
"      </a>",
"      ]. Skin occlusion, skin friction, hormonal changes, or dietary factors related to excess weight may be contributing factors in HS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"       \"Overview of therapy for obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Diet",
"      </strong>",
"      &minus; The growing evidence supporting the clinical observation that dairy consumption and high glycemic load diets may be exacerbating factors for acne vulgaris has led to support for the concept that a similar process may occur in HS [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/5,15,16\">",
"       5,15,16",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41836945\">",
"    <span class=\"h2\">",
"     Hurley stage I (mild disease)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local therapy is the preferred approach for the treatment of patients with mild HS. We typically initially manage these patients with the general measures described above and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H3\">",
"     'General measures'",
"    </a>",
"    above). In addition, intralesional corticosteroids or short courses of systemic antibiotics with antiinflammatory properties may be beneficial for calming acute flares.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41836960\">",
"    <span class=\"h3\">",
"     Topical clindamycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    is often utilized as a first-line therapy for mild HS due to a randomized trial in support of its efficacy for mild inflammatory lesions and the relative safety and tolerability of this regimen. In the three-month randomized trial, twice daily treatment with clindamycin 1% solution was compared to vehicle in 30 patients with fairly mild HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/17\">",
"     17",
"    </a>",
"    ]. At the time of the initial evaluation, most patients had visible pustules, but only half had inflammatory nodules or abscesses (mean nodule and abscess count of two to three).",
"   </p>",
"   <p>",
"    The trial found that patients treated with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    had significantly fewer pustules at one, two, and three months after the start of treatment than patients in the vehicle group. Lower counts of abscesses or inflammatory nodules were also noted in the clindamycin group, but this difference failed to reach statistical significance at the two and three month time points. Treatment with clindamycin was well-tolerated. Two patients treated with clindamycin and three patients treated with vehicle reported slight burning sensations at the sites of treatment.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    appears to be beneficial for improving the number of mild inflammatory lesions in patients with HS, the ability of the drug to treat secondary infection (an exacerbating factor for HS), could contribute to the benefit seen in these patients. Whether clindamycin has a direct impact on the pathogenic mechanism of HS is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H943169\">",
"    <span class=\"h3\">",
"     Intralesional corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional corticosteroid therapy is often useful as an adjunctive therapy in HS. The intent of treatment is to accelerate the resolution of early, painful inflammatory lesions.",
"   </p>",
"   <p>",
"    The efficacy of intralesional corticosteroids for HS has not been evaluated in formal studies and the use of this therapy is based upon clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/10\">",
"     10",
"    </a>",
"    ]. To perform the procedure, a 30-gauge needle is typically used to inject 0.1 to 0.5 mL of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide (concentration = 5 to 10",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    into the center of each painful papule or nodule. The procedure is usually performed once monthly for one to three injections until the nodule resolves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link\">",
"     \"Intralesional injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H943176\">",
"    <span class=\"h3\">",
"     Systemic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although long-term systemic antibiotic therapy is typically reserved for Hurley stage II disease or refractory milder cases, our experience suggests that an abbreviated, 7- to 10-day course of a systemic antibiotic can quiet intermittent, acute flares in patients with mild disease. We typically utilize",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    (50 to 100 mg twice daily). Alternative therapies include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (300 mg twice daily) and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"      amoxicillin",
"     </a>",
"     /clavulanate",
"    </span>",
"    (500 mg to 1 g every eight hours). The choice of antibiotic depends upon factors such as the patient's drug allergies, tolerance of drug-specific side effects, history of response to specific antibiotics, risk of drug interactions, and drug cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5758489\">",
"    <span class=\"h2\">",
"     Hurley stage II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hurley stage II HS is characterized by inflammatory nodules, sinus tracts, and scarring. Both medical and surgical interventions are utilized in the management of these patients.",
"   </p>",
"   <p>",
"    The two major forms of pharmacologic therapy utilized in the management of Hurley stage II HS are systemic antibiotics (usually given for several weeks or longer) and hormonal therapy. In addition to antibiotic and hormonal agents, procedural interventions may be beneficial. Minor surgical procedures can be utilized to treat individual nodules or sinus tracts, and as in Hurley stage I disease, intralesional corticosteroid injections may be used to calm acute, painful inflammatory lesions. (See",
"    <a class=\"local\" href=\"#H12150177\">",
"     'Punch debridement'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Local or extensive unroofing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H943169\">",
"     'Intralesional corticosteroids'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605053\">",
"    <span class=\"h3\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism through which antibiotic therapy improves HS has not been definitively determined. Since infection is considered a secondary event in HS rather than a cause of the disease, the antiinflammatory effects of antibiotics are thought to be the primary reason for the improvement in HS observed during treatment with these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/18\">",
"     18",
"    </a>",
"    ]. The antiinflammatory action may allow for the repair of defects in the wall of the ruptured wall pilosebaceous unit, thereby promoting healing of lesions of HS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6265?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotics may also help to improve infection, when present, as well as the odor that can accompany HS.",
"   </p>",
"   <p>",
"    There is no evidence that long-term antibiotic therapy alters the natural history of HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/19\">",
"     19",
"    </a>",
"    ]. Relapse often recurs after the discontinuation of therapy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5758756\">",
"    <span class=\"h4\">",
"     First-line antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the use of antibiotics in HS are limited. The only randomized trial of systemic antibiotic therapy for HS is a trial that compared oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (500 mg twice daily) to topical 1%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    in 46 patients with stage I or II HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients were treated for at least three months, and no significant difference in the efficacy of these agents was detected.",
"   </p>",
"   <p>",
"    Tetracyclines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ) are usually well-tolerated and are the most common antibiotic agents prescribed for HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/21\">",
"     21",
"    </a>",
"    ]. In 2012, tetracycline became commercially unavailable in the United States, leaving doxycycline (50 to 100 mg twice daily) and minocycline (50 to 100 mg twice daily) as the preferred agents. A typical course of treatment with antibiotics lasts two to three months. &nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    and cephalosporins have also been used for long-term antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10646808\">",
"    <span class=\"h4\">",
"     Clindamycin and rifampin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    is an option for patients who fail to respond to conventional antibiotic therapy. Support for this regimen stems from a few retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In the largest study that evaluated this regimen, 116 patients with primarily Hurley stage I and II HS were treated with clindamycin (300 mg twice daily) and rifampin (600 mg once daily) for 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/22\">",
"     22",
"    </a>",
"    ]. Significant decreases in the Sartorius score were observed, and 8 of the 70 patients (11 percent) who were available for the week 10 assessment achieved complete remissions (Sartorius score of 0). No long-term follow-up was reported.",
"    <br/>",
"    <br/>",
"    Good responses to combination therapy have also been reported in smaller retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In a retrospective study of 34 patients with stage I, II, or III HS who had failed various other treatments, 16 (47 percent) achieved a complete response (defined as &gt;75 percent improvement) to clindamycin and rifampin administered via various treatment regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the long-term benefit of treatment was variable. In the study, 8 of 13 patients who responded completely to a regimen of clindamycin 300 mg twice daily and rifampin 300 mg twice daily (including nine patients treated for &ge;10 weeks) relapsed after an average of five months (62 percent). In addition, patients with more severe disease were less likely to respond to therapy.",
"   </p>",
"   <p>",
"    Combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    is not typically used as initial therapy due to concern for drug-related adverse effects. Diarrhea is a common side effect of this treatment regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In particular, clindamycin therapy occasionally results in",
"    <em>",
"     Clostridium difficile",
"    </em>",
"    infection. Patients should also be advised that rifampin often causes orange discoloration of bodily secretions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=see_link&amp;anchor=H9#H9\">",
"     \"Rifampin and other rifamycins\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29058548\">",
"    <span class=\"h4\">",
"     Other antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    , a sulfone drug with antibacterial and immunomodulatory properties that is utilized for the treatment of multiple neutrophil-predominant skin diseases, may be effective in HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/21,25\">",
"     21,25",
"    </a>",
"    ]. In a retrospective study of 24 patients with Hurley stage I to III HS who were treated with 50 to 200 mg of dapsone, six patients (25 percent) achieved clinically significant improvement and three patients improved slightly (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/21\">",
"     21",
"    </a>",
"    ]. None of the four patients with stage III disease improved with therapy. In addition, dapsone (25 to 150 mg per day) was associated with reductions in disease severity in a case series of five patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/25\">",
"     25",
"    </a>",
"    ]. As with other antimicrobial agents, the disease often recurs after treatment cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/21,25\">",
"     21,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    appeared to be beneficial for reducing disease activity in a retrospective study of 28 patients with longstanding HS that was refractory to other treatments (short-course antimicrobials, surgical drainage,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical excision) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients with stage I or II HS appeared to benefit most from this intervention.",
"   </p>",
"   <p>",
"    Combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (10 mg once daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    (400 mg daily), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 mg three times daily for up to six weeks) appeared to be beneficial in a retrospective study of 28 patients with long-standing HS that was refractory to other treatments (short-course antimicrobials, surgical drainage,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical excision) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/26\">",
"     26",
"    </a>",
"    ]. Of note, 14 patients were given a two-week course of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    and oral metronidazole immediately prior to treatment with this regimen. Complete remissions were attained in all six patients with stage I disease, 8 of 10 patients with Hurley stage II disease, and 2 of 12 patients with stage III disease. The mean duration of treatment required to achieve complete remission was two, four, and six months, respectively. Relapses occurred among 7 of 14 complete responders followed for 2 to 12 months despite prophylactic treatment with other antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5758773\">",
"    <span class=\"h3\">",
"     Hormonal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgens contribute to the development of HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/18\">",
"     18",
"    </a>",
"    ]. A beneficial therapeutic effect of antiandrogenic agents in HS is suggested by a retrospective study in which 16 of 29 women treated with various antiandrogenic drugs (55 percent) versus 6 of 23 women treated with oral antibiotics (26 percent) responded to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/27\">",
"     27",
"    </a>",
"    ]. Antiandrogenic therapies that have been reported to be effective in formal studies or case series include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    (CPA) administered with estrogen, an oral contraceptive containing estrogen and norgestrel, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     Cyproterone",
"    </a>",
"    acetate is not available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6265?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa\", section on 'Predisposing factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     Cyproterone acetate",
"    </a>",
"    was compared to an oral contraceptive pill in a double-blind cross-over trial of 24 women with moderate to severe HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients were treated with 50 mcg of ethinyl estradiol (cycle days 5 to 25) and 50 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone",
"    </a>",
"    acetate (cycle days 5 to 14) for six months and ethinylestradiol 50",
"    <span class=\"nowrap\">",
"     mcg/norgestrel",
"    </span>",
"    500 mcg (cycle days 5 to 25) for six months. Although six patients dropped out of the trial prior to completion due to drug intolerance or worsening of disease, both treatment regimens were associated with clinical improvement, and no significant difference in efficacy was detected. Overall, improvement occurred in 12 patients, including seven patients who achieved complete remissions. Treatment appeared to be most beneficial in patients with disease that was not complicated by infection. A treatment regimen containing cyproterone acetate (100 mg per day) plus ethinyl estradiol was also associated with clinical improvement in a case series of four women with HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports and a small case series have documented lesion resolution in men and women treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The efficacy of other antiandrogenic therapies, such as drospirenone-containing oral contraceptives,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    has not been studied; use of these agents is based on anecdotal reports of clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, we frequently use hormonal therapy in the management of HS. We have female patients who have responded well to combination treatment with a drospirenone (or norgestimate)-containing oral contraceptive plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    (50 to 100 mg per day) as well as male patients who have responded well to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9540652\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery can be used for the treatment of individual nodules and sinus tracts that occur in Hurley stage II disease. Unroofing of nodules and sinuses is usually sufficient; wide excision is typically reserved for Hurley stage III disease. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Surgical procedures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because these surgical interventions do not arrest the underlying disease process, the general measures described above and medical therapy are required to maintain control of the disease. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'General measures'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5758497\">",
"    <span class=\"h2\">",
"     Severe and refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to typical Hurley stage II HS, both medical and surgical therapies are utilized for patients with refractory Hurley stage II HS and Hurley stage III HS.",
"   </p>",
"   <p>",
"    The value of surgical intervention in HS arises from its efficacy for removing the nidus responsible for continued inflammation and treating disease sequelae. In sum, surgery is used to promote healing of nodules, to eliminate interconnected sinus tracts, and to remove",
"    <em>",
"     en bloc",
"    </em>",
"    tissue that is scarred beyond repair. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Surgical procedures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although extensive surgical intervention offers the greatest likelihood for the resolution of active inflammation in the treated area [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/32\">",
"     32",
"    </a>",
"    ], the procedure can be disfiguring. Thus, medical therapy is often attempted prior to such surgery.",
"   </p>",
"   <p>",
"    The main pharmacologic agents utilized for the management of severe and refractory disease are biologic therapies and oral retinoids. Based upon the data in support of its efficacy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    is considered a first-line pharmacologic agent for the treatment of severe and refractory HS. However, the requirement for intravenous administration, the presence of patient-specific contraindications, and the expense of the drug prohibits treatment in some patients. Alternatives to infliximab include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    . However, the data in support of these agents are less robust than for infliximab therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"     Ustekinumab",
"    </a>",
"    , a newer biologic agent, has demonstrated benefit in small numbers of patients.",
"   </p>",
"   <p>",
"    Immunosuppressive agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are occasionally utilized for acute relief, but are not indicated for the long-term management of patients with HS due to the potential for serious drug-related adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H316619545\">",
"    <span class=\"h3\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacologic therapies utilized for severe and refractory disease are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9540620\">",
"    <span class=\"h4\">",
"     TNF-alpha inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologic TNF-alpha inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ) have been utilized for the treatment of HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Infliximab is given through intravenous infusion; adalimumab and etanercept are given as subcutaneous injections. Additional studies are necessary to compare the efficacy of these biologic TNF-alpha inhibitors to each other and to other therapies used for HS. Based upon the available data, infliximab appears to be the most effective biologic agent for HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      <strong>",
"      </strong>",
"      &minus; A beneficial effect of infliximab for HS was demonstrated in a trial of 38 patients with moderate to severe HS [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/37\">",
"       37",
"      </a>",
"      ]. During the initial randomized, double-blind phase of the trial, patients were treated with either infliximab (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on weeks zero, two, and six) or a placebo infusion. This phase was followed by an open-label phase in which patients in the infliximab group received maintenance doses of infliximab at weeks 14 and 22, and patients in the placebo group were given the opportunity to receive infliximab according to the same treatment regimen.",
"      <br/>",
"      <br/>",
"      By week eight, patients in the infliximab group were more likely than patients in the placebo group to achieve a 50 percent or greater reduction in disease severity scores. In addition, on physician global assessment, 47 percent of patients in the infliximab group attained 75 to 99 percent improvement compared with none of the placebo-treated patients. Significantly greater improvements in quality of life and pain were also noted by infliximab-treated patients. Improvement with infliximab has also been reported in case series and uncontrolled studies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/33,38,39\">",
"       33,38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      <strong>",
"      </strong>",
"      &minus; Compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , the effects of adalimumab on HS appear to be less impressive. Although improvement in HS during treatment with adalimumab has been reported in some open-label studies, case series, and case reports [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/33,34,36\">",
"       33,34,36",
"      </a>",
"      ], randomized trials have yielded modest results:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A manufacturer-sponsored randomized trial in which 154 adults with stage I to III HS who previously failed to respond to antibiotics or were unable to tolerate antibiotic therapy were treated with 40 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      weekly (after loading doses of 160 and 80 mg at weeks 0 and 2, respectively), 40 mg of adalimumab every other week (after a loading dose of 80 mg at week 0), or placebo yielded more favorable results for weekly dosing of adalimumab than for placebo treatment after 16 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/40\">",
"       40",
"      </a>",
"      ]. In the trial, 18 percent of weekly adalimumab recipients versus 4 percent of placebo recipients achieved a clinical response (at least two-grade improvement in a novel scoring system). In addition, compared with placebo-treated patients, significantly more patients treated with weekly adalimumab had clinically significant improvements in pain scores after 2, 4, 12, and 16 weeks (48 versus 27 percent at week 16). There was no significant difference detected in the rate of clinical response between patients treated with every other week adalimumab (10 percent) and placebo-treated patients (4 percent).",
"     </li>",
"     <li>",
"      In a randomized trial performed in 21 patients with Hurley stage II or III HS [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/41\">",
"       41",
"      </a>",
"      ], fifteen patients were treated for 12 weeks with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      (80 mg at baseline, followed by 40 mg every other week) and six patients were given placebo injections. Although the reduction in the Sartorius score was greater in the adalimumab group throughout the study, the difference was statistically significant only at week six. Significant changes in the Hurley stage were not detected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      <strong>",
"      </strong>",
"      &minus; Data conflict on the efficacy of etanercept for HS [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/42-45\">",
"       42-45",
"      </a>",
"      ]. Although a randomized trial comparing etanercept (50 mg twice weekly) to placebo in 20 patients with moderate to severe HS failed to identify statistically significant differences in physician or patient-assessed measures of efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/42\">",
"       42",
"      </a>",
"      ], some uncontrolled studies have found more favorable results [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/43,46,47\">",
"       43,46,47",
"      </a>",
"      ]. The induction of HS during etanercept therapy has been reported in one patient [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maintenance therapy may be required to maintain the effects of TNF-alpha inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    trial, three of five patients who were followed through to 52 weeks relapsed after the discontinuation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/37\">",
"     37",
"    </a>",
"    ]. In one of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    trials, all patients relapsed after the discontinuation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/41\">",
"     41",
"    </a>",
"    ]. The transient benefit attained with treatment with these agents can be useful for reducing disease activity prior to surgery. Doing so may facilitate definition of the disease for the surgeon and may assist with post-surgical healing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H943208\">",
"     'Preoperative measures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Multiple adverse effects are associated with anti-TNF therapy, including risks for infection, heart failure, demyelinating disease, and malignancy. The adverse effects of TNF-alpha inhibitors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9540636\">",
"    <span class=\"h4\">",
"     Oral retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral retinoids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    have antiproliferative and immunomodulatory effects and can be beneficial in some patients with HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/51-56\">",
"     51-56",
"    </a>",
"    ]. Isotretinoin therapy is highly effective for the treatment of acne vulgaris; however, the effect is less consistent in HS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"       Acitretin",
"      </a>",
"      <strong>",
"      </strong>",
"      &minus; A retrospective study of 12 patients with recalcitrant Hurley stage II or III HS treated with acitretin (mean dose 0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily) for 9 to 12 months with or without topical therapy found that all patients improved, and that nine patients achieved marked or complete remissions [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/51\">",
"       51",
"      </a>",
"      ]. The first initial signs of improvement were noted within approximately two months. Improvement often persisted after treatment, with nine patients maintaining responses for 6 to 45 months after the cessation of therapy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       Isotretinoin",
"      </a>",
"      <strong>",
"      </strong>",
"      &minus; Studies of isotretinoin therapy have demonstrated improvement in lower proportions of patients with HS. In a retrospective study of 68 patients with various stages of HS who were treated for four to six months with isotretinoin (mean daily doses of 0.5 to 0.8",
"      <span class=\"nowrap\">",
"       mg/kg),",
"      </span>",
"      16 (24 percent) achieved clearing of disease, and 25 showed lesser improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/56\">",
"       56",
"      </a>",
"      ]. All patients who cleared had disease that was mild or moderate in severity, suggesting that patients with more severe disease may be less likely to respond to this regimen. The response to treatment persisted in some patients; 11 of the 16 patients who cleared completely maintained the response during follow-up periods ranging from 6 to 107 months (mean 57 months). In a separate series of 88 patients treated with isotretinoin for an average of eight months (mean daily doses range = 20 to 140 mg per day), improvement was reported in only 14 patients (16 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Potential adverse effects of systemic retinoids include cheilitis, xerosis, hyperlipidemia, and depression. Retinoids are teratogenic, and use must be avoided in women who are at risk for pregnancy and during pregnancy. Pregnancy should also be avoided for one month following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    treatment, and for three years after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    . Thus, the use of acitretin is typically avoided in women of childbearing-potential. In the United States, isotretinoin can only be prescribed through the",
"    <a class=\"external\" href=\"file://ipledgeprogram.com/\">",
"     iPLEDGE program",
"    </a>",
"    , an internet-based risk management program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=see_link&amp;anchor=H7#H7\">",
"     \"Oral isotretinoin therapy for acne vulgaris\", section on 'Isotretinoin safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1357106\">",
"    <span class=\"h4\">",
"     Conventional immunosuppressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressants are occasionally used to calm the inflammatory process in severe HS. Since immunosuppressants are not curative and may induce severe adverse effects, they are rarely utilized for long-term therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H943208\">",
"     'Preoperative measures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Systemic glucocorticoids",
"      </strong>",
"      &minus; A three- to four-day course of 40 to 60 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      tapered over the subsequent 7 to 10 days is often sufficient for acutely reducing inflammation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      <strong>",
"      </strong>",
"      &minus; A few case reports describe moderate to marked improvement in refractory HS with administration of cyclosporine A (3 to 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day orally) given for several weeks or several months [",
"      <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/57-59\">",
"       57-59",
"      </a>",
"      ]. The duration of treatment with cyclosporine is often limited by adverse effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link&amp;anchor=H17#H17\">",
"       \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Side effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H854218\">",
"    <span class=\"h4\">",
"     Ustekinumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    , an interleukin",
"    <span class=\"nowrap\">",
"     (IL)-12/23",
"    </span>",
"    inhibitor given via subcutaneous injection, have been reported in a few patients with moderate to severe refractory HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Ustekinumab injection is a simple office procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26976383\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with severe HS that is refractory to medical therapy, surgical excision of the affected area can lead to the local quiescence of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/32\">",
"     32",
"    </a>",
"    ]. Less extensive surgical procedures may be employed for the treatment of individual lesions. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Surgical procedures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SURGICAL PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In severe disease, both medical and surgical treatments are needed to stop the development of new lesions and control inflammation. Surgery helps to control inflammation by removing debris and active sinus tracts, which act as foreign bodies under the skin and perpetuate both the inflammatory process and the progressive sinus formation.",
"   </p>",
"   <p>",
"    Surgical approaches to HS include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Incision and drainage",
"     </li>",
"     <li>",
"      Punch debridement",
"     </li>",
"     <li>",
"      Unroofing",
"     </li>",
"     <li>",
"      Excision",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H943208\">",
"    <span class=\"h2\">",
"     Preoperative measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical treatment may be administered to calm inflammation prior to surgical intervention in cases in which the margins of nodules or sinus tracts are difficult to define. The choice of an antiinflammatory agent before surgery depends upon disease severity. Antibiotics, as well as short courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , are used for stage II disease. For stage III disease, systemic glucocorticoids (40 to 60 mg per day for two to three days followed by a 7- to 10-day taper) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (4 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally) have been used to settle inflammation. Biologic agents, including TNF-alpha inhibitors, may also be utilized to calm inflammation in patients with severe disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Incision and drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incision and drainage (I&amp;D) of individual nodules provides only short-term relief and generally should be avoided. Lesions treated in this manner tend to recur with no long-term benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    I&amp;D is performed only for relief of pain in the setting of a tense abscess that is too painful to bear. The lesion must be deeply incised under local anesthesia. Packing the wound for a few days may be needed to prevent premature superficial closure while the wound fills in from below.",
"   </p>",
"   <p>",
"    Because I&amp;D does not cure HS, the use of other therapies to control the disease is indicated. Repeated I&amp;D is not an effective or appropriate method of managing HS.",
"   </p>",
"   <p>",
"    In our practice, we have come to favor punch debridement over I&amp;D for acute inflammatory nodules due to the favorable results that we have observed with this intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12150177\">",
"    <span class=\"h2\">",
"     Punch debridement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Punch debridement is a procedure that we have successfully utilized in our practice for the management of acute inflammatory nodules in HS. The procedure involves the use of a 5 to 7 mm punch instrument (identical to that used in a punch biopsy) to deeply excise the acutely inflamed pilosebaceous unit within an inflammatory nodule plus a small amount of surrounding tissue. This is followed by aggressive debridement using digital pressure, and then curettage or simple grattage (scrubbing) with gauze wrapped around a cotton-tipped swab. The object is to remove the fractured follicular unit with the associated sebaceous glands and, more importantly, the bulge area containing the stem cells responsible for inducing growth of the subcutaneous sinuses.",
"    <br/>",
"    <br/>",
"    Ferric chloride is used for hemostasis and petrolatum dressings are applied after the procedure. The wound is allowed to heal via secondary intention. Pain relief and healing are swift. Our pilot study to evaluate the efficacy of this procedure is currently underway. To date, we have not observed recurrences in treated areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Local or extensive unroofing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical unroofing (also described in the literature as deroofing) is the primary surgical therapy for severe Hurley stage II and Hurley stage III HS (",
"    <a class=\"graphic graphic_picture graphicRef53340 graphicRef70778 graphicRef50847 graphicRef64990 graphicRef57893 graphicRef66627 graphicRef81667 \" href=\"UTD.htm?40/56/41866\">",
"     picture 2A-G",
"    </a>",
"    ). The procedure may be performed on an individual sinus or fistula (local unroofing) or on all such lesions in an affected region (extensive unroofing). The technique consists of careful unroofing and debriding of sinuses and inflamed tissue by a surgeon who has experience with this procedure. Under local or regional anesthesia, sinus tracts are entered and opened widely with scissors, explored with scissors tips or a malleable metal probe, and are unroofed until no residual tracts of inflammatory activity remain.",
"   </p>",
"   <p>",
"    The entire roof of each tract should be completely removed and the base explored for hidden entrances to other sinuses. The active proliferative inflammatory mass that is attempting to repopulate the area with pilosebaceous structures must be completely removed by rough gauze grattage (scrubbing) or by sharp curettage with a spoon curette, such as a 6 x 8 mm #0 oval or a Volkmann bone curette. The residual epithelialized sinus floor may be left exposed to assist healing by secondary intention or it may be dissected away [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Ferric chloride solution provides adequate hemostasis, but an electrocoagulation or electrodesiccation device is occasionally useful for hemostasis or for cutting where appropriate.",
"   </p>",
"   <p>",
"    Generally, in wounds up to 4 inches in diameter, simple plain petrolatum applied to gauze in a very thick (4 to 5 mm) layer and applied to the wound will suffice as a postsurgical wound dressing. The petrolatum must cover all surfaces of the gauze to avoid adherence of gauze to the wound. Daily dressing changes involve gentle cleansing of the wound followed by the reapplication of petrolatum. The epithelializing margins of the wound must not be d&eacute;brided, or even touched. Loose clothing should be worn to avoid friction in the reepithelializing areas.",
"   </p>",
"   <p>",
"    After the initial few days, the gauze is eliminated and simple thick applications of petrolatum to the wound edges is sufficient. Healing progresses inward from the wound edges and upward from the wound base and may be accelerated in large wounds with mesh grafting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carbon dioxide laser excision with healing by secondary intention can also be used to perform the unroofing. In one study using this approach, healing took four to eight weeks and the scars were flat and linear [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/66\">",
"     66",
"    </a>",
"    ]. Only one recurrence was noted along the margin of the surgical scar in a previously treated area. In a retrospective review of 185 HS areas in 61 patients, carbon dioxide laser excision was comparable to &lsquo;marsupialization&rsquo; for excellent quality of healing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/67\">",
"     67",
"    </a>",
"    ]. The procedures are performed with a local anesthetic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wide excision (margins well beyond the clinical borders of disease activity) of the involved areas combined with continued aggressive medical management is the treatment most likely to achieve disease cure in patients with chronic and extensive stage III disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/32,68\">",
"     32,68",
"    </a>",
"    ]. Due to the extensive amount of tissue removal required, wide excision should be reserved for only the most severe cases. Although local excision with primary closure (eg, Pollock procedure) has a lower morbidity than wide en bloc excision [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/69\">",
"     69",
"    </a>",
"    ], it has a higher recurrence rate. In one retrospective study of patients who underwent incision and drainage (n = 6), local excision (n = 14), or radical wide excisions (n = 11), the recurrence rates after a mean follow-up period of 72 months were 100, 43, and 27 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/70\">",
"     70",
"    </a>",
"    ]. Of note, wound dehiscence is a constant and increased threat in this population.",
"   </p>",
"   <p>",
"    It is essential to note that wide excision should not be the destructive \"en bloc deep to the fascia\" technique used in managing malignancy. Tissue should be removed until only soft, normal-appearing subcutaneous fat remains. The only time that it is necessary to remove more than the epidermis, its appendages, sinuses, and associated inflammation is when a (very rare) true fistula (to an underlying hollow organ) is encountered.",
"   </p>",
"   <p>",
"    The best method of skin closure after wide excision is controversial. Primary closure is best avoided in active disease to avoid burying residual foci of the disease process. Such residual activity will surface and spontaneously heal if second intent healing is permitted.",
"   </p>",
"   <p>",
"    Healing by secondary intention has shown good results, but after extensive tissue removal, wound closure may take months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Healing is accelerated with mesh grafting and vacuum assisted closure (VAC) techniques.",
"   </p>",
"   <p>",
"    When more conservative measures fail, extensive surgery remains the only option for patients with severe Hurley stage III HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/73\">",
"     73",
"    </a>",
"    ]. When successful, the results are often very satisfying for patients with severe disease that could not be adequately controlled with medical or less aggressive surgical therapy. Closure with advancement of local flaps or split-thickness meshed skin grafting is occasionally utilized for extensive cases. As noted above, burial of active foci of disease resulting in disease recurrence is a potential risk of primary wound closure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADDITIONAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional therapies that have been reported to be effective in small numbers of patients are reviewed below. In particular, Nd:YAG lasers, intense pulsed light, oral zinc, and topical resorcinol may be useful as adjunctive or alternative therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H857492\">",
"    <span class=\"h2\">",
"     Laser and light therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the ablative carbon dioxide lasers used for unroofing lesions, other light based therapies may be beneficial for the management of HS. In a randomized intraindividual trial of 22 patients with Hurley stage II or stage III disease, treatment with a 1064-nm neodymium-doped yttrium aluminium garnet (Nd:YAG) laser significantly reduced disease severity in inguinal, axillary, and inframammary sites [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/74\">",
"     74",
"    </a>",
"    ]. The mechanism of action of the Nd:YAG laser in HS may involve follicular destruction or dermal heating leading to the disruption of the inflammatory infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with intense pulsed light was also associated with improvement in disease severity in a randomized intraindividual trial of 18 patients with Hurley stage II or III HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/76\">",
"     76",
"    </a>",
"    ]. Additional studies are necessary to determine the role that laser and light therapy should play in HS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Zinc supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zinc salts have antiinflammatory and antiandrogenic properties and may reduce disease severity in HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/77\">",
"     77",
"    </a>",
"    ]. The efficacy of zinc gluconate (90 mg per day) was investigated in a pilot study of 22 patients who had failed to achieve satisfactory improvement with systemic antibiotic therapy, antiandrogens,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/77\">",
"     77",
"    </a>",
"    ]. All but one patient had Hurley stage I or II disease. Among the patients, eight (36 percent) achieved complete responses (disappearance of lesions or no new lesions for &ge;6 months), and the remainder achieved partial remissions (&ge;50 percent reduction in the number of nodules",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a shorter duration of inflammatory lesions). However, relapses occurred upon tapering of the dose to &le;60 mg per day.",
"   </p>",
"   <p>",
"    Additional support for a beneficial effect of zinc gluconate in HS stems from a prospective study of 12 patients with Hurley stage I or II HS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/78\">",
"     78",
"    </a>",
"    ]. Deficiencies in innate immune markers detected in lesional and nonlesional skin from patients with HS were improved following three months of treatment with zinc gluconate (90 mg per day).",
"   </p>",
"   <p>",
"    Gastrointestinal distress may occur as a consequence of zinc therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/77\">",
"     77",
"    </a>",
"    ]. These symptoms can be minimized by avoiding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/57/17300?source=see_link\">",
"     zinc sulfate",
"    </a>",
"    and administering zinc gluconate with meals (30 mg twice or three times per day in adults).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16991762\">",
"    <span class=\"h2\">",
"     Topical resorcinol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical 15 percent resorcinol in a proprietary cream base applied once daily to inflammatory nodules reduces pain and promotes healing of lesions. In an open study of 12 patients with Hurley stage I or stage II HS treated with topical 15 percent resorcinol, all patients experienced a reduction in pain and a reduction in duration of painful abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/79\">",
"     79",
"    </a>",
"    ]. Resorcinol is a topical peeling agent, and local desquamation occurred in all patients. Recurrences of pain or lesions may follow discontinuation of the medication.",
"   </p>",
"   <p>",
"    The availability of the topical resorcinol product is limited. Extemporaneous preparations of this material are notoriously unstable. It is custom compounded using a stable proprietary European base vehicle. In the United States, the product can be obtained from Bedford Pharmacy, 209 Route 101 # 2, Bedford, NH 03110, (603) 472-3919. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1357215\">",
"    <span class=\"h2\">",
"     External beam radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective study of 231 patients with refractory HS treated with radiotherapy found that 38 percent had complete resolution of symptoms and an additional 40 percent had some degree of improvement in symptoms following radiation treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/80\">",
"     80",
"    </a>",
"    ]. Although radiation therapy may be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/80,81\">",
"     80,81",
"    </a>",
"    ], this modality is rarely used for HS due to concern for the occurrence of long-term adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary clinical improvement has been described with use of 5-aminolevulinic acid (5-ALA) and exposure to different wavelengths of laser, visible light, or intense pulsed light. The technique is undergoing refinement [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/82-85\">",
"     82-85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16991814\">",
"    <span class=\"h2\">",
"     Botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insufficient data are available to determine the role of botulinum toxin as a treatment for HS. Complete remissions lasting 6 to 10 months occurred in an adult and a child after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    , respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22778?source=see_link&amp;anchor=H24777445#H24777445\">",
"     \"Overview of botulinum toxin for cosmetic indications\", section on 'Formulations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average duration of untreated disease is around 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/5\">",
"     5",
"    </a>",
"    ]. In women, the disease may remit after menopause. Early diagnosis of HS is essential because most cases can be effectively treated when diagnosed at an early stage. Hurley stage I disease can be controlled well in the majority of patients. Stage II disease is somewhat more difficult to control, and stage III disease is very difficult to manage and requires a multidisciplinary treatment approach. Although cure is possible, the disease may recur even after extensive surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, squamous cell carcinoma develops within sites of HS. Squamous cell carcinoma tends to be seen in patients who have suffered from HS for 10 years or more, and is often advanced at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/44/24266/abstract/88-90\">",
"     88-90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/23/22897?source=see_link\">",
"       \"Patient information: Hidradenitis suppurativa (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1357267\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disorder characterized by the development of pustules, inflammatory nodules, and sinus tracts, primarily in intertriginous areas. Physical pain, odor, chronic drainage, and disfigurement are common features of this disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6265?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Successful treatment of HS involves prevention of new lesions, minimization of the inflammatory component of the disease, the eradication of chronic sinuses, and the limitation of scar formation. The methods used to manage HS have included behavioral and dietary changes, topical and systemic medications, and surgical interventions. (See",
"      <a class=\"local\" href=\"#H856174\">",
"       'Principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient education and psychological support are important components of patient management. The avoidance of skin trauma, the institution of careful skin hygiene, smoking cessation, dietary restriction of dairy and foods with high glycemic loads, and weight reduction are also commonly recommended. Formal studies have not evaluated the impact of these interventions on disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The level of disease severity strongly influences the approach to the treatment of HS. Patients with Hurley stage I HS present with single or multiple abscesses without associated sinus tracts or scarring. For these patients we suggest treatment with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Adjunctive therapies include general measures, intralesional corticosteroids, and short courses of systemic antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H41836945\">",
"       'Hurley stage I (mild disease)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with Hurley stage II HS exhibit recurrent abscesses with sinus tract formation and scarring. For the treatment of the inflammatory component of Hurley stage II disease, we suggest treatment with systemic antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment is typically continued for two to three months or more. We usually initiate treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      . Combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      is typically reserved for patients who fail to respond to other antibiotic regimens. Concurrent use of antiandrogenic agents may provide additional benefit in women. (See",
"      <a class=\"local\" href=\"#H5758489\">",
"       'Hurley stage II'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The nodules, sinus tracts and scars of Hurley stage II HS are not cleared by antibiotic therapy. Surgical intervention can be used to treat nodules and unroof sinus tracts in patients with these lesions. (See",
"      <a class=\"local\" href=\"#H5758489\">",
"       'Hurley stage II'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgical procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Incision and drainage does not alter the clinical course of HS and should only be performed when immediate relief of pain from a tense abscess is required. Incision and drainage should not be used for routine patient management. Punch debridement is an additional option for acute, small, nodular lesions. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Incision and drainage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12150177\">",
"       'Punch debridement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hurley stage III HS is characterized by diffuse or near diffuse involvement of the affected intertriginous area with fluctuant nodules and interconnecting sinus tracts. Medical therapy may be beneficial for decreasing inflammation.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      is considered the first-line pharmacologic agent for this indication based upon the evidence in support of its efficacy. Alternative agents that may have some efficacy in severe HS include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"       acitretin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For patients with severe HS in a localized area that has failed to respond sufficiently to medical therapies and that has progressed to a point where surgical unroofing is unlikely to be sufficient, wide surgical excision offers the best chance for the local quiescence of inflammation. (See",
"      <a class=\"local\" href=\"#H5758497\">",
"       'Severe and refractory disease'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/1\">",
"      Wolkenstein P, Loundou A, Barrau K, et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/2\">",
"      Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010; 90:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/3\">",
"      Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol 2011; 91:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/4\">",
"      Kurek A, Peters EM, Chanwangpong A, et al. Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol 2012; 67:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/5\">",
"      Danby FW, Margesson LJ. Hidradenitis suppurativa. Dermatol Clin 2010; 28:779.",
"     </a>",
"    </li>",
"    <li>",
"     Hurley, HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Dermatologic surgery, Roenigk, RK, Roenigk, HH (Eds), New York 1989. p.729.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/7\">",
"      Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 2003; 149:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/8\">",
"      Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/9\">",
"      Sartorius K, Killasli H, Heilborn J, et al. Interobserver variability of clinical scores in hidradenitis suppurativa is low. Br J Dermatol 2010; 162:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/10\">",
"      Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012; 366:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/11\">",
"      Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/12\">",
"      Canoui-Poitrine F, Revuz JE, Wolkenstein P, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009; 61:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/13\">",
"      K&ouml;nig A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999; 198:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/14\">",
"      Simonart T. Hidradenitis suppurativa and smoking. J Am Acad Dermatol 2010; 62:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/15\">",
"      Di Landro A, Cazzaniga S, Parazzini F, et al. Family history, body mass index, selected dietary factors, menstrual history, and risk of moderate to severe acne in adolescents and young adults. J Am Acad Dermatol 2012; 67:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/16\">",
"      Melnik BC, John SM, Schmitz G. Over-stimulation of insulin/IGF-1 signaling by western diet may promote diseases of civilization: lessons learnt from laron syndrome. Nutr Metab (Lond) 2011; 8:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/17\">",
"      Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983; 22:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/18\">",
"      Nazary M, van der Zee HH, Prens EP, et al. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. Eur J Pharmacol 2011; 672:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/19\">",
"      Harrison BJ, Mudge M, Hughes LE. Recurrence after surgical treatment of hidradenitis suppurativa. Br Med J (Clin Res Ed) 1987; 294:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/20\">",
"      Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998; 39:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/21\">",
"      Yazdanyar S, Boer J, Ingvarsson G, et al. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology 2011; 222:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/22\">",
"      Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 2009; 219:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/23\">",
"      van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009; 219:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/24\">",
"      Mendon&ccedil;a CO, Griffiths CE. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 2006; 154:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/25\">",
"      Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: A case series of five patients. J Dermatolog Treat 2006; 17:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/26\">",
"      Join-Lambert O, Coignard H, Jais JP, et al. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology 2011; 222:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/27\">",
"      Kraft JN, Searles GE. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg 2007; 11:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/28\">",
"      Mortimer PS, Dawber RP, Gales MA, Moore RA. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol 1986; 115:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/29\">",
"      Sawers RS, Randall VA, Ebling FJ. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol 1986; 115:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/30\">",
"      Joseph MA, Jayaseelan E, Ganapathi B, Stephen J. Hidradenitis suppurativa treated with finasteride. J Dermatolog Treat 2005; 16:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/31\">",
"      Farrell AM, Randall VA, Vafaee T, Dawber RP. Finasteride as a therapy for hidradenitis suppurativa. Br J Dermatol 1999; 141:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/32\">",
"      Ellis LZ. Hidradenitis Suppurativa: Surgical and Other Management Techniques. Dermatol Surg 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/33\">",
"      Shuja F, Chan CS, Rosen T. Biologic drugs for the treatment of hidradenitis suppurativa: an evidence-based review. Dermatol Clin 2010; 28:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/34\">",
"      Rambhatla PV, Lim HW, Hamzavi I. A systematic review of treatments for hidradenitis suppurativa. Arch Dermatol 2012; 148:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/35\">",
"      Blok JL, van Hattem S, Jonkman MF, Horv&aacute;th B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol 2013; 168:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/36\">",
"      van Rappard DC, Leenarts MF, Meijerink-van 't Oost L, Mekkes JR. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat 2012; 23:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/37\">",
"      Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/38\">",
"      Lesage C, Adnot-Desanlis L, Perceau G, et al. Efficacy and tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa. Eur J Dermatol 2012; 22:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/39\">",
"      Delage M, Samimi M, Atlan M, et al. Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers. Acta Derm Venereol 2011; 91:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/40\">",
"      Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 2012; 157:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/41\">",
"      Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol 2011; 165:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/42\">",
"      Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 2010; 146:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/43\">",
"      Pelekanou A, Kanni T, Savva A, et al. Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial. Exp Dermatol 2010; 19:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/44\">",
"      Pellegrino M, Taddeucci P, Peccianti C, et al. Etanercept induced hidradenitis suppurativa. G Ital Dermatol Venereol 2011; 146:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/45\">",
"      Lee RA, Dommasch E, Treat J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2009; 60:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/46\">",
"      Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008; 158:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/47\">",
"      Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006; 154:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/48\">",
"      Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008; 158:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/49\">",
"      Blanco R, Mart&iacute;nez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol 2009; 145:580.",
"     </a>",
"    </li>",
"    <li>",
"     Jacob, SE, Kerdel, SA. Biologics for hidradenitis suppurativa (Verneuil's disease in the Era of biologics). In: Hidradenitis suppurativa, 1st edition, Jemec, GBE, Revuz, J, Leyden, J (Eds), Springer, Berlin 2006. p.145.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/51\">",
"      Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol 2011; 164:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/52\">",
"      Hogan DJ, Light MJ. Successful treatment of hidradenitis suppurativa with acitretin. J Am Acad Dermatol 1988; 19:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/53\">",
"      Soria A, Canoui-Poitrine F, Wolkenstein P, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients' outcome assessment. Dermatology 2009; 218:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/54\">",
"      Dicken CH, Powell ST, Spear KL. Evaluation of isotretinoin treatment of hidradenitis suppurativa. J Am Acad Dermatol 1984; 11:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/55\">",
"      Norris JF, Cunliffe WJ. Failure of treatment of familial widespread hidradenitis suppurativa with isotretinoin. Clin Exp Dermatol 1986; 11:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/56\">",
"      Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol 1999; 40:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/57\">",
"      Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990; 126:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/58\">",
"      Buckley DA, Rogers S. Cyclosporin-responsive hidradenitis suppurativa. J R Soc Med 1995; 88:289P.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/59\">",
"      Rose RF, Goodfield MJ, Clark SM. Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin. Clin Exp Dermatol 2006; 31:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/60\">",
"      Sharon VR, Garcia MS, Bagheri S, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol 2012; 92:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/61\">",
"      Gulliver WP, Jemec GB, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2012; 26:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/62\">",
"      van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 2010; 63:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/63\">",
"      Danby FW. Commentary: unroofing for hidradenitis suppurativa, why and how. J Am Acad Dermatol 2010; 63:481.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Lapins, J, Emtestam, L. Surgery. In: Hidradenitis Suppurativa, Jemec, GB, Revuz, J, Leyden, J (Eds), Springer, New York 2006. p.160.",
"    </li>",
"    <li>",
"     Jemec, GB, Revuz, J. Treatment. In: Hidradenitis Suppurativa, Jemec, GB, Revuz, J, Leyden, J (Eds), Springer, New York 2006. p.183.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/66\">",
"      Finley EM, Ratz JL. Treatment of hidradenitis suppurativa with carbon dioxide laser excision and second-intention healing. J Am Acad Dermatol 1996; 34:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/67\">",
"      Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg 2010; 36:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/68\">",
"      Rubin RJ, Chinn BT. Perianal hidradenitis suppurativa. Surg Clin North Am 1994; 74:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/69\">",
"      Watson JD. Hidradenitis suppurativa--a clinical review. Br J Plast Surg 1985; 38:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/70\">",
"      Ritz JP, Runkel N, Haier J, Buhr HJ. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis 1998; 13:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/71\">",
"      Ramasastry SS, Conklin WT, Granick MS, Futrell JW. Surgical management of massive perianal hidradenitis suppurativa. Ann Plast Surg 1985; 15:218.",
"     </a>",
"    </li>",
"    <li>",
"     Hughes, LE, Harrison, et al. Surgical management of hidradenitis-principles and results. In: Acne and Related Disorders, Marks, R, Plewig, G (Eds), Dunitz, London 1989. p.367.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/73\">",
"      Menderes A, Sunay O, Vayvada H, Yilmaz M. Surgical management of hidradenitis suppurativa. Int J Med Sci 2010; 7:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/74\">",
"      Tierney E, Mahmoud BH, Hexsel C, et al. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg 2009; 35:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/75\">",
"      Xu LY, Wright DR, Mahmoud BH, et al. Histopathologic study of hidradenitis suppurativa following long-pulsed 1064-nm Nd:YAG laser treatment. Arch Dermatol 2011; 147:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/76\">",
"      Highton L, Chan WY, Khwaja N, Laitung JK. Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg 2011; 128:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/77\">",
"      Brocard A, Knol AC, Khammari A, Dr&eacute;no B. Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology 2007; 214:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/78\">",
"      Dr&eacute;no B, Khammari A, Brocard A, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol 2012; 148:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/79\">",
"      Boer J, Jemec GB. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol 2010; 35:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/80\">",
"      Fr&ouml;hlich D, Baaske D, Glatzel M. [Radiotherapy of hidradenitis suppurativa--still valid today?]. Strahlenther Onkol 2000; 176:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/81\">",
"      Trombetta M, Werts ED, Parda D. The role of radiotherapy in the treatment of hidradenitis suppurativa: case report and review of the literature. Dermatol Online J 2010; 16:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/82\">",
"      Gold M, Bridges TM, Bradshaw VL, Boring M. ALA-PDT and blue light therapy for hidradenitis suppurativa. J Drugs Dermatol 2004; 3:S32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/83\">",
"      Strauss RM, Pollock B, Stables GI, et al. Photodynamic therapy using aminolaevulinic acid does not lead to clinical improvement in hidradenitis suppurativa. Br J Dermatol 2005; 152:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/84\">",
"      Guglielmetti A, Bedoya J, Acuna M, et al. Successful aminolevulinic acid photodynamic therapy for recalcitrant severe hidradenitis suppurativa. Photodermatol Photoimmunol Photomed 2010; 26:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/85\">",
"      Schweiger ES, Riddle CC, Aires DJ. Treatment of hidradenitis suppurativa by photodynamic therapy with aminolevulinic acid: preliminary results. J Drugs Dermatol 2011; 10:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/86\">",
"      Feito-Rodr&iacute;guez M, Sendagorta-Cud&oacute;s E, Herranz-Pinto P, de Lucas-Laguna R. Prepubertal hidradenitis suppurativa successfully treated with botulinum toxin A. Dermatol Surg 2009; 35:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/87\">",
"      O'Reilly DJ, Pleat JM, Richards AM. Treatment of hidradenitis suppurativa with botulinum toxin A. Plast Reconstr Surg 2005; 116:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/88\">",
"      Williams ST, Busby RC, DeMuth RJ, Nelson H. Perineal hidradenitis suppurativa: presentation of two unusual complications and a review. Ann Plast Surg 1991; 26:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/89\">",
"      Grewal NS, Wan DC, Roostaeian J, Rubayi SR. Marjolin ulcer in hidradenitis suppurativa: case reports. Ann Plast Surg 2010; 64:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/44/24266/abstract/90\">",
"      Lavogiez C, Delaporte E, Darras-Vercambre S, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology 2010; 220:147.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7605 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24266=[""].join("\n");
var outline_f23_44_24266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1357267\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H856174\">",
"      PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H856823\">",
"      Treatment goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16990907\">",
"      Staging and scoring systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3023157\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41836945\">",
"      Hurley stage I (mild disease)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41836960\">",
"      - Topical clindamycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H943169\">",
"      - Intralesional corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H943176\">",
"      - Systemic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5758489\">",
"      Hurley stage II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H605053\">",
"      - Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5758756\">",
"      First-line antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10646808\">",
"      Clindamycin and rifampin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29058548\">",
"      Other antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5758773\">",
"      - Hormonal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9540652\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5758497\">",
"      Severe and refractory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H316619545\">",
"      - Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9540620\">",
"      TNF-alpha inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9540636\">",
"      Oral retinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1357106\">",
"      Conventional immunosuppressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H854218\">",
"      Ustekinumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26976383\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SURGICAL PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H943208\">",
"      Preoperative measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Incision and drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12150177\">",
"      Punch debridement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Local or extensive unroofing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Excision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADDITIONAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H857492\">",
"      Laser and light therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Zinc supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16991762\">",
"      Topical resorcinol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1357215\">",
"      External beam radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16991814\">",
"      Botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1357267\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/7605\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/7605|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/14/42212\" title=\"picture 1\">",
"      Severe hidradenitis suppurativa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/13/35039\" title=\"picture 2A\">",
"      Hidradenitis suppurativa draining inflammatory nodule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/47/27376\" title=\"picture 2B\">",
"      Hidradenitis suppurativa and surgical unroofing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/27/37296\" title=\"picture 2C\">",
"      Hidradenitis suppurativa sinus tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/22/12641\" title=\"picture 2D\">",
"      Gauze grattage of an unroofed hidradenitis suppurativa sinus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/46/20195\" title=\"picture 2E\">",
"      Extensive hidradenitis suppurativa with multiple sinus tracts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/17/6417\" title=\"picture 2F\">",
"      Hidradenitis suppurativa nodule and sinus tracts unroofed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/18/31008\" title=\"picture 2G\">",
"      Hidradenitis suppurativa wound healed",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/7605|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/60/26572\" title=\"table 1\">",
"      Modified Sartorius HSS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=related_link\">",
"      Intralesional injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=related_link\">",
"      Oral isotretinoin therapy for acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22778?source=related_link\">",
"      Overview of botulinum toxin for cosmetic indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6265?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/23/22897?source=related_link\">",
"      Patient information: Hidradenitis suppurativa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=related_link\">",
"      Rifampin and other rifamycins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=related_link\">",
"      Smoking cessation counseling strategies in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_44_24267="MD responsibilities LTOT";
var content_f23_44_24267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Responsibilities of physicians prescribing long-term oxygen therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Documentation of the need for LTOT as outlined in text",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Selection of a qualified oxygen equipment supplier",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Completion of Form HCFA-484 (in the United States):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Oxygen flow at rest, during exercise, and during sleep, where appropriate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Oxygen delivery systems, including:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        A. Stationary unit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        B. Portable or ambulatory equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        C. Oxygen-conserving device, if desired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        D. Nasal cannula or transtracheal catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Justification for portable or ambulatory oxygen, if requested",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Verify that the supplier has correctly restated the prescription before signing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor use and environment (with home oxygen supplier)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reevaluation for possible changes in the prescription",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renewal of therapy as required",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24267=[""].join("\n");
var outline_f23_44_24267=null;
var title_f23_44_24268="Causes secondary hypogonadism";
var content_f23_44_24268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of hypogonadotropic (secondary) hypogonadism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Benign tumors and cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Craniopharyngiomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Germinomas, meningiomas, gliomas, astrocytomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Metastatic tumors (breast, lung, prostate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        \"Functional\" gonadotropin deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic systemic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Malnutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypothyroidism, hyperprolactinemia, diabetes mellitus, Cushing's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anorexia nervosa, bulimia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Infiltrative diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hemochromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Granulomatous diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Histiocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pituitary apoplexy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs - Marijuana",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Isolated GnRH deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Without anosmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Kallmann syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Associated with adrenal hypoplasia congenita",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        GnRH deficiency associated with mental retardation/obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Laurence-Moon-Biedl syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Prader-Willi syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic forms of multiple anterior pituitary hormone deficiencies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital malformations often associated with craniofacial anomalies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24268=[""].join("\n");
var outline_f23_44_24268=null;
var title_f23_44_24269="Aphasia syndromes";
var content_f23_44_24269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F72780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F72780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Aphasia syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Syndrome",
"      </td>",
"      <td class=\"subtitle1\">",
"       Flu",
"      </td>",
"      <td class=\"subtitle1\">",
"       Rep",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comp",
"      </td>",
"      <td class=\"subtitle1\">",
"       Read",
"      </td>",
"      <td class=\"subtitle1\">",
"       Write",
"      </td>",
"      <td class=\"subtitle1\">",
"       Localization",
"      </td>",
"      <td class=\"subtitle1\">",
"       Wernicke-Lichtheim model",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Broca's",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       \"Broca's\" area- left inferior frontal, often anterior MCA branch occlusion",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Wernicke's",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       \"Wernicke's\" area- left superior temporal and inferior parietal region, often posterior MCA branch occlusion",
"      </td>",
"      <td>",
"       8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anomic",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       &plusmn;",
"      </td>",
"      <td>",
"       &plusmn;",
"      </td>",
"      <td>",
"       Temporal, parietal, and occipital regions of cortex outside of classical language areas",
"      </td>",
"      <td>",
"       6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Conduction",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       &plusmn;",
"      </td>",
"      <td>",
"       Superior temporal gyrus, inferior parietal region adjacent to temporal lobe; classically in arcuate fasciculus",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Transcortical motor",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Left mesial frontal, especially supplementary motor area; anterior cerebral artery occlusion",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Transcortical sensory",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Left posterior watershed zone between MCA and PCA territories",
"      </td>",
"      <td>",
"       7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Transcortical mixed",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Anterior and posterior watershed zones, effectively disconnecting perisylvian cortex from other cortical regions",
"      </td>",
"      <td>",
"       4,7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Global",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Large MCA or left carotid inclusions infarcting a vast region of the left hemisphere",
"      </td>",
"      <td>",
"       4,5,7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pure word deafness",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       Left or bilateral superior temporal gyrus lesions",
"      </td>",
"      <td>",
"       10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pure alexia",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       Left occipital lobe with involvement of splenium of corpus callosum",
"      </td>",
"      <td>",
"       9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aphemia",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       Motor cortex outflow to articulators",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pure agraphia",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       +",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       Left inferior frontal region",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Language disorders acquired through brain injury. The first eight rows are aphasic syndromes. Numbers in the column labeled 'Wernicke-Lichtheim model' refer to lesion labels on Figure 1.",
"    <div class=\"footnotes\">",
"     Flu: fluency; Rep: repetition; Comp: comprehension; Read: reading; Write: writing; +: relatively spared; -: impaired; ACA: anterior cerebral artery; MCA: middle cerebral artery; PCA: posterior cerebral artery.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Mendez, MF, Clark, DG. Neuropsychiatric aspects of aphasia and related disorders. In: The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioral Neurosciences, 5th ed, Yudofsky, SC, Hales, RH (Eds), American Psychiatric Publishing, Washington, DC 2007. p.522.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24269=[""].join("\n");
var outline_f23_44_24269=null;
var title_f23_44_24270="Occipital fracture";
var content_f23_44_24270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Occipital fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This computed tomography of the head identifies an occipital fracture (arrow) with an associated posterior epidural hematoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24270=[""].join("\n");
var outline_f23_44_24270=null;
var title_f23_44_24271="BP norm birth to 1yr boys";
var content_f23_44_24271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Age-specific percentiles of BP measurements in boys - birth to 12 months of age; Korotkoff phase IV (K4) used for diastolic BP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 606px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Task force on blood pressure control in children. Report of the Second Task Force on Blood Pressure Control in Children-1987. Pediatrics 1987; 79:1. Copyright &copy; 1987 American Academy of Pediatrics.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_44_24271=[""].join("\n");
var outline_f23_44_24271=null;
